var title_f42_43_43696="PDA pulsed Doppler echo I";
var content_f42_43_43696=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulsed Doppler tracing  in a patient with patent ductus arteriosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 403px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The pulsed Doppler tracing from a patient with a patent ductus arteriosus and significant left-to-right shunt was obtained by positioning the sample volume in the left pulmonary artery. Note the continuous run off pattern of flow during diastole (arrows, lower panel). It is important not to confuse this run-off pattern with continuous right-to-left flow in the patent ductus arteriosus, which is a very uncommon finding. This patient had a jet of continuous left to right flow when the sample volume was placed in the patent ductus arteriosus rather than the left pulmonary artery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Doyle, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_43_43696=[""].join("\n");
var outline_f42_43_43696=null;
var title_f42_43_43697="Patient information: Osgood-Schlatter disease (The Basics)";
var content_f42_43_43697=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/85878\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/37/33361\">",
"         Painful and swollen area in Osgood-Schlatter disease",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/21/36179\">",
"         Patient information: Giving your child over-the-counter medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?30/1/30738\">",
"         Patient information: Normal sexual development (puberty) (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Osgood-Schlatter disease (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H600345265\">",
"      <span class=\"h1\">",
"       What is Osgood-Schlatter disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Osgood-Schlatter disease is a condition that causes pain on the front of the knee, right below the knee cap (",
"      <a class=\"graphic graphic_figure graphicRef85759 \" href=\"mobipreview.htm?32/37/33361\">",
"       figure 1",
"      </a>",
"      ). This condition usually affects children ages 9 to 14.",
"     </p>",
"     <p>",
"      Osgood-Schlatter disease happens after a child has a growth spurt, which is when he or she grows a lot in a short amount of time. The disease commonly happens in children who do sports or activities that involve a lot of running or jumping.",
"     </p>",
"     <p>",
"      Osgood-Schlatter disease can affect 1 or both knees.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H600345297\">",
"      <span class=\"h1\">",
"       What are the symptoms of Osgood-Schlatter disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Osgood-Schlatter disease causes pain and sometimes swelling on the front of the knee, right below the knee cap. Doctors call this spot the &ldquo;tibial tuberosity.&rdquo;",
"     </p>",
"     <p>",
"      The pain usually gets worse over time and can be severe. It gets worse with running, kneeling, jumping, climbing stairs, and walking up hills. The pain gets better with rest.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H600345312\">",
"      <span class=\"h1\">",
"       Will my child need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. Your child&rsquo;s doctor or nurse should be able to tell if your child has Osgood-Schlatter disease by learning about his or her symptoms and doing an exam.",
"     </p>",
"     <p>",
"      Most children do not need X-rays. But the doctor might order an X-ray of the knee to make sure another condition isn&rsquo;t causing your child&rsquo;s symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H600345327\">",
"      <span class=\"h1\">",
"       How is Osgood-Schlatter disease treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Osgood-Schlatter disease usually goes away on its own after a child stops growing. This can take 6 to 18 months.",
"     </p>",
"     <p>",
"      During this time, there are things you can do to ease your child&rsquo;s symptoms when they get worse or flare up. You can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Put ice on the knee &ndash; Put a cold gel pack, bag of ice, or bag of frozen vegetables on the painful area every 1 to 2 hours, for 15 minutes each time. Put a thin towel between the ice (or other cold object) and your child&rsquo;s skin.",
"       </li>",
"       <li>",
"        Give your child a pain-relieving medicine &ndash; Over-the-counter medicines include",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (sample brand name: Tylenol&reg;) or",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      After the pain improves, the doctor will probably recommend that your child work with a physical therapist (exercise expert). The physical therapist can teach your child exercises to strengthen and stretch the leg muscles.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H600345342\">",
"      <span class=\"h1\">",
"       Can my child continue doing his or her sport or activity?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Children with Osgood-Schlatter disease can keep doing their sport or activity, as long as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The pain isn&rsquo;t too severe.",
"       </li>",
"       <li>",
"        The pain improves within a day with rest.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      To help protect the knee from getting hurt, the doctor might recommend that your child wear a pad or brace made to cushion the front of the knee.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H600345357\">",
"      <span class=\"h1\">",
"       Does Osgood-Schlatter disease cause long-term knee problems?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Not usually. In some children, though, the knee swelling lasts for a long time, even after the pain has gone away.",
"     </p>",
"     <p>",
"      Also, although uncommon, some children have knee pain even after they stop growing. If your child&rsquo;s pain doesn&rsquo;t improve after he or she stops growing, let the doctor or nurse know. He or she might recommend other possible treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H600345372\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/21/36179?source=see_link\">",
"       Patient information: Giving your child over-the-counter medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/1/30738?source=see_link\">",
"       Patient information: Normal sexual development (puberty) (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?42/43/43697?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 85878 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-ACA0B7D5D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_43_43697=[""].join("\n");
var outline_f42_43_43697=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H600345265\">",
"      What is Osgood-Schlatter disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H600345297\">",
"      What are the symptoms of Osgood-Schlatter disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H600345312\">",
"      Will my child need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H600345327\">",
"      How is Osgood-Schlatter disease treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H600345342\">",
"      Can my child continue doing his or her sport or activity?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H600345357\">",
"      Does Osgood-Schlatter disease cause long-term knee problems?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H600345372\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/85878\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/37/33361\">",
"      Painful and swollen area in Osgood-Schlatter disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/1/30738?source=related_link\">",
"      Patient information: Normal sexual development (puberty) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_43_43698="Minocycline hydrochloride periodontal microspheres: Drug information";
var content_f42_43_43698=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Minocycline hydrochloride periodontal microspheres: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/36/33347?source=see_link\">",
"    see \"Minocycline hydrochloride periodontal microspheres: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F196969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Arestin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F196976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Tetracycline Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3182128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Variable-dose product; dependent upon the size, shape, and number of pockets being treated",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3182129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F196963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder,sustained release microspheres, subgingival [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Arestin&reg;: 1 mg (12s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F196952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F196964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration of Arestin&reg; does not require local anesthesia. Professional subgingival administration is accomplished by inserting the unit-dose cartridge to the base of the periodontal pocket and then pressing the thumb ring in the handle mechanism to expel the powder while gradually withdrawing the tip from the base of the pocket. The handle mechanism should be sterilized between patients. Arestin&reg; does not have to be removed (it is bioresorbable) nor is an adhesive dressing required.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15162768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. May be used as part of a periodontal maintenance program which includes good oral hygiene, scaling, and root planing.",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F196974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Tooth disorder (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (9%), pain (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dental caries (10%), dental pain (10%), gingivitis (9%), mouth ulceration (5%), dyspepsia (4%), mucous membrane disorder (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (8%), flu-like syndrome (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Anaphylaxis, angioneurotic edema, erythema multiforme (oral minocycline), pruritus, rash, Stevens-Johnson syndrome (oral minocylcine), swelling of face, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F196965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Known hypersensitivity to minocycline, tetracyclines, or any component of the formulation; children &lt;8 years of age",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F196956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Autoimmune syndromes: Lupus-like, hepatitis, and vasculitis autoimmune syndromes have been reported with oral minocycline use; no further treatment should be given if symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Anaphylaxis, angioneurotic edema, urticaria, rash, swelling of the face, and pruritus have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: May cause photosensitivity; discontinue if skin erythema occurs. Use skin protection and avoid prolonged exposure to sunlight; do not use tanning equipment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: May cause tissue hyperpigmentation, enamel hypoplasia, or permanent tooth discoloration; use of tetracyclines should be avoided during tooth development (children &lt;8 years of age) unless other drugs are not likely to be effective or are contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Do not use during pregnancy. In addition to affecting tooth development, tetracycline use has been associated with retardation of skeletal development and reduced bone growth.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Use in an acutely abscessed periodontal pocket has not been studied and is not recommended. The effects of treatment for &gt;6 months have not been studied. Should be used with caution in patients having a history of predisposition to oral candidiasis. Safety and effectiveness have not been established for the treatment of periodontitis in patients with coexistent oral candidiasis. Not clinically tested in immunocompromised patients (such as those immunocompromised by diabetes, chemotherapy, radiation therapy, or infection with HIV). Not clinically tested for use in the regeneration of alveolar bone, either in preparation for or in conjunction with the placement of endosseous (dental) implants or in the treatment of failing implants.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F196960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F196966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to Warnings/Precautions.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5946303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Misc",
"     </b>",
"     (Arestin Dental)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (1): $43.25",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F196955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Minocycline, a member of the tetracycline class of antibiotics, has a broad spectrum of activity. It is bacteriostatic and exerts its antimicrobial activity by inhibiting protein synthesis.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10048 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-042A3B073A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_43_43698=[""].join("\n");
var outline_f42_43_43698=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196969\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196976\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3182128\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3182129\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196963\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196952\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196964\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162768\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196974\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196965\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196956\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196960\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196966\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5946303\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323425\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196955\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10048\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10048|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/36/33347?source=related_link\">",
"      Minocycline hydrochloride periodontal microspheres: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_43_43699="Graves retroorbital fat";
var content_f42_43_43699=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F72169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F72169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Graves' ophthalmopathy: Retroorbital fat and muscle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 360px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFoAhwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorxH4o33iCx+KUl7oN1cPFpfh9L2fT1dtlzGZ5UkwoON4U7gf9gUAe3UV88WfjrX9K8FeHVXUxZqdBe+huLmA3DajeCQgW249yMHj5vm9BXYW3irxTeap4wke4tbG10KxhuDZNab5DJJZebtMm4YCyc/dOcY4oA9Xor54vfH/jaz0W61BtYsZPJ0Ww1vy/7PAz5zBWhzu6c5Ldc9NvStzxJ8RNXsfilBpVjeoLL+1rTT5bK4hRWKShQzp/GwySQ5IHIGD1IB7XRXAfAh3k+FuktIzOxlu8ljk/8fUtd/QAUUUUAFFFFABRRRQAUhIUEkgAdSaSWRIo2eRgqKMkmucubi41acxwZS2Xrnp9T/hUVKigrsuEHIv3WuW8TFYlaUjuOB+dacL+bCkmMBlDY+tZltZW8CEKisyjJduSf8K1UxsXHTFY0azqSaHNRWwtFFFdJmFFFFABRRRQAUUUUAFFFFABRXk/xku5bfxH4eXVpZ4vC5iuGm23D20Mt0FzFHPKgyiE9D0zng4rI8G+KdX1X/hFNN8OMNFtNSivpmW9Z9RZBFIoGx3KMQQTjPQHvigD2+ivDtH+IWu6n8TI9FtNRj+yXlxf2qw3ECLLatEjtGSi8gZUD5iSwycCorL4keL7/wAJ6/qtvZIsujwQWM8ZtyxF55mLiTA5IRMHb0Gc9AaAPdqK8AuPiR4ki8LtcJrWjTYv/LF2kkQdofL3bQx/ciQH1IyCOM16d8OoF1DT4fFE73rahqtnCky3MQhwIy+CIxnaTv5OSCApGKAOxoryCDxxr7/EEaaZ4i51p9PbRvs2HSyCEi839cHAP93nA5rmdP8AiDruvaWIX1K2vvtem6r/AGhaQWwQ2CxLIIpC4PViFGD6jA70AfQtFfN0+u+LbHwOulQ60XjfwdBq9tJb25imt9rRIUDq2T8pOX9ecDpVq/1vW4tW1nW9C8SW88ln4ZgvHuPsodLrbLJlQN2F6YJ5PHagD6HorwnxB8TtZt/GWn29ldxxwtcWEU9jPCi71nVCxj6uw+Y/PkAHAwepg0HXtdtVstK0XUI7NtT1vWlknmgE5QRBpFwCR6Y/x6UAe+0V4ToHxC8XyWUlxK1tqc9z4XfWbe2itdnlzJKI8cMS4IJYj1GBjpTW+JGu2+lX80Gr2d/ZQ3mnxJq7WgSNfOz50ZAIB2YB4wRnB5oA94orwi4+ImtroAK6su2bWZrKy1n7LHHBcwpGGBYsCq/MSAVU7tpA6E1W0bxfrms6v4M1HU9bFjbapo84e3EZENxMku3aBuxvYYIPVeccGgD6AorwH4cav4rtdH8MaXaapb3CarodzPZxyWoBt5osbMtuJcEtzn8MV3Xwf8W6v41tdQ1S/iFtYR+TaxQmPaxnWMG4Yn+7vbA+h/AA9EoopHdY0LuQqgZJPagBScDmsu71u2gYrGDKw67en51n3l3Pqk5htcrAOp6Z9z/hV20sLeBcbVdwMl25/wD1Vy1cSo6I2VNLWRpWs32i2jlAxvUHHXFS0yHHlJjpjtT66Iu8UzJ7hRRRVCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqjrN59ksyVOJH+VP8AGk3ZXY0ruyMzV7h7+7Wztz8in5j2J/wFX4YUtIVCjCKOfUn1qno9oYoPObiSTpnsKvMzHLN+Q/nXl1JurKx0PT3UDsG+YjHse1X0+4v0rM3Z+bJx02kd604/uL9K68MrXsZ1NkLRRRXUZBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVn6Bo1h4f0qHTdIg+z2URdkj3s+CzF25Yk8sxPXvWhRQAUUUUAFFFFABWfrejWGuW8MGqQefFDPHcou9lxIh3K3ykdD26VoUUAFFFFACMNykHODxwcVn+HtF0/wAPaRBpmj24trGHdsj3M2CzFiSWJJJJJyTWjRQAVga3dNc3C2Nvzz859T6fhWpql2LS0eQH5z8qD3rJ0a1Ija4kJ3v0J9PX8a5sRV5I2RtSjb3mXra3WzgVVxheWPcn1p7MH+YjAx0P9aGLEkt27Doai3bvmyQOm0jrXFCN/eZfmzTi/wBWn0p1Mh/1SZGOKfXqx2RzvcKKKKYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5l2Op6x6wRn9B/ia1Ndu/s1mVU/vJPlHsO5qDSLf7PaKxGHc5J/kK5cTU5VZG1NWXMWmIZApBB/lTGbrgg496lfAAGahQbnI4BB6etcsI2RaEw3T5sD9a0o/8AVr9BXDaH4nbUvEVzZMifZTuWAgc/L6+ucE13Uf8Aq1+grroKzZNaLjZMWiiiukwCiiigAooooAKKKKACiiigAooooAKKKKACiiigAopruqIWdgqqMkk4AFcdq/ju1tpGj0+E3RHHmFtqZ9u5qJ1IwV5M0p0pVHaKOzorzYeJvE1589paEIeR5dsWH5mp4/FPiGz+a/00yR9yYWT9Rx+lZfWYeZs8JPuvvPQqK5HT/HenXHy3cctq3qRvX8xz+lXJ/GWixD5bppD6JGx/pVqtTavcydConblZ0VFcmfHmk5x5d39fLH+NXbHxdo92wUXPksegmUr+vT9aarQezB0Ki1cWb9FNR1kQOjBlPIIOQadWhkFFFUdYu/slmxU/vH+Vf8aTdlcaV3ZGTeOdS1dYhkwxnHHp3P8AStU4MYTG09B7VS0a38m181gQ8hzn0Harz4Gec15k5e0nqdD7LoRs3pjjtmm4bGPmAHOfWlHLkcAj071y1j4oe58WzacUj+x7mhjYD5tw7k+hIIxWiVyoxbvbodzD/qkx6U+mQ/6pPpT67o7I5XuFFFFUIKKKKACiiqmpalY6XAs2p3ttZws2wSXEqxqW64yxHPBoAt0Vmab4h0XVLk2+mavp15cBd5it7lJGC+uASccijVPEGi6TOsGq6vp1lMy71jublI2K5xkBiOODzQBp0VT0vU7DVrdp9LvrW9gVthktplkUN6ZUkZ5HFZ9x4v8ADVtPJDceIdHimiYo6SXsSsjDqCC3BFAG5RVcX1odP+3i6g+w+X532jzB5ezGd+7ONuOc9Kybfxl4YuJ44bfxHoss0jBEjS+iZnY8AABuSfSgDeoqnquq6fpFutxq19aWMDMEElzMsSluwyxAzwePaqul+JNC1a5NvpWtaZe3AUv5VtdRyttHU4Uk45HNAGtRWTq/iXQtGuEg1jWdNsJ3Xesd1dJEzLnGQGIOMg81Y0jV9N1m3afR9Qs7+BW2NJazLKobAOCVJGeRx70AXqK5+58a+FrW4lt7rxJosM8TFJI5L6JWRgcEEFsgj0rWGoWZ03+0Vu7c2Hlef9pEg8vy8Z37s4245z0oAtUVzlv478JXM8UFv4o0OWaVgkcaX8TM7E4AADckmtXWNX03RbUXOsahaWFsXCCW6mWJCxzgZYgZ4PHtQBeorG0fxV4e1q6Nto+uaXf3IUuYrW7jlcKMAnCknHI596Nb8VeH9BuI7fW9b0zTp5E3pHdXSRMy5xkBiMjPegDZorO0TXNK162e40TUrPUYEfy2ktZllVWwDglSecEce9Zd5498I2V1Na3nijRILmFzHLFJfRKyMDgggtkEelAHS0VUTU7F9K/tNLy3bTvK8/7UsgMXl4zv3dNuOc1gW/xF8F3M8UNv4r0OWaVgkaJfRksxOAAM8kk0AdVSMwRSzEBQMkntVDXNb0vQbL7ZreoWmn2m4J51zKsabjnAye/B49q4u08faN4v1Z9J8OalaXhRPNPkzKxcA4JwOQoyOaic1BXZcIOTN5c6tqhcj9xH0B9O351tfLsYE8DqK5zUfE3hzwq0VnrWuabp1y6eaEurhY2cEkbgCemQR+FXtE1zRvEFrJcaFqVnqMEbeW8lrKsihuDgkd8HNeXUk6juatp6IvbdsYTjdjv61X1Gf7Npl5cDOYoncfUKawr/AMf+ELK9ntL3xRo9vdQOY5YpLtFZGHUEE8EVb13ULS58FahqFrdQzWMlm8qXEbhkZNv3gw4I963Ss0UrNnB+Awf+Egsj3y2f++TXtCfcX6V4B4A8Y+GP+EitFPiDSw7ZRF+0LlmIwFHuSele2azrml+HtMS913ULawtcrH51zII13EcDJ78GuqnuVi2nJWNSiue0Dxt4Y8Q3xs9C1/TNQuwhkMNtcLIwUEAnAPTkfnS+IvGnhrw3dR22v67p2nXEieYkdzOqMy5IyAe2QfyrY4zoKKyfDviTRvEttLceH9TtNRgify3e2lDhWxnBI74IrI1H4k+C9Nv7iyv/ABRpFtdwOY5YZLlVZGHUEZ4NAHW0VRttW0+60ddWt7yCTTGiM4uVcGMxgZLZ6YwOtc3a/FDwPd3kNra+KtImuJnWOONLhSXZjgAe5JoA7KisvxF4g0nw3YLe69qNtp9o0giEtw4VSxBIGfXAP5VneHvHnhXxHqH2HQtf06/vNhk8m3mDNtGMnHpyKAOlornvEnjbw14YuorbxBrdhp1xKnmJHcShCy5IyB6ZBqx4Z8UaJ4ptprjw9qdtqMML+XI9u+4K2M4P4UAbNFcdqfxO8E6XqFxY6j4m0y2vLdzHLDJLhkYdQRXRWesadeaKur2t5DLpjRGdblWyhjAyWz6YBoAv0VxNr8V/Al1dQ29t4p0uWeZ1jjRZclmY4AH4muh8SeItI8M6eL/X7+CwszIIhLMcLuOcD9DQBq0jMqKWYhVAySTgAVw9r8WPBV/c/ZtL1231C62lxDbZdiB1PTH61yfj34qaVDGNOu7yDTFnXcfPf55EzjsMAZFZTqxhp1NqdGU9dl3NvX9YufEt+bDTW2WCcu5OAwHVm/2fQVa8LxaN/p409VvZ7OIs8rDJZsHAHZenua8+iVPG3hK4tvBuvW3nJMDcshJWXj5Yy2OPWvPLfxxqvw/v9R0xtT0xLoZgnjEyvtI7exrpwmChVg6lSa5+z0sOvX5f3dP4V+JrXvjj4lanfPvn07SLQNwscZmfH1bj9BU938Qde06PP9rF5AMcIoyfwFUtP8N+Ldf0pdXVbW10iSI3H26edVTysZL4GTjAJ6VseBIvhnpuoW8+oeL9P1rV3cLDHhhErk4GAR8xz6169sJh462k/v8A+GOT3mdb4P8A7Y13QZNR8TxRB5yPsoEQjk2/32x1B7A1uafZaXb4W/tpZWz98ucD/gIx/WtXxPrGmeHrA32vXsVlabxF5sudu45wOAfQ/lXO6R4y8LeIdQFhoutWd9dsjOIoiclR1PIrwcTSp15N2tftodMK1SCsmdlDp2jTRg29jA6nhWCZGfSo7zwtpc2FWEwu3GY2IwfociuN1/xZovhG9iXU9Yt9PuJU8xI5SfnXOM8D1rovCPjDQ/FdrcXOj38V69uyrIY8ny2I+nfmvncXha2F9+Mm4nRTrOWl9Ss+ma14eLy6TdPLApy0YGcfVDwfqK6Xwx4rg1Yi3uQtve/3c/K/+77+1c1q/wAUfBWjanPp2p+I7a2voHKTxsr7kb04XFPvrTSNd0Qa9p17GlqYTci7CkJJGBncRjPAB5FaYfGVaTSqLR+pcnCqrT37no0jrGjPIwVRySe1c27Nq+oZORbx9Pp/ia808OfEPwpczpZT+M7K5lmlSOBMysSTwANyjHJFek6/rejeENGF7rl7HY2CyCMyuGOXPToCecV6VWu5JJK1zBRjTbs7m4oAQLgBcdKgA2xhe59fWuW8N/Efwh4p1IaXoOu217fOjOIo0cEqOp5UCpvFvjrw14SubeDxHq8Ony3CF4lkVjvUHBIwDWNOEk9UJNHQyy+TBNKf+Walj+AzXkvhBmk8QWEhPzPOGJ+pya7jS/FmheKvD+q3PhzUodQgt4nSR4wwCsUJAOQO1eR6D8QPCeieJIYtX1qC2ktZCJVZHOwgHjhT3rpgnqdFKSUZNn0jD/ql+lOrP8P6pZ61otnqWmXC3NlcxiSKVVIDqe+CAa0K647I4HuFFFFMQUUUUAFcx8QfA+i+PdHh0zxFFNJaRTi4URSmM7wrKOR7Ma6eigDz3wD8IfCXgPWX1Xw9bXMV48LQFpbhpBsJBIweOqipPH/wl8KePdWh1LxHa3M11DCLdGiuGjGwMW6D3Y131FAHNeAPBOi+A9Hl0zw7DLDaSzG4ZZJTId5Cg8n2UVxesfs/eAdX1e91K+sbxrq8ne4lIu3ALsxZuM8ck16zRQBjL4a0xfCH/CMiJ/7I+x/YPL3nd5OzZjd1zjvXAaT+z/8AD/StUs9Qs9OulurSZJ4mN5IQHVgwOM88gV6xRQBzfjzwVovjvR4tL8RwST2ccwuFWOVozvAIByPZjWH4E+EXhHwNrTar4dsp4L1oWgLSXLyDYSCRgnH8Ir0CigDhfHvwp8J+PNUg1DxLYzXF1DCIEZLh4wEDFsYUjuxrV8B+CdD8CaVNp3hu2kt7SaYzurytIS5AXOWJPRRXS0UAeV6z8BPAGsave6lf6XcPd3kz3EzC8lUM7EsTgNgck13cPhrTIvCQ8NJC39kCz+weUZDnydmzbuznp361s1yHjPxN9hT7Dprhr1+GZefLHp/vVE5qCuy6dOVSXLE85vvhX8MPCeqWtzZ6PcSapaypPEq3spCOpDKWy2OoHHP0rW8a6Re/EvR49P1fTF/stZlnQeYYvnAIB3ZBPDHpWJrniXT/AArL5EkSX2vv87LKfkgz6/3mqx4z1f8Atz4UQJ/wkBttTmlEkxs5vLkxk/KMcgdK0hgsRVSnL3U9jWVSlS92Ku+7IPCHwni8Faq2p+HEitL5ojCX+2M+UJBIw3HUD8ql8beDrbxPfW+oeN9BOrPbxeTHNHcPGFTJOMxNjqT1FePWlla6ZJ9oe/vJ7jH+smu3c/qa6LwpqfijVNVjtPClzehgf3kpcmOMerE8V1/2NNR53Ut+RCxSejgme2fDCLwb4T0qXTvD0LaVFPL58kU8zuC5AXIdieyj0rD8RfCn4U6hqd7quq2yS3l5M88zJfyks7HJIVW45PYVr3uiLLawieTzb1VxNcIoXzW7nA4puneH9NdwLm4nEmf9WwCg/jXj1qtWgm2rpdUaxjQn1a8gm13RLTwuvhnS9Mll0dbQ2IjllZcw7du3PLdOM5zXnVj8KNA+2219o/hVraS3lWWKQXEx2spBBy74PIr2+y02wss+TbwooGd4X5m/E81cmlEIRyML1Oeg9yewryJ5nVm7Q/r7jZKnHSMfvPPPEPgS58cWq2fi2dp7QSCbyhKwwwzgjbgDqav+B/hd4T8D6kdR8P2MkF+YjbvK87vuUkEjBOOoHata58R2sdyWhmeQdCYoSw/MkfpU9hq9pdzJ5bvvVtziRShA9cdx9DxUzWMa5pXt6/puXOlJrmcbfIo+Nfhn4U8a38OoeJNK+2XcMIhR/PkjwmScYVgOpPNXvBvg/QvBWnT2fhmwNlazS+dInmvJufAXOWJPQCuiaX5wQDjvUb4JGB15Nd1Ntu19EcaR418Tfhb4Ibz9Tm0UPq2o3Jkkm+0y8k/M7bd2P071s+GLG3g+FWsaUqEWEUT26RlicIUAK569/wBad46uzea20KnMVqvlgDpu6t/h+FNtNTtbXwXf2Rf/AEueQgJg8g7efpgGuxXtqdkaSUFpqzkPh38KfBra7HO2jgyWqieM/aJfldWUqfvc4Ne3+LPCujeMtETTPElmLyy3rN5ZkZPnAODlSD3Ncb8OV/4mFwf+mH/swr02L/Vp9BWtNtyZzYqKUtEcZ4O+Fvg7wbqzan4b0dbK9aIwmQTyv8hIJGGYjqoqTxl8NPCXjPUob/xNpCX11DF5CO00iYTJOMKwHUn86ueKvGuj+F7u1tdUa7NxcxySxx21rJOxSMAuxCA4AByT6VetvEmi3Gl2GpJqdollfKGtpZZBGJc9AA2Dn261scpV8GeDNA8F2VxaeGdPWxt55PNkRZHfc2AM/MT2ArntZ+DHgDWdWu9S1Pw9HPfXcrTTSm4mG9yck4DgD8K6mHxPosusajpa6jAL7T1RrmNzt8sOCQcnAPAOcE474q3c6vpttGj3OoWcKO/lq0k6qGf+6CTyfagCGx8P6ZY+G00C1tRHpCW5tVt97ECIjBXJOehPOc1x2nfBP4eabe215ZeG4Y7m2lWaKT7RMSrqQQeX5wQOtd3PqNlb3kNpPeW0V3NzFC8qq8n+6pOT+FZnifxXpXhzRL7U72cSQ2Q/exwMryD5lUjbnqCy5+tADvF3hXRfGGlpp3iSwS+sklEyxM7KA4BAOVIPQn86x/Cfww8HeEdV/tPw7okVjfeW0XmrLIx2nGRhmI7Ct258QWEccElvKt6kt2lkTaujiORjj5vm4x3HX2qvp3jDw9qNhcXtrrFn9kt5jbyyySeWqOCRg7sdwcHoccZoAoeMfhz4T8ZX0F54m0eO/uYI/Kjd5ZF2pknGFYDqTV7wf4O0DwbaXFt4Z06Owgnk82REdm3NjGfmJ7VI3ibTf7d0vSopDPNqUEtxbyxYeJkjxu+YH/aGMVt0AcDrHwe8Bazqt1qWp+HLe4vrqQyzStLKC7HqcBsflXV2Gg6ZYeHk0KztFi0lIDbLbhiQIyCCuSc9Ce9adFAHmq/CD4b6I6akvh21t2tGWZJTLKdjKQQeW5OQKz/FVsPiZjTLuyR9HhlEpSQnAYZAZsEZOCcAf/XrU8S3s3iLxAmk2cmLSJsMw6Ej7zH6dBXS2dtBp9iILSNwEOVCjJY+p9TXj47HuD5IHdTpKnG8ldv8DjfC3wn8GeG7r7ZY6Un2zBj8wu/APUbd2Kp+L/BvhnxXqkB1HRba4W0QwxudynGckfKRxnNd5ql0tvYvLG37zbtzjnJ4FZGnxAID3NTlcZ1ZOvN36IxrS+yUfCXhPRfC9tNb6Bp8dlFM4kkVCx3MBjPJNU9R+F3gvVtRuL/UvDtpcXlw5klldny7HqThsV18SVcjSvaOczLXQ9PttDXR4LVE0tYDbC3BO0REYK9c4wT3rmbX4Q+A7W4huLfwxZRzQuJI3DSZVgcg/e9RXoKJmpRF7UAc74j8O6X4k0/7FrtjFfWm8S+VLnG4ZweD7msPRfh94W8Pagt9omhWdleKrIJog24Keo5Nd40XtVadMA0AcB4t8FeH/ElxFca7pNvezwrsjeTdlVznHBHeqGg6JpvhB3PhyxgsVdg0iR5xJxjnJ9K7e8XrXP6kgxkUmk1Zgc1428D+F9ZuYdXk0CzlmvJGa4mIJZnIGM8+zflW/pWl3Gk6KunQRJNo/kmA2DE4EZGCqk9OCa0vDEiy+ZZzBWQ/MFYZBHcfng1tNbospjVnTbg4ZScD6jr+lefN06T9jN2XS/Y9TD1oOnyuKOV0D4Z+ARJbXVn4a08TxlZopQjAqQeDjPBBH5iu18RaBpXiXTzp+t2MN9ZlxIYphldw6H680um27QS/ulAiAPXgsSck+w9q0MkqcnBB6VxRnq+VtpM5akY83unKaF4A8J+HNRXUNC0Cysb1EZBNCmGweCOvesf4s+HtA1XSY7nWdItL69H+j28kykmME5bHPtXfN1479a87+IF39p1aO0Q/u7ZOQP77cn9MV3Ur6Nl0YKUkin8M9H0/RPCfiODS7OK0idS7CMHk+Ww7/Suf8KeA/C+s+IvO1XQrG7klV5JGlQku2Op5rptF1K1sfC+r28kgW5myETHLZXH+NSfDxf8Aic59IW/pWt2rs3lFJT0PSdE0+00vSbWx023jtrOBAkUMYwqL6AVepkH+pTPpT66Y7I8x7hRRRVCCiiigAooooAKKKKACiiigAooooAKKKy9c1yy0aHddSZkI+SJOWb8PT3pOSirscYuTsjUrI1bxFpmlMUubgNKP+WUY3N+Pp+NcdPrWueJGaLT0+yWvRmVsce7/ANBViy8KWdtGsty5vJiR8n3VJ+nU/jXnYjMoU7qO51xwqj/EfyRDf+KNU1x3ttHga3hPDSA/MB7t0WqOl6UsMu8sJZR/H2B9v8a6DVJVRVsraNYkIyyIAAB6cUtrAFAFVhFOsvbVfl/mTVqqK9nTVkYfiPwdo/icK2q2ubhV2rcRHbIB9e/41xlx8EbZ3P2bxBdRxZ4WSEMQPqCK9fij4qwkdezSxlakrQlocjimeV6R8FvD9o6yajdXuosP4GIjQ/gOf1r0LTtMtNMs1tNNtYbW2XpHEu0fU+prWEdBjqKuIq1v4krgklsZrxcHiqF3CpBBFbjx9azruLrWIypaagylLe8Akh+6rk8r9avatZG606WMzsEkCj5hwCrZ59vWsS5TGQRwauadq8Ye3s7mXbIzYTd/GB7+o/kPavJxmDVN/WKK95dO500KslJImg0rykH7oNx94EEfnUsGmiG7jufLDtjaApBAB4JP4Z4qfXZBFbDydMn1GTcCIrcxBz75kZV/Ws1fEup7wF8H66MYBHm2X/yRXG8fOorRSXz/AC2OuVeTR1nmKVC+tUtSu1sbG4umxiNCQD3PYfnisZ/EWohR/wAUfrwPQEzWPX/wJrlfGXifUJhBYf8ACM6xDj95IrS2mT6fdnPvXoUoPqc1OPNKxmiN5WZ3OXYlmPqT1qvdwGNN3vTrO/vyvHhnV2HtJa//AB6m6xe362QZvDOrxqW4ZpLXB/Kaumx6HOjrfh0v+lXZ/wCmIH/j1ekRf6pPoK8f8CazfwzXRj8L6xPmNQfLltBjn/anFd3F4i1QRrjwZ4gxgf8ALax/+Saqn8TPOxTvI5z4pfD2/wDGmvaVc2mpf2fb2tndwPJFK6S75FAXAUYZMjDAkZBIrm9X+FWuala6K1wuivJa6T/ZNxZJPJFBtDEiSNxESCwI3DaOQMGvSf8AhI9U/wChL8Qf9/rD/wCSaP8AhI9U/wChL8Qf9/rD/wCSa3OU8+1b4WarKfEqWS6IRrGl21os0rOJYJYk2tg7CSr9S2c8DINaHiv4ZSzyW7eHbTQkh/sqfTJLS5jMcUTSlSbiMIpzJxzkDPqK7ez17UZ7qKKXwprdtG7BWmllsykY9SFuC2PoCfasD43alq2meBXl0G5Frcy3dvbvNuKsqPIFO0gHBJIGewJxzigDmdR+FGqSXMkMF9YXFtcx6akl/chhd2ptAoJhABB37cnLLgsetWNW+Ftxe+G/HUCR6T/bWuahLPaXjg7o4GaJhG77Nw5RjtGRkiopfiHqWh+KtN0BY7XULJL610i5mLSNKk0irkmRyNxDEnhTwBkgnA6H4P69ruvafrMniK4sp5LbUJrePyOGUK7AqwwBtGBtPU85oGYKfDXWJtTbUpf7GspZdb07UHsrNn8iKG1BB2nYMyNu/ugcDmq6/DLXrPSL/TtNXQI4JNYN8rLujkntyZD5bMIiYiu4BSu7gsMjv6HL4h1NJXVfB+vSKpIDrNY4b3GbgHH1Apv/AAkeqf8AQl+IP+/1h/8AJNAjjfh/8OdX8Oah4ZmvLiwaLS479JFhkdv9fIGTbuUZAA5zj8a9Xrmv+Ej1T/oS/EH/AH+sP/kmj/hI9U/6EvxB/wB/rD/5JoA6WqOu3w07SLq6PWNDt92PA/XFZH/CR6p/0JfiD/v9Yf8AyTXN+O9b1a80lLdPCeuQkuHO+WzO4Dt8twT3FRUbUW0aUoqU0mWPAdkY7Ce9bAkmbYGb+6Ov5n+VdTC7MPlYEoMH0Nclp2r6ja6fb26+EdeJiQKcS2WM/wDgR65rqIpTLDE0sDQyFVJiYgsvGSDtJHHsSPevkKzbm5M7Zy522YXiVmMtpEXyDufH5f41YsgAqis3X5431eFFcFliyy91yxxn8Kv2Z6V9VhKap0YxXY4Ju8m2a0Iq5GKq2/Iq5HXQSWI1qWmJ0p+KAEI4qrcLwat9BVa4bg0AYd6Otc/qWNjV0F+2Aa5nUpOGoAwNZvJrHSp720cpPalZlI7gEZB9iMivS9Ovo7vTba5tzuFwiuPoRmvKfETj/hHtS94WFdP8GtS+1eFfs87fvLGRoAf9k/Mv8yPwrw84hdRl2PSoU+bDOfZ/mjubcSx7cOrJu6dMVabaw3EfMaqRrvaGTccFuQO4q5IygEk4wf1rkwC5lYxnuV7udLS2muJP9XEhYj1xXlLLJdzyzynLyMXY+5rsvHF4UtoLBCN0x8yTH90Hgfif5VhWlv8Au+nFe3BWR00I2XMYN5bGOMtjiuk+Hi/8TVz6QN/MVW1i1Yaa0m07cgbscVe+Ho/4mEx/6Yn/ANCFN7GlX4GekW/+pT6VJUdv/qU+lSV0x2R473CiiiqEFFFFABRRRQAUUUUAFFFFABRRVPVL5bKDceZG4RfX3+lJuyuxpNuyIdX1JbRPLiw07dB/d9zXLJ4aR719R1N3mDkERuc8/wC0f6VtaVZmWT7Xcnc7HcoP860XXzFZG9ePrXk4yo6sXGJ1U5ez0XzKalAI0ijVIlGAAMAfSleVIyzKqhEGS3AxQXcupfjacYXrVPXP+PKfGdpUcHjuB/WvEoU3WqKnfdlyfKrmVagzTPM/LOSa1oE6VRsVwq1qxLxX2KSirI4SaJKtJHmo4hwKtxjimA0R01o6npDQBTZMVSu48jpWpIKpTjigDnb6P5TXJa/byXNjMISVuIv3sLDqrryD/T8a7XUcBTXMSMDOy0mrqzKhNwkpLodd4a1GPWdFtb+DarSRgsp7MOGH55rRhG+QySnD9AueOvWvPvhNcgLqmlSEj7NceYhz/C2QR+a/rXoT7JZYgF5Vuo9BzXyE6Vq7h5npV4ezm4rb9CZVIYIee5PvXmt7Mb/WrmcnIaQhf90cD9BXoGrTm30u9nXkpExU++MV5/o8YMi19HTVkLDrdm7b2+yBQo5bAq744jA8NsqgYikjAx25xViwi33EK9lO4/hR4vAfw5eexT/0IVUnqkE5e/FGR8Px895/uL/M16BD/qk+grgfAQw15/uL/M130X+qT6CtKXxM5sX8Y6iiitzlCq9/Y2moQeRf2sF1DuV/LmjDruU5U4PGQQCDViigDKuPDeh3OqDUrjRtNl1EMri6e1RpQy42neRnIwMHPGKs2OlafYXN3c2NhaW1xdsHuJYYVR5mGcFyBljyeT6mrlFABRRRQAUUUUAFc3ft9v1pYhzHGcH8OT/hWtq94LO0Zgf3r/Kn19az9DgEcDTP/rJOmfSuXE1OVWRtTVlzFiaKRZVlj24xjb0pFkYN91nIHOBwKsMpKlR3PBPaoFLoSuN5HYHrXzOIpckrrqbJ3Wp49aX73XjfX8tkIwVeeyMV/qK7iymyBzXm9tt0v4m3lvc/LFcXUtuxPYSnch/76KV2lvKbaYxS5DKSpHoRX0mCqKULf1qa5lSUKkZR2aX5WOvtJM1oxt0Nc3Z3QwOa1obkEDmuw841UkHrUnmj1rN870NBm96AL0kvHFU55ODzUTzgDrVG5uwAeaAK+oTAA81yeqT5JArU1G5znmueuG8x6AMPxZNs0N488zSJGB685P6CrHwXvjbeKbuxc/urqDzMH++h/wAGb8qxvFswk1G2tV6QIZW+pHH6fzqPwjN9g8c6RMDtDT+Ux9mBXH/jwrycd+8Ukuh9Pg8PbBOL3km/8vyPoVdnnkKcrwR7VKoIO08knOTUEwEpjUKMbgMj/PtTryfyLa5n6+XGzg+4FcWWxvFvzPEl0OB1ec3/AIhuXzlVfy1+i8f41pRRbY+BzWPoyFnDNyTya6qyh8y4hXHG7J+g5r2ju0ivQf4rhCeFLiMAfulQ/Q7hk/qaxvh+P9NuP+uP/swrpPE3z+H9R/65f1Fc74CGL2f/AK4/+zCs07o54O9KR6Fb/wCpT6VJUdv/AKhPpUldcfhR5z3CiiiqEFFFFABRRRQAUUUUAFFFFADJZFijaSQ4RRkmubj3arfNNMCIE4C+3YVZ165aaZLKDk5BbHr2H9au28K2tusaLlccnuT3NcWJq291G8Fyq/VkhZdwA4GPypAdrcdPXuaHKsnqKhZ2I/d7Sc85NcsKd9WNIhuWeKcOu3D/AChjxg9h+NUdYVxZTeYQWwh4H+0K1JUE0DowGSPyPb9a4v4h3clppWnX+/8AdxXSCbacjYwI5/GuXkjQxUJ9Hf7zaMHVXItzUtGAC1rQHIrnLacYHPHatqymBAGa+hOE1YzwKtRniqUbcVMjYoAtGkqMOPWhn4oASU8VTnPBqaR6zrybAPNAGXqr8GuZUFrontWpqlx1ANZ2no01wqgZZmAFGwGJ8PbvyvHt1Hj5LtJo2B9VfcP6168mVnKgjywmQAOnIrxLTJBZ/EwE8LHqcsR+jZH9a9rhjVZdynJKc9+9fNz97Ewl3X+Z7ePjZxfdIr6xC1xpF7EmSWhJAx6c/wBK4TTnEbrXo68MGA5PUn/CsiXR9LtGkvLj93Ch3nzHwg/z6V60ZW0OWlUULpljRl/cG4fgNwufT1qr4wbZ4dnBxmR0Xjp97P8ASrem6tp+qM6WFyspjXlApGB6gEdKyfHkoXTrSEf8tJd2PZR/9ejeRKblUVyt4FOLm4X1iB/Ij/Gu+h5iTnPArgPBXF+49Yj/ADFegRcRJk9hW9P4jPF/EOooorc5AooooAKKKKACiiigApHZUQsxAVRkk0tYfiG6LFLOHJdyC2P0FTKXKrlQjzOxVJbV9Q3MCLePjHt/ia2dp3ArhQowAahs7cWlsqKMnqx9TUxYY4rypydSRu30QpPHPf1qtcK28GMkFiNpA496V3Yg+XgnPc04gvGecOBkY9axxOHU6btuhx0Z4d8V7JovGMhzj7RbpKrjj5hlc/mBXWWcw8QeHLXWYR+/27LpB2kXhj/X8aq/GezX+zdN1GLLNBKYpG/2XH+I/Wuf+FusnTvER06ZmFpqRAA7LMv+I4/KsaFWUacasN4/iux7VSj9ZwafWP6f8DU6a2u2jODWva3wIHNS6xoO/NxZIfmJynT8R/hXOTRzW8jKQyMOqsMEV7mHxNPER5oM+dlBxdmdWt77043ox1rkBdyrwc0jXrnua3JOomvwB1rLudQznBrHaeR+5oiikkPQ0APuJ2kJFWdJ077VI8k+VtYVMkzdMKBk1f0nQZrp1aQFIj/Eep+gqX4kyRaP4HvY7RjG0qi2AB6lyAf03V52Lxyg/ZU37z/A6MPQdWai+p4+9w2p6heXzrtNw+VUfwqeg/AbR+FR6gzW0sc8ZxJDKJFPoRgj9RVjTEG2IerD+dGtx4WQ44BGfzNZKNo2PslZPlWx9EWkyzeRLEAElTzT+IBz+tOv4muLC6iXJMkLKOMc4NYfgC5N74W0adjlha+UT7qQv/stdGM7lYD5u+eKxwS5YW82fKVY8k3HsedaW4iZc8V2mirlGuG4XG1Sf1qOfRtNjmlvJwY4xmR9z4Qep+lTabrGm6jM0Gn3KSNGudiqQMe2RzXe5XWhdSrzR91EXid9nh2+YkfOoXjpywFYPgc7dRYf3oj/ADFafjiXy9EjjHWWZR6cDJP9KyvBvGqx+6MP0oj8I4L90z0S3OYU5zxUlMg/1K/Sn11x+FHmvcKKKKoQUUUUAFFFFABRRRQAVFczLb28krdEBP1qWsPxHOW8q0j5Zzkj+QqZy5VcqEeZ2INFiaWSW7l5ZjgZ7k9a1mZgyhvXtUdtCsNvFEvUDH+NPbjJJryb887m7d2RyMFI9+2M1GFYqQ0a/hTtwK5LDB4pNgKlSpwDxz1rcZIhOBuGDXO+MNLTUvCl/p8IBmKHYB3ZTkD9K31+UgDGwDrmogI1uZSyAMPnVu5z/wDXFcGOVoxmujNKcnCXMuh5d4Z1I3uiwkn99CBFJ+A4P4iujsL/AAcE8iuIvYv+EV8ZT287GPT7ghtxHSNjkN/wFsj6Ct+5SSzuGVxh1/Ij1HtXr4auqsELHUFSnzR+GWq/yO3tL9WHNXlnUjg1wVtqIGMnBrTh1PAHzZrpOI64Tj1pGuFx1rmf7SGPvVDLqfHDUAdBcXigdaxr6+UKeax7nUGOcHmsye4eQ4BPNAE9zOZZeK6DwrZGSbz24RDgH1asfSdNku5lReCeSx6KPU129pDDb26QKchWwBn8zXmZlilSp+zXxM1pQcnc8P192tfFmszjrDqHm5/EH+le7WhQ7HRyd6lsH04NeIeLogfFfiSPHBkVh+KA16z4IvFv/C+kzuczfZgpP+78p/lXA1rSl/Wx7uPV6MJf1sjYvbq3sbaS7unEcUY5Y859h7+1eW+INZudfusvmOzQ/uoc/q3qf5Vr+PbiW41cWhY+RAqkJ23EZJ/XFZVpacA4r1oxscVGmkuZnQ/DyyMct3cY4CCMfUnP9KPHUpfVbWHPEcO7HuSf8BXQeF7YW+jx8cyuXP8AIfyrkfE8nm+Jrv0Tag/BRQtZCi+aq2avg4Y1H/tk39K7+P8A1a/SuC8IjGof9s2rF+L/AI+1HwhqejW9nd2lpbXVpczyTTWb3PzRqpRQqsCAxOMngZyela0/iOfF/Ees0V5Te/FefSdN0WPUNEe51q60tNTube2lARI2OBs+8WYkHC/rSt8Ub631PxbLc6Iz6Lo9nbXkbq4SbbKhYBwSeW7AAbcHPatzjPVaK871P4j3NkyQjwzeG+FjLqkttJcxKY7SMgeZuUsCxzwuc+uKiu/ixZI8txaaZdXGj2sdlJeXvmKhgF0FMWIzy3DqTgjGe9AHpNFeTeNfiRqUfhfxhc6DplxbPok72h1GRoni81HjGAhO45Vz/Dgeuau6h8Q5hqa6ZcWV1pWo2+s2FlNGrRzCSO53FDu6AEKc45GOCaAPTKK8o0b4n6o3hm/1PWNEtopYtTewgjW6VBKQzgqBlmZ12gHaDuJyBgHFjw38QbjxN4m8KCyie00/UbW+a5tZVUsssLqo+bGcZz6deRQB6ZNIsUTyN91QSa53Ska5upryXrnj6n/AVc8SXBWBLdPvSHJA9P8A9dTWUC29pHH/ABd/r3rixVS3um8Fyxv3JmZhgMM5PaopH24POCfTNSOMHOSccVCXBBbcMZxXPTVkUhqqTuDRrj2qWMkAZGCPSo9gwVKnb2560q/KQFA2Dqc9K0GYni/Sv7Z8OX2mgHe8RKH0ccqfzAr5+geR4w8ZaK4jIkRhwUkX/wDV+lfTbsVckDIYDp1r588U6d/YnjLUbNVIhd/tEIP91+cfgcj8K8zDfu6kqTPayupdSpv1/wAz2Dwlrn/CQ6DbXqkFk+SeIdVkHX8O49jWvcW1tfMRcxKABxuHP4GvHvh1qw0bxM1lKcWepYC56LKPun8eV/EV7MjfaHOzC7Bg7hXFVjLD1PcfocmMoKlNq2hhT+G4HDNDI6gH+Jcj86o3Pht7aNpGljbaM7QDkiurLFYv3m/cewHBpk8qPbbWQ5bhuPzrohmdeDSk7+qOJ0U9kcfDYKw4AqS0Cw6nBHIoKlwCKt2A2TSRE52MV/Kq2sx+VOsijkYNfTSSqQaXVHItGdhJ9+I27KGzgg+leYfG+6KwaRZBwwkke4fH+yAB/wChGvSUMUkNvcQ7RI+Cvvkd68e+M83meK7SE4zDaZIA6FnP9AK+SwkX7ZJ9D28vjzVo+VzA04bTAPQp/MU7WUJjuB6j+tPslzdxr28xR+oqbWF5kX1Q/wAxXu9D27+8eg/Bm5E3hZY9xzBcyx4+oDf1rvLiaG1ge5uXWOKNdzSE8AV5b8C51K6xatjckiSp68qyn/0Gtr4gXE0t/FY7iLeNFfYO7HPJrPDQ+Jef+R4GMp3xMomP4l1241648tN0Vgh+SLu3+03v7dq2fh7Zlb+efHEcW38SR/gawrS0JxxXf+ErYQaWz45lk5+g4/xrseiJq2hTsjH8fSk3VhB2VGkP1Jx/Sm+ERjVYf91v/QTVTxjIZPEbr2jiRR+Wf61d8KD/AImcJ9m/9BNC2BK1L5HoMH+qX6U+o7c5hTnPHapK6YfCjynuFFFFUIKKKKACiiigAooooADwMnpXNWeb3VZrluUQ5H8hWxrM/kadKwPzMNg+pqjo0QhslZ+smW/DtXJip2jY2p6RbL/ynOOMVDKAE2gA57E+tSkKwIPHHbio2Kqm5iAijkk8DFcdIpDONuSdqgZJzwMVlTeIbKN8Issoz95VwP1rN8Qas1whgtci3z8z9PM/+t/OsaUBUCjtXUo9zrp0Lq8jurW6gvYDNbvkDg8cqfQinXKsVV0IDoeT6r3/AMfwrldCumstRjVz+7nwjj0z0P511+dsmBgMTk+9ZVqSnFxezMqkPZy0OH+KOjrqnh37ZbqzXFjmXpy8Z++Pfj5vwrnPh5fJrNi2h6g/+l2w3WspPLRenvt/kR6V6iyrHI8coDRsuI1PQjuP89q8I8WWV34P8TqNNt55ngYXFqyFB+7P8LbmGQOVOO1eVh+dXpXtKOx6OH5a9J0J+qO31TRLqyYl1ynZ05H/ANasz98nriuk0TxpNquki5tPCmtyxuSrFZbTCuOo+acHg+oFJdXMtynmN4K1tSerJNZL/wC3H9K9ClmdvdrLVdmjyJ0HF2ObM8o7mkMkrHqa2Xtrk4P/AAiniJQTx+9sT/7cVUvheWexj4V1wIx2/PJZdfwuDXdTxlGo1GMtWYuDRXjid8ZNbOkaQ91Jw2FH3m64/Cs/7defZzt8KaznHXzbP/4/Vnwz4jv4Z5Ih4X1iUkZ2rLaZ4+s49aeLnOFKUqe4QSbszurO0jsbdPKXK9T6n3NTbwsiyMmM57Vzv/CQamCo/wCER14Ke3m2X/yRTU13UzPhvCevGMDgedY9f/Aivk5Kc3du7fmjsVkjgfGMJTxrrqkYLxxSfmoFdn8Jbrf4aNq5y1vcTIvHQEhv/Z68+8Y6reN40unk0DVIjLZoPLkkti2AeuVmIxx65rU+F2vXtvdarbxeHdWuSTHPtiktQUym3J3TAc7R0zXsQhenTfax6teSnhfRLo/Q6bxZFnxJN/tKh/8AHRT7e3xGOKyfEesX767vfwvrMZMafK8tpnp7TkVZg1jUBF/yKutHjtLZ/wDx+vTSOSnJcqPQ7VBFbW6DHyoB+led6uCfEOoE/wDPdq6YeINUVVH/AAh+vcAD/W2P/wAk1wmr6tff29es3hrV0LSbtjSWuRkZ5xPj9aiK1ZhQl7zO18Ir/pjn0iP8xXQal4Y0fWby0vtUskubm3glt42dm2iOVdsilQdpBHHINeX6X8QbPR55Re6XdpIUCrH9ssQ557KbgE9OwrqNK+JTX+2O08FeMZBgYk+xwrG30cyhSPoa2pp8xhineWhqn4c+F/sdhbLp80aWMbQ27x3s6SJGxyU8wOHK5/hJIHpUt98P/DN9LcyXOnMWubVLOcLcyoJYlGFDBWAJA4DHn3pfGMWp638PNYh0+yubXVbqzlSG2kljWVXIIALK5QH3DV5bN8N9et59Sm0+1vRJHNpdzYE6mTiUY+1vhpME8DJbr/DmtjlPWvEHg3QfEItxq1h5xt4zCjLNJG3lnGUJRgWU4GVOQfSor3wN4bvdTgv59KiNxCIlUI7pGwj/ANXujUhH29twOO1cBdaD40XXpbSLTppdOfxZDrAv1v0AFrld0ewsGwApJHfsDXP6V4D8cxWfiKO2hltJ7qzZI7u8vFN1I5mV2TzI5GDBkVl3sqsMjAAzQB6rqeh+E1Fz4avoFH/CSzzXklqZZc3MihDIwYH5cAJwCB6DrU9r4C8N20SJFpxJW9i1HzJLiWSRp4/uOzsxZtvYEke1cFb+ENWfxHod3o3h2bw7b2seoozTXyT+VJLbxpHJgO2AWU8Ln7uTjNYWieA/Fltoes29xba1Dd3OnLbytBqEAW5mEyEyKS5JYr5mS+zIJXPOQAeqzfDrwvN9p3aa6/aLsXzeXdzJtn+b502uPLJ3tnZjOec4FWtF8E+H9FnsJtMsPJksVmW3bz5G2CVt0n3mOckd847YrI+D2javofhu5ttcs4LOR7t5IkjPzFCqgF1Duitx0Rsd+pNN8Q+PrnSYZxL4M8Vttyokgt4JVJ5AI2Sk4/Chj3NdM3+tSSE5jiOR9BwK2TtOQOK8o0j4o6daQsbzQ9ZtS563jWltx/21nWul0/xv/afOn+HdTuh2+z3mnv8AyufrXlVlJyubyavZHWyABCBg59TTAPlx93HXB4GK58+IdSCc+D9e2qOSZrHAx/281z+t+MtQuLcw2vhjWY4m4dmltMt7DE54rWMW0XCLk7I6y48QWUT7UEk2DyyDA/WrtneQX0Jkt2OV4II5X8K8rfWL5Ywv/CNauD1/1lp/8eq7pPiTUdPvY5T4a1go/wArqJbTkf8Af+tOQ6JUo8vu7npxUuowfnXkE968w+M+ms1nY6zEh3W8vkynrlG6H8G4/wCBV1p8Q6msnHg/XQxP/Pax5/8AJis3xFe6jq+i3umSeENcWK5jZQTNZZU9j/x8djg15mKpOE41o/MWFreyqKX9W6nkV3CLvT90ZO9OVI4I/wAn+dexfD/Xzr/h+2eYFruDMNzjruA6/iMH8TXhul6jeW8sltPpF8Zo2MciBoeCOCOZPrWx4W8T3XhfxJ9pfSdRWxuwI5UDwZ3fwsP3uOp7kcE808Xh/bU7x3R7WLiqsGle61WjPoHDzkSRybUB+UFetKA0geN2AZuCa5uPX9UMJ3+E9c2Bs5Way4/8mKSPxJqHl8eE9eZ933vNsv8A5Irx/ZPd2+9f5nh+hPqEX2TWCO0ihh/L+lLrEHm2gcelY/iDWNT2wTyeFNbRlbBZpbPkHtxcHuKli1zUZ7AqPCettx1Etl/8kV9VgJ81CN+mn9fI4qi942/Dc6vpexseZC20E/mK8j+KZZ/H82/GfIg49Otdf4d8QajbahNB/wAIvrEnmc7BLaA5H1nx0NedfEzUruXxvczSaJqFsxhi/dSyQFhjvlZSP1rzJUPZ4uXnr957GUzXPr2/yLFocXeR2lB/8eq1rP8ArnH+8KzdOlklaVpLeW3YSH5JCpPX/ZJH61q6uu64cejN/Wu3oe1e7TNH4JSiPxVqMTH/AFltkD1Kt/8AZV1/jFN2vj3hT+tcF8Jn8v4hQr/fgmX/AMdB/pXonixf+J5GTnmFev1NFBWueXjVbFX7or2tvhBxXaafGItPtU4GFB/Pn+tc3aJ+7H0rqYAVt4R6IM/lW09jixD0R594jyfEt7n+8o/8dFa/hRf+Jih9EY/pWd4lTb4ku/8Aa2N/46K1/Ca/6Y59Iz/MU+hbf7r5Hawf6lc+lSVHb/6lOnTtUldMPhR5L3CiiiqEFFFFABRRRQAUUUUAYPiaQs9vbr1PzEfoP61oRIscCID90AVmTnz/ABEO6x4/Qf4mtV0755JzXmYqV5HRtFIGYAlpMAAZ5rjNY1L7dcN5fFuhwo/ve5rR8Wah5UQs0bLty+Ow7D8a5hTtQDuaKFP7TOvD0tOZj2O+TnoOaZnfMM9KDuB2AfMacyBMAcsOSa6TqCUkvnOCOc+ld1aXH2qyguEG4uoJGe/f9a4fYVy0g57Ct3wneY32bnrl4/6j+v51MldGFeN43XQ39u9euWU5BPY1x3xN0hr7Qhe2yb7mxdpNuMsyEYdfyAP4V2bcNzyeoAqtcpGk6XMmQpwrg9Aex/p+VebioNWrQ3X5GNCo6c1JdDxnwJ4iXQNWAmcNpN6QHPaNzwsn07H/AOtXsjKjDERPTPtmvGfGOhx6L4hmtY4/9AvN1xbDtg/fjH0PI9jXWfDnxMs8UWhai2byAf6K5/5bxDoP95f1H41y4ukqkFWgepi6SqRVen8/68up3skhMR3HBHQDnmqeoQS3GlzBlBYruXnncOauPNvkTahAJxyKXa5jALjHpXnwm6c1OL1R5bWlmc/pjia2/CsyJjYa1HIchC2G+hrTgAtNYngI2oW3KPY1D4mttirIo4zX2ica1O/Rr8zg+FnSM6vw3zOOi4pI9hxGyssmfU/zqpolwLjTomHMynb9SP8A61Xn3u6BwOvXNfGVISpycHujuTTWh5b8RQF8awYGM2QB98F6y/hv4l0608UXu1rm632iptsraW4JZWI/5ZqcfU4HvWv8R1x4008dQbRh/wCPNSfC7/kcp/ewf9JBXuYX3qMb/wBanrTu8Lp2/UteJ9Zv7jVI5bTw7qKq0YAa7aOBTgntuLf+O1b0oeKdSdEj/sawXqWIluyo9x+6H6/nXezwW9wuyaKOUIcgMM4p6eXAojAihQnCKMLn8K7ufTRHkqraNjnW0DVbl/8AiYeKb8nr5dpFDbr7/wALP/49XH+IfCOkpr0yXUU98Cqtm+uZLjOVGeHYj8OleqEEEZA6dT61yPixMa1E3doV/QmiEncKCXMWvBGnWdhb3AsrS3t1+VcRRhB39BXaQ/6pPoK5rwwuLGZvVx/Kulg/1Kf7oral8TMcT8TH0UUVucwUUUUAFFFFABWJ4nmxFDCvVjuI+lbdc9qOJ9fiTqE25/nWVaVomlJe9c0baMRWiR9CqgVl6h4Z0DUTnUtE0y546zWqMfzIrYdMjcTjPPFYXinUPs1sLZG/eyDnHZf/AK9eVFNysjWEed2RxmraDosly6aZFdWUCcf6JeTQqx/3VYDHtis19EulYC117VYgP4XMUw/8fQn9a2VbanuaDuUgY+Y13x91WPRjTjFWRhta+IEkAj1WwuF9J7JgT/wJZAP/AB2ny3PiGNgJdO064X+9DeMjf98tHj/x6ttkCDGfm6mnBDnc44xwKY7dmaOn+Kr99PhkuvDGsDChTLC0EysRwcBZN/X/AGasDxno4Ui9Oo2TDn/S9OniVf8AgTJtI/GjwpeeXO9o5+WQlk/3u4/EfyrpWxnn6gCsakYyTjJaM4akHCVj568e3ujx+LRfaPqthdQXo3yrBOjGOUcMCAcgkYOD70l1Al7p+OGBGP8ACvVfij4Yi8R+GJylrHLfQ4mi3KCSVzlefUZH1rx7w7JElmkcUapCvARRtAB9vz/EVzUbRTpvp+XQ9/B1pVaSfWOh6n8K9f8A7X0oWF43+m2OIpAT/rI+iN+XB9x712syzKqwooGSMNXgKXU/h7xBa6tbbisbgTqv/LSI/e/Mcj3Ar3nTLlL+wS8tZRPDIoeJx3U9K8rFUPZy02Zw46j7OXtI7P8AMdqVs9xYTIzB22EAY6HtWb4cm8yEo3XFbEO+YttyozyD3NYNufseuzxkBVL7gPY16GTVdZU/n/n+h5NaPUp3Q+xa1HLjAD8/Q8H+dedfGCMReN1KrtRrOMgfRmFeq+KLfKCUCvLfisTPdaFckgl7WSFvqrD/AOKrsxtL97CovNfqv1O7J52r8vdMzM4u7gj1JFaGoYN0fcn9RWTbvvZW/vIp/StO9YZjc/7B/lQj32tUVvh5J5XxG0rnG9nT80avV/GUZW9tZccGMr+R/wDr15B4OPl/EbROOtyB+jCvoaeKG4UxTRRygchWGeaKbseXmUuStGXl/mc5pA+0tHGgz/ePoK6hz8wA257A1HGIrZAqrDDGThQMLk05gQQSB9TVylc8ypU52cb4tj26+G/vwof5j+lanhNfnnb0QD9f/rVT8Yr/AMTK0J6mEj/x41peFVxDcN7qP51b+E2b/cnUW/8AqE+lSVHbf6hMenapK6ofCjzHuFFFFUIKKKKACiiigAoPA5oqvqMnk2M79whx9aTdhpXdjE0c+de3U55znH4n/wCtWlNL5MbPIMIilj+AqjoUZWzZx95n4/CoPFF00dkkIOHlOD9B1/pXkzTnUsdajzTsjl76YyyyzPzJIcn29qjhXYoY8sentTGO6QCnuwUe9di0PRtZWFT/AFjOe3AqewjEssjN91Bk1VU4jzWhbIyaY7AYMp6n0poUincSbizHvTbeZ7eeKVBh4zuFOVRks2DjpTF+Z3Y9hQPpY76OVZoI5oyPLdQ3rwRS7QQY2XKEYIxwaxPCV35ltLbMfmiO5f8AdP8A9f8AnW1jB2tvbPf0rGSszzpx5ZNHOeMdBXW9Gex8wi9iIltZMcqw6Z9jyDXjqCSVEdC1te20uQR96CZT/jX0Hcq7R74l/fJnaPUdx+P868o+IelDT9Rh1u2QiyviEulx91+zkds/zHvXn017Cq6T+F7f5HqZfX/5dv5f15nW+DfEp8Q6W6TqsOoW7AXEYPQ9nUf3T+nSunEbB1KupJ65H614fFPc6XexapphH2iEYZT92aM9Ub26c/Q1674d1Sz1vTIL+zYtGwwyE/NG3dSPUVw4vDeyldbMzxeH9m+aPwsh8TRmGS2u15MbbHI9Ccj9f51avEW90s45OM1Y1G3S5sp4mGC4wo757frWd4anMtsYZPvLwQe1ezlNf2lJwf2fyPIqxs7lTwpcNBczW7c8bgD6jr/n2rom3HiRNq5yGz0rldQzp+rpKBgbs/411fmu+1gu6MdCD1rgzelyVVNbP8/+GNaLurHmPxIwPGmkkcoLVgD/AMDNM+GGT4yfH/PjJn/v4tS/EzI8XaOpAB+zt/6HR8LFz4rvD/dsj+sgrqwn8GJ7jf8Asny/U9TyE3M5AVRljj9a8zv7mXUr2S4lJYsflB/hHYCvQtSO3S708geS5Htwa4LTYg69K7YI8zDpas63wrfyXVi8VwxaWDA3Hqynpn6Vm+LBjVbX/rh/7MaueFo9l3c+nlj+dUfEz+br4jH/ACzhUH6kk/1ppe8OKtV0Nrw0f9BlHo+f0/8ArV0kP+qT6CuZ8O/LFOvsp/nXTQ/6pMegrSl8TOXFfEx9FFFdByhRRRQAUUUUAFc5p5E+sXUx5A3Y/PAreupPKtpZP7qk1h6BGfs8sn8TNge+P/11y4qVo6G1JaNmk7GNcvwgBJNcJqNx9ouJZ2HzOeM9h2FdR4kumh04pnEkp2fh3/w/GuMc7nArmw8dHI7sNDTmHQLtXe3J7e1OXmUuf4f50jNtFNU/Jmuk6SzZRCe5bd90Lk1HcybmZu3arVijLYSygYaT5QfaqiqNxLEMB0x3oJW5HE7xyRumVdTuU+4rvbadbm1injPyuNx/qPzrhF+eUsegFb/hG7ys1o55U70+ncfyNRJXRliI3XN2OgTjAx8p9BxXg3jrRh4b8WzLErCyvM3EXoMn51H0PP417uQQcEuwb9K534heHf8AhIvD0kcC/wCn2pM1qfVgOV/EcVzzjqprcMDiPY1Pe2ej/wAzyYot5aMh5dVOP9pe4/DqK3PhPrj2GoSeHbqQiGXdLZuTwG6mP8eSPfNcnpF0cBTlJYz0I5GPb2PBqbW7QyRpd2ZaKVGDoyHmNxzx/MVFakq0LM9ypSU4unLr+Z77DKDGoj3eaDyMd6y/EELxSW1ycblO1iPQ9P1/nWX8P/FZ8QaG7Sqo1G3+S6QcEns4H91uvsciulvLb7RZyLJJudkwB6GvHw85YWum+n5Hz1ek4twluR3ai70nI5IFeO/E6FlstPk7RXDL+Dr/AIqK9Z8PTGSBoZPvDgg1yHj/AEj7Xp15bBfnK74/94civq6sOeDRhgqqo14ze1/z0PNNOfMcJ9tv5GtW7ObSMj+4P0Nc7pMuVIPGCGx6Z4P8q3mO6xx6bh+uf61wReh9dNalbw38nxE0M/8AT4o/Mmvo0A7+cAdzivnHRMDx3oZ6f6bF/wChCvoqY4t5zyAEY/Tg04Hj5t8cPQ871a6k1PUZZXYlAxWMdlXtiuo8I30k1vJa3DFmhAZGPUr6H6VyumR7yPeun8NxeXqUn/XI/wAxXQ1oc1WK5LdiDxgP9NsfXy2/mK0fC5/0e4X3U/zrM8WuG1i2jHVIcn8Sf8K0fDXytMPVAf1/+vS+yRb9z/Xc6m25gT6VJUdt/qEx6VJXVD4UeY9woooqhBRRRQAUUUUAFZXiSTZYBf77gf1rVrB8SsZJ7WAd+fzOKio7RZpSV5ItaahisYQMZK559+a5TxNO0+rPGpz5YCfj1P8AOu1C7RgEBRxXn07h7m4m7u7EfTNedRV5NnZhleTkVCBG/BycVIE2rvf7x6D0pifNLk9BT3Jd1QdWOK6TtJbe1MxjB+WPG5j7U/ULkykInES8KoqzeyCGJLdOy8mspsvIFWm9CY66sc7gLignZHjueTSTKsa4zlu5pwTI3vwOwoKLnh6QwarbHOBISjfj/wDXxXaSELg5APYE8VwNo5F1CwH3ZFI/OvQXAJOQKzmcmIXvJkanGFyobqQKoavpkGo2d1Z3fNrdIUPqpPp/Me9X8jCksmT3x1pkyJcwSwglewI/hPYj8a5q9L2sLLfp6mMZOLujwgWt1o2pzaVqH+uh5jftKnYj/PqKt6Bq8nhXWPtSbm0q5I+0RjnYezD3H6ivQPG2gJr2mRi2Ij1S0JMRJ53DqhPof8DXmdrOLmKSG4Qq4JSWNhgqR7VjSnHE03Ce/U+gpVViIPmXqv1PcbecTqJ49ssMqgo6HIIPINYWDYa+4HEc3zj8ev61x3w98QPpd6mg30v+jSN/oUrdAx/5Zn2Pb34rvNfiY2sd2yjfGwPHoeD/AErnwblhcVyS2en+X4ni4zDuk7fcM8S2/m2yyoPmXmrGgXPnaQFKlmjOz/D9Kkt2W70/B54rI0R2tdWe2JAD9AemRyP6162ZUPa0HbdanDSdpHMfFH5fFWhuRg+Q4Jz/ALQ/xqT4UAHxFqTdxaKPzkP+FJ8W0b+0tCncYdvNXjt900vwhw2t6w3pbxj/AMfauPBu9GJ9A/8Acr+X/tx6DrZI0S+I/wCeLdsVx2irlTXYa6caHfAf88jweo5rktDIzgmu+Gx59D4WaSXc2nu0kCIxZcEODWTaSSXV9NPM26V2yxrYuYJHt5ZVQmNB8xHasfSDmQn1NUbJLdbnU6GMSyL6p/Wumh/1SfQVzel8XQ91NdJCMRIParp/EcGK+IfRRRW5yBRRRQAUUUUAZ3iCTy9Mcd3IX/P5VBpCGPT48Yy2W59zUfihyUt4h1LE/wBP61oRx7I1RSAFUL+VcGLetjeOkEch4ruGk1IQg58tQOPU8/4ViMoicc5Per9+4k1G6mznMjBfoOKojDy89BVQVopHqU1yxSHqmBvk69hUkNs0+wDhWJJb0FRyMWIHc8CtK5f7NaxwJ97byauw22VtQuNyiKLiFBgAd6qM21AKa+WcKoyadMqxpgnLEdfSgaVtAB2x89TzVjRpTb6layk4Bfa30PH9agVN6724XsPWmqx3ZA+6QaBNXTR6HIQuCTgjpk8U1GKkcqHJzx3qRgG6ioyQFDFkB7EisDzTxb4paA2ieIV1a0TFhfvubHSOb+JT7MOfrmsuwmR0wSTG46/T+or27XdMtdd0i70u6B8qZcbgOUbqGHuDg18/PBd6HqtzpmpDy54XwT2P91x7EVFuVnv4Gv7anyS+KP5FiWS98OazHqulkLMnDofuSKeqn/ZP6HmvavDOsW/iTS7a9sJMKRh0cfNE46o3+eleTx7buHy3wGHAz29voaztH1W78G639rt1aSxmIW5t8/eUdx6OO3r0rjxmG9ouaO5piKHt46fEvxPZJGax13c2Nk3z5HTPerHiODzrYTKMkVXv5bfU9Ft9RsZVmiIEsbr3Q/5/Sr9k4vNOKnkgYr0surOrQV91ofL1ock2j5+1a0+weIriEDajtvT6Nz/PNXIW3QSD0wfzGP6Vs/EjTjF5d2ow0L7HP+yeh/A4/OuftJMqfR1/+vUVI8k2j6rBVvb0Iy6rR/Ik0Jd/jzw+o6m8hP5EH+lfQ1+SNNuz/wBMn7Y/hNeBeCo/P+I3h/P8Mpf/AL5Rv8K971I40y9x18l+D16GlD9Tz80f7yC8v1OJ0NMkVs/aZbCUzQIjErtIbOMVlaCRuGTWzcQSSxSvGhZUGWx2rp6GUrdTBSaW91OSe4YNIxGcDAAHYV1GifLdEeqEVymmndcsfeur0vi7j9wR+lJ7E1F7rR09vxCmcdO1SVHbjEKgelSV0Q+FHkPcKKKKoQUUUUAFFFFABXO3LfaPESjqseP0Gf510RIUEnoOa5rRsz3lzPjJPT8TmufEytA2pdWaGpyfZ9OuZSxyqEge/avP2fC4zzXZeKZCmlMhPzSsq/h1/pXGuAFAFcuHXu3O/Cr3bihdsWT1PNXNKgEk/mv91RnmqsmWCqvU8Cr85FrarAp+ZhljXQjeXYr3sys77ecnr3NQr+7TH8R6mog26TPYdKfsZvmfhf1NA0rDUUO+W6ClnkoGS21PwokAVcdWPU0AWdNj8y/soh3kUn8Dn+ldzJ8wIBIJ9K53wtYsXN7KPlwViz39T/T866Fw56BfxrKb1OKvK8rLoNLDaOd2OM4zzTsgc49ycUm4KQDhT2HrTXIiOfmJbtmpMSO5iZJftEIG7AVx6j1+o/lXnvxG8OuJf7d0qLcyL/pcaD/WL/fA747+30r0lC2Rx8uOpPNV5z9kQsiFojwVAztz/SuDEUnTl7en8zow9aVKSaPBp1jv7MMp+b7yMDyp+teleANeTxBpL2eov/xMbYbJkP8Ay0XoHH17+/1rkfGnh1/D149/aLnS52/eRj/l3c9v909vQ8VhWt9Jo2q22r2a+Y8f30z/AK2M/eX64/UU6sY4qlzw3R7VSnHFUvd+X+R67ocjQTy2sp+ZG289/Q1X12Jre7S5j4ZSDkUT3kN2LDWLE7rS6QAN79s+/UfhWrfxC8sNy9cV7GGq+2pKb67/AKny04uEnFnH/FVlk07RbpDkC56+zIf8Kr/B0/8AE31sf9MYv/Qnp3igNceB76JsF7KaOYZ67d2OPzNQ/B1x/b2qj+/ao35Of/iq82hTdJypvo39x7tOfPgJeX+aZ6hcRC5tZrc9JEK56jkV53au9pcNHKCrocEHsRXo6nLjao24/EVDLaW0swlmtYpJ15DlAT7c11RlY86nU5LlfTo2GkOXUhpVZtp9COK4zQ2yRXoasGfnB7EZrz2BDZajNA3BjkK/rVxdzWjLmcjrdN/4+k/3T/Kuli/1a/Sua0ht1wp9FNdJCcxJ9K1p/Ec2L3Q+iiitzkCiiigAooooA57Uz9o12GLqI8Z/ma0btxDazSscbEL4+grL04/aNWuZuvXb+eB+lS+JJDHpE+T80mIx+Jry6z56ljqUdYxOKaT5eTlj1oRdsRY9TSOAqYFOk+4FHXpXSemWdLg865V2+6vNLfzqZX289s/4VM3+h2YjB/eOMn2rMLbnH90U9iVq7kiDYnP3j1NMUCR/m+6KdsZ+WO1aQH5gqD6UFCzyce3an2sRlmtoV6yOoP50yQBF55Y962vC1iZZ/tkg/dx5WPPdvX8KTdiZyUY3Ook5DYJGfSoyQFwSX28HjNOcMQQAv40mQuNxCn+dYnnC5xzjnGScVyPxH8JL4k00T2SourWwzC548xe8bH0Pb0P411bERHd8xJ7A09S3Hy/KRnJPIoNKdSVKSnHdHzdp108UjQTq8c0TFGSQYZSOqkeorVukjvINrDJI6+v/ANcV3XxO8ESasx1nRUB1KNMT2/T7Sg6Y/wBsdvXp6V5lpd8sihGLBs4+bggjsfQip20Z9HRrRxEOeO/VdjY+Hmvt4d1g6RqT/wDEnvSVUseIJD0I9Fboffn1r1HRnayvpbWU/dbb9R2NeN6xaJe2rgqC4HTsc/411ngbxA9/Yx294xbULECJ3Y8yx/wN9Rjafw9aMOvZVnbaX5nnZrhuePt47rf/ADOp8Z6alxHLHIuYpkKt+NeMWRe3kaCcESQOUYH8q+hLmNdQ0zj7wFeLeNbA2erpcgYS4HlP/vDofy/lXViIXXMuhz5PX5ajpPaX5on+Gq5+JGmD+4k5/JD/AI17yVWSN4mHyupUnqMHivCfhQd/xFtGPX7NMfx2gGvds5YbVGPyNcsdjTNf4y9F+bPOoi9heSQygq0bEHNdvoCu1j5kikGU5APp0FWLi1tp5Ve4topZF+6zID+tTq4Ljpkds9K1c7o46lbnjax51pZ/ftng7jXXacP9Kh/z2rmJ4vsetXUJ4AlJH0PI/nXT6Swe5iI7An9K06HTN3jfyOng/wBUv0p9R25zCtSV0Q+FHjvcKKKKoQUUUUAFFFFAFXU5PL0+4YddhA/HisvQIytozr95mPX0FWfEkmzTwmeXcD8OtP0+Ix2cKjg7QT+PNcOLfQ3hpAwfFsnz20OeQGc/yH9a5sjc4x0HNbPiaQPqzAdERV/Hr/WqGmwrL5rucRqRk+1FJWikejS92mh9uiwwm6l+iD1qs+ZmLzHAPapL2cTS5HEa8KvpSWlpc37lbaMsAcFjwo/GtGXtqyIFd+FGAKbLJuOM10tp4cgjUNdyvK3dU+Vf8T+lakNlaQZ8u1iUDvtBz+dQ5oyliIrbU4iEM3ywI8jH+6pNa+m6BNO4lvsxRf3P4m/wrp9xAUR7QD29qDu2naN2T0PFJzMpYhvbQXKxxgRqNqjChemPSmp8pACtzz16UoXBUjIH90dKciN1JY+x5qDAZjC8hevy4Gadj1AY56+lNluIIB+9mhjA/vOF/nVB/EGjoxVtTtNw6gSg07PsK6L7gkKShJHoelPBOSDyO5Pb2qpbatp10dtvfWsjeiyjP5VcK856f1pWfUdyheWcUlrPHJCtxazKVkjIzlT/AErxXxXoMvhu8EDM0mmznNtOecH+4x9R+o/GvdlJGASevYVS1nSbTWbCa0vYg8Uq4Kngg9mB7MOxrkdB0pc9Lbqv8jswuLdGWuz3PIvAGqmCWfw/dtttr1t9qW6Rzjnb9G/n9a9L0G58y2MUn3hxg9q8Y8T6Hd6BfmxvSxQ/NbXA43gdPow4+h9q7nwdrzahFHNM4N0PkuAOPnH8WP8Aa6/ia7MJK0mls/zNc1w6kliaez3/AMy94gtP3d9bnIjuIXiP4jj9QDXK/CC72eLYkbgz2skZHuuD/wCy16TrNuJ7XzEGTjNeV6ZH/YPxH0yT7tvNcgqewD/Kw/M/rWteFnzoyy6opU6lB9VdHtWsXj6fpV3dpGJHhQsFJ4P/ANauT0nxy0lwE1O2jSJjjzIc/L7kHOR9K7WeFJopYZgPKkUowx68GvIJ7NrW7lt5Ad8TlD+BqIJNGVGMZppnr8bpJGJYGV42GVZOQ30rmfFenSeeuoW6EggCYDqCOh/Kud0W+vNOfNrIdh6xtyp/D/Cuph8TKyjzrNlbuUfj9aai09BqnOnK8dSTwqXlikmYEIBtUnue9dbD/qk78VlW86XFqssLZjI4zwQe4Na0P+qTPXArWi7yZy4iTk7sdRRRXQc4UUUUAFQ3snlWk0ndUJH5VNWd4gk8vTJB3chaUnZNlRV2kZ/h6MiGVx94tgZ9B/8Arqp4tkKw28RPLMXP4cf1rW0mIx2EWOCRuP41zvip92pIoOdkYz9STXlw1qnZS96qYbDcwA7c1ctY1SNrqb7q/dHqaZp8ImlmJOEA5PpS304lkCrxEnCj+tda7na3d2IpC1wxeU4HpUeV3gKMCpba2uL2Qpaxl8dT0A+pres/DkSANeTM7d0j4H59T+lJtIUqkYbnNzS5OAaWHJ4iVnc/3Rmu3hsbOD/VWsQx/EVB/U1YDEKBEEUHoOlTzmLxC6I5bTtBuLlxJeAwQ/3f42/Dt+NdSipDCqRKAiLhQvQUHdglfmyeh4oC424yvPIFQ3cwnUc3qIvy7flb5uTz0pcYDZC47YGaVEbO7LfTNNkmhgH72WKMD+84WlvsRcdj1+Y5xx2prglBlOQegNUZNf0iNyr6naBh2EoP8qlt9X025bbBf2rt6CVc07PsK6LgJ3dDj69K81+I3gM3kk+t+H0/05vnuLVelxj+JfR/5/WvS9vQ/wCTTBleCT1wMDpUtXN6FedGXPA+cLG/E6AEjeMgZ4z6gjsar3E8ulajDqVlklc7l/vKfvKf89QK9e8eeAodcLajpGy11bqwPypcf73o3o3515NcxXFvNNZapbyW10n+sikGD7MPX6jrUu59DQr08THT5o9n8KanHd2sTxuGilUMp9Qaw/iDov2qzuI0HzON0Z9GHIrlvhtqZt3l06RsGFt8fPVCf6H+Yr1PUUF9pm4DLKK9GLVSF+58vWpywldxW8Xp+h4z8LrryviFpDN8vmiWIg9iUbj8xXvuoXDWlhdXCp5jQxtIFz97Azivn7VIj4f8eabfAbLc3Uc+RwAdwDj8jn8a+iZFUllcAxsCGGOoPFcKXK+V9D0swmqrhWjs1+RwmmeO5XuAuo2sYhY4Lw5yv4HrXbwSxTwrPbOkkTjKuvOa8l1CwNjqVxbMD+6cqM9x2P5Yq/o97d6dJvtJSoP3kPKt9RWrgmYyoKSvA6vxXp0kxS/tkLMq7ZVA5x2NO8Jl5i8pB8tF27j3JpLfxPuUedaEP3Mb8H863LS5S6tRLA3yHseCp9DSu0jNynCHK0attzAnOeOtSVHb58hM9cVJXXD4Uee9woooqhBRRRQAUUUUAYHiMmW6tbcdTz+ZxWoAeQv3ayLs+b4jQdkx+gzWpLIY7eRzgKqls/QV5mJd52Oi2iRwOqzebqVy46NIwH4HFK7GC3W3T7x+ZzTLRBJPGX6KC7VLaWz6jf8AlR8Anc7f3R610JWR6ekVr0JNJ0xr+Us7FbdD87j+Q966+JI7eJYoFVEXgADoabBHFDCsMAXykGNo5NJfXlvp1o9zezLHCnVm9fQDufas276I4qlRzfkTLGAQSBuHpUF9e2enxCS9nhgQdN7AZ+g6muKuPEus63ctB4etmhgHBlKguR6knhf51havoOoWQ+1akplLHDSmTzCD7mqVPS7MeY6688d6bE220hubs9MquxfzPP6U6HXdevwGsNFjhiPSS5kP/wBaofBljaxaZFdiFGuZC3zsM7QDjA9K6JmLHJJNbRpK1zOU7MyHt/EU6/vtYtLbP8MEGSPxNV38Nfaf+QjrOo3PsG2j8ua3qK0UIonmZiw+E9Ci5NpJK3rJIT/KrQ0LRlGBpsGPxrQoqrIV2Yd54S0e6UiON7aQ9GU5H5GuXmfWfCt+YLe8Zo/vKj/NG4+h6fhXolct4wt21DVNOs7cA3BRiSf4Vz1PtwaicVbQqLu7Mu6J43sbxlh1FfsNweMscxsfZu34/nXUhTkMu0rj5TXKQ+EdKEIS4NxNJjlw20fgKi/sjVdCjMnh68a5thybSYbsfQf4YrGVF7otTRv+INFsvEOmPY6lFujb5kccPG395T2NeLXWnX/gTxPEuoEy2Nx+7F0owsi9ifRl7j0r1nRvFtpfSfZ71fsN593bIflY+xPQ+x/WtfV9Ls9W0+Sw1K3We1kGCp6g+oPYj1FYWcXfqduHxPInTnrB7r9UZOlT+fbeWxzxXC/EXSZWtPtVqD9os3E6AdSByR/X8K6WxtLnQblLK5kaaJR+5nI5kTtn/aHQ/n3rT1aETwB1GfUetd2lSPqcVOboVVOPR/195uWF2t/Y2l7FgxXESzAg/wB4Z/rXH+NbMR6nHdIPkuF54/iHB/TFdL4ZsxY6DbWik4h3Kqn+AZJA/AHH4UzxPa/a9GlPWSE+av4df0z+VcivGVmdFOaU7x2OSsogUHFX1tuKp6W4JANbqqCua1OxuzL3h0FLOZCcAPkflXSQ/wCqT6CsLSF22sh9X/pW9F/qk+gp0viZ52J+IdRRRXQcwUUUUAFYXid8i3hHViT/AEH863a5/VD5uvW8Z6Lt/wAayqu0TSl8VzURSihV6ABfyrhNel36vcsOgbYPw4ruwxCknG0c5rz6IfabpWbozGRvp1rgw6u2zswy1bHbjb2wiX/WSfM3sPSn6Zp0l/OQW2xJy744HsPemxwyX+oeVD1c8nso9a7G1gitoFgtwPLTqOpJ9TXRKVjarU5FZbiwRRWkKxW6hUXsOTn1PrUqxjgsBuHpUd1cQ2Vs9xdyrFDGMs7cAVxN54q1TV7o23hu2ZY/+ezJucj1weFH1qFFyOJyO1vLq1sYfMvJ4oIx3kYD8q5u98daXAdtrHcXZ9UXav5t/hXJaxoOqWym91MNMScNI0u8jPrXQ+CLC1Fh9saFHuC5UMwztA9BWkaavYly0uW4fEGt6gA2naIscR6SXEhx/Spmg8R3C/vdVsrXP8MEO4j8TWuzM33iTSVuqUUZubMF/Dj3P/IR1vUbn/ZVto/Knw+EtDj5a1lmb1kkJ/lW3RVcqJ5mZ66FoyjA02DHvk1Vu/CejXSkJC1u56MjZA/A1tUU+VBdnnl4mreFL4R2d8/lMNyqfmjce6npXSaL45tLkrDqsf2Kc8eZ1iY/Xqv4/nUHjSNrybTbOBd1y7MQPQe/t/hU1t4R0xYAt2000uPmZW2jPsKwcOZ2NFJJXOtUbtjxlGjIypHP5Gud8aeFbbxTZRrI32e/hybe6A5Q91I7qfSqX9hajoqtL4avnkiHLWk2GB+g6flg1b0jxfbXE32bVI/sF4Dt+f7hP1P3T7H86ynTaNaVZwkpxdmjwu/S+8MeJVS+h8q7tTl1U/LJGe6nuCOR78V7f4bvUuLdQGykigg+oNXfF3hbT/E+npBfoVlj5guY/vxE9x6r6joa4HwmL/QL6XQ9WXbcWvzQuPuzQk8Mp9B09uKrDy5XynZjakcXTVVaSjv6d1/XUsfEbw5/aNjLHHxMvzxN6N6fj0r0Hw1etqXh7S7wjDS26F8nkMBhh+YNVLpFvbMOBlgKs+GIki0kQou0LI7AfU5/mTV1ofaRxQrNwVN9Hdfr+hg+ObMC6t71BxKvltx3HT9P5VkWkeQOK7jxBa/bNHuEPLoPMTHqP/rZFcXp7gkCoi7o7aErwt2L0dvkdK6Dw2CkVyhOBlT/ADrPhQYFbGjJtjnb1IH6US2Cs/cZvW3+oT6VJUdv/qU+lSV0w+FHlPcKKKKoQUUUUAFFFFAHN2p8zX7h+oBb/CrOvP5Oj3R3clNo/E4/rVXRRvu7p+56H6mjxYxTTApOd8gB/AE15U/eqnZFXmkckkhWEqoy74AArsdJshYWKo3yzP8ANI3v6fhWD4WtBPdmdx8kPIz/AHu3+NdZgFskHnselbzfQ3xE9eVDXkSGKSaZljjQFmZuigdSa4AJN4z1tp5C8WlWxwg74/8Aij+gq9451CS9u4fD9gC0shVpyD0HUL/U+2K3NMsotNsI7WHkLyzf327mtaUOrOKcixBHFa2629pGsUK8BVqvqdt9t0+4tz/y0QgZ9e361Zorpt0MShoNo9lpNvBMAJVBLAHOCSTV+inwoZJAo6d/pSSsrA9SSG3aQZJ2rVhLaNeoLfWphgDiimMaYoyMbFx9Kp3EHlncvKH9KvUjqHUqehoAy6jSCJLiSdUUTOAGfuQOgqaVGjYq35+tLHG0hwo49e1AhlKCQcjg1Z+xnH3x+VV5I2jbDD/69AFDVtKstWj23sIL9BKvDD/H8a5uaPxD4ZRmsJxe6cvO2Rd4QfTqv4HFdjSqxU5FTKCZSk0ecXHje8u9QsjfW0EVrG58wRgncCMZ59Otek6eYnhHlhcEZBHpXE+MvDULQy31ioQDmWIDj/eH9RUngDVWMBsZyTJbgbSe6dvy6flSjp7oS11OzDfZ58n7h4b/ABq0QDnOGVuuR1B7VFIolj3DrUdvJsIik+7n5T6e1RVp82q3KhK2jON1Swk0i+OATbucxt7en1FXbS7R0HzV1d1bxXMLQ3KK8Z7H/PBrPtNBsbWbzV8x9vIV2yB+nNYqa6nfGure9uXbFPJskD8Ejcc+9a0P+qT6Cs933Dr1PBIzWjF/q1z6CroO8mzjrO+o6iiiukwCiiigArnCfM8SOeu0n9FxXR1zWnfvNXunP+1/OufEu0Dal1Zoao/kaZdOT0jbH1xgVwMMnlxHH3iNorsvEzGPSJATkuyr+uf6VznhuzF1fBnGY4vnPv6D8/5Vy4fSLZ20LRg5M6DRLEWViDJ8s8oy5/u+grRyFVnchVAySeMAd80Y3Pk5OeMdq5Hx7qbsIdDsQWubrBkC9kzwv4/yHvVpczOaUm3dmbdNN4z1zZEzR6RanhvX/ax6nt6CuwtYYbK2W3s4xFCvp1PuT3NVNF06PStOS2jwX+9I4/ib/CrtdkI8qOeTuRXcIubWaB+VkQqc+4qj4cspdP0mOCcAS7mZgDnGTWnRVW1uK+lgqaGBpOei+tRxoXcKO9aYGAAOgpiIUtY165Y+9SeVHjGxcfSnUUDKVzB5fzL93+VV61WAYEHoazZY2iYg9Ox9aBEAgiFybjYvnldm/vj0qSnRxtIcIPxqx9jOPvjP0oAqg46VV1TTrPVItl9CHOMCQcMPxq7JG0bYYfjTKLXA5CWz17w2rPpFwbuwHPlOu7b/AMB6j8Kw9S8Y3F/cWX9oWNskcEm5njBL4IwQCenrj2FemKSpyDXJeMPDcNxDLe2SCOVRukjA4YdyPQ1k4JaotSvodLo0MBiDRSNJE4DJk8EGrTZt5tyj5e4HpXD+AdUdFOnTnJiG6I+q55H4f1rv2AmjyOtaaSRL0ZKCOGByp5zjtXDa7pr6XfGSNT9lkOUI7f7NddBJ5R8uT7hPB/un/CrFxDHPE0VwivG3BU965JJ035HXRq8ruchY3asgBPNdTpqeXZqzcF/nP07VTt/D9hDP5iiVgOdjNx/LNajOCvGMdAccUpSurI1q1VJWiX7f/UJn09akpkH+pTPpT664fCjz3uFFFFUIKKKKACmTNshdvRSafVbU22afcH/YI/Sk9ENK7Mfw8uYZm/iLAfp/9eqnjI7bKAHr5h/lWhoK7bHcMZLn+lUfE0DXV3p1vn/WOxOOw4z+ma8ta1Tspv8Ae3JvD9t9n0mINw8v7wj1z0H5Yq5d3CWVlPcynKRI0h7ZAGcf0qQgFtqjgYA4xiuX+IV032K102E/vbyUAj/ZBH9SPyrZe8yJyu2yj4KtJJmudYvPmubl2wT2Hf8Aw/CupqK0gW1tYoI/uRqFH4VKBk4Fd0VZHM3dksEJlb0UdTVzyIsY2CnxoEQKO1LTArm0TPDMB6VNHGsYwoxTqKACiiigAooooADg9QDRRRQAU2RBIm1qdRQBmOpRyp6im1avh8yN6jFVaBGfr15HZaZMz4Z5FMaJ/eYjGK4FLTUdKaHUTaTRoh+8y4DA9QfTNd5ZWckl21/fqPtHKwx5yIU/+KPc1p8MrJIodGG1lPIINQ4uTuWpW0INFvo7q2jljbdG4yKvXMORkdDXG6fnQdfk0xmP2S4/e2zHtn+H9P0967W2kDJg1SdyWrEENz5f7ucnb0D+n1q2FGAQcjHBBqKa3DDIqsElgJ8piueo7H8KynRUtUVGbRcORj5Sc9eelaUf+rX6CsZbuQD54lJ9VOK2YuYkPsKVKm4N3HOSktB1FFFbmYUUUUABOATXOaCN73L9yRj9TW9dtstZm9EJ/SsXw8uLWRu5fH6VyYt+6bU/hZW8XnZpqA9TIP5Gjwzb+TpQc4DzHd+HQf596PFcTXCWUC/flmwMduP/AK9aYVVCxoPlRQAMdMe9YU9IWOjm/dpBJIsEEk0pxGil29gBmuH8IwyahqF5rl2P3srkR5/hHt9BgfnWt4/vTBoq2kR/fXjiID/ZHLf0H41d0y1Flp8Fsv8AyzQA+57/AK100I9TmqMs1JDEZWwOAOpqOtOFPLjC9+9dJkNFvEBjYD7mozaITwzAelWKKBjY41jGFH406iigAooooAKCARyM0UUAA4HFFFFACOgdSrDis2VDG5U9q06q3w+434UAVKp6tex2FhLPLg4GFX+8x6CrlZtvaSXF+15fKAYyVt4s5CD+8f8AaP6Un5AvM4IWOpWSx6itrNGsZ3ByuBj0Psa9F0HUUvbSKaM/K46eh7iratgnIyDwQeciuTjH/CP+IzajI0+9+eHPRG9P6flUpchTfMdpcRBl3DoahhuDD8k2TH0Dd1/+tU1rKGQA06aAMMiqlFSVmSnbYkVV2qVO5eoIOaacqB8pJPXmqXlyQsTExTPXHQ/hUq3Ug4kjVvcHFc0qD6GqqdzZg/1SfSn1HbndBGcYyoOKkrpirJIye4UUUUxBRRRQAVQ11tulze+B+oq/WT4lbGnqv95x/Wpn8LLpq8kJow22EQx94E/rTJIw+rq5HEMJx7Fj/gDViyBS0gCjP7sfypiq4Mpccs3Y9sf/AK68qHxs2T1bHJncc5Pv/wDWrhLiT+1PiERnMVmNi/VRk/8Ajx/Su73CNHdz8qZJPsK8t8J36rr32m4YKLkvlj0BY5FdVLe4pHolSWwzOn1zUdPhbZKrHoDXac5pUUtJQMKKKKACiiigAooooAKKKKACiiigCC7jaRV2jOO1UmUqcMCPrWpQyhhhhkUAZVFPmj8uQr27UygRheM7I3OkC6i4uLNvMVh1255/Lg1p6JeC8sYLhcfvEBPse4/Op5oxLBLEwysiFD+Irm/AUp/s6SFjkxTMv58/1NTtIfQ7iM5FI2D1pIelMlYA1QhHVa1Iv9Wn0FYE9yEyM81u2zbreJvVAf0oAkooooAKKKKAKertt024P+zj8+Ko6Eu2xUkZ3MTVjxC23THH95gP1pmmArYW4A525/M5rhxjN4fAR3MYk1S2J6Qo7/icAf1qZSS3c98+n4Um2QSTM45OAoB7f5NPQcnPQcZNZQ+FF30OD1uT+0/HlrbZzFaAA/X77f0H4V1ledaNqEf/AAlT3srARzTyZY9gxIB/lXovYHtXdS0VjCY+EZmQe9aVZkbbXVvQ5rTBBGR0rUlBRRRQAUUUUAFFFFABRRRQAUUUUAFQ3cbSRjbyQc4qaigDLZWX7wI+opK1WAYYIyPQ1nXEflyEdjyKBEdZHi2x+36JIV/19t++jI68dR+XP4Vr0ABsq3KsMEexpNXVhp2ZQ8OX323Tbecn5mXDf7w4P61vxtkVwvgdjEt9ak8Q3BwPr/8AqruIOgoTugejHNjuKidU9KdKwBqnNchTjvTEblv/AKiP/dFSVBYv5lnCw7qKnoAKKKKACiiigArC8Ut+6t09ST+n/wBet2ue8RHffW0Xt/M//WrOq7RZpS+I1IvkVV44A/lUU22QDr1PQ1MVDDBXn1qBwFCqCAe3FeXS1bZojN8STm38N6lNwCIHAwc8kYH864/wj4ft7iwS6vk8xX4jjyQMDjJrovH0nl+FbkDjzGjT82B/pTvD6eXodiv/AEyB/Pmu+jFPcmbtsWLOzhs1K2+9U/ulywH0yeKsUUqKXYKvU10mJftG3QjPbipabEgjjCinUDCiiigAooooAKKKKACiiigAooooAKKKKAKl+OUPfmqtWb4/vFHoKrUCFHUVyPgf/j41MD7v2nArqbmYW9tLM3SNC5/AVzfw9iLWMszdZZ2b8sD/ABqXuNbHcKcR5rB8QatDp9u80zEKOAB1Y+grXu5NkWBXlfjC7N7rC24P7q3HI/2j1/TFOTsrgldlXUtXvtVL7nMFsekaHqPc969p0MbdF08elvGP/HRXhx4XHtXuWjf8gew/64R/+gis6cm27lzikkXKKKK1MwooooAxvE74s4l9Xz+QNWbX5IIlBH3F/lVDxQ257aMe5/kK0lUbApHQYrzsW9bHQvgRHNhxjk844NVNTn+zaReT8Dy4XYYOeimrThUAUYGSSKxfGUnleFNQI4LRhP8AvpgP60QWyH0OQ8GaDDeWQur1S8X3UjzjJHUmuws7GCyBFsHRCPub2Kj6AniqfhRPL8PWY9VLfmTWtXdGKSuYSbuFXrNi0WD/AAnFUlBZgAMk1owRiKPb36k1ZI+iiigYUUUUAFFFFABRRRQAUUUUAFFFFABVa/Hyoe+as1Uvjyi/jQBVoHWikdxGjO3CqCx+goEcl4Uz/bus+nnD+bV30eBHmuD8BAztf3TD/XXBP5D/AOvXbXEmyHAqY7DluZeuanFY28k0z7Y0HPqfYe9eb6lrd9qjsFc29seiKeWHuaueN7xrrUorNW/dxje4/wBo9P0/nWQAAAB0rOpO2iNIRvqz2fwioTwzpgHaBf5Vr1leFP8AkW9N/wCuC/yrVrVbGb3CiiimIKKKKACsa+sribWIZljzCu3LZHb2ooqZRUlZlRk46o0GikwQPwqIwS4XjoOeR6UUVhHCwjsNVGjn/G+k6hqWjw29hbmWTzldhvUYAB9SO5FXtP066hsLaJ4sOkaqRuHBA+tFFbRgo7Ccmyf7Fcf88/8Ax4VPaWsqOxdMccciiirJLXlv6UeW/pRRQAeW/pR5b+lFFAB5b+lHlv6UUUAHlv6UeW/pRRQAeW/pR5b+lFFAB5b+lHlv6UUUAHlv6UnlP6frRRQBTmtZ3lZhHx25FR/Yrj/nn/48KKKAMvxLpupXGkSwWNuZJZCFI3qvy9+pqfw1o0+m6XbQSx7ZET5huB+Y8nv6miilbW476WLl9aXUiHy4tx9NwGf1rzdfB/iB5pZprH95IxY/vo+//AqKKUo824KVh58Ha7g/6D/5Gj/+Kr1bTYnh061ikG2RIkVhnOCAM0UUowUdhyk5blmiiirJCiiigDG1ayuLnUIHjj3RIBk5A781otHJyB0oorCph41Hdl87skQ+RLtTjkdckVieMdMvtQ0B7aygMkzSISu9RwDk8kgdqKKaoxQOoyTR9Mu7bSrSGWLbJHGFYbgcH86ufYrj/nn/AOPCiitUQTWtrKkm50xx6irflv6UUUwDy39KPLf0oooAPLf0o8t/SiigA8t/Sjy39KKKADy39KPLf0oooAPLf0o8t/SiigA8t/Sjy39KKKADy39Kp3FrPJKSE46DkUUUARfYrj/nn/48Koa9p+oS6TcRWcG+aQbAN6jg9eSfSiihq4XsR+E9DudM0qCK4i2zcu43A4YnPY1qXlpcyKQkef8AgQoooQHnE3hHxBPe3FxJYcyOSP30fTt/FS/8Ifrv/Pj/AORo/wD4qiis3TT1LVRo9P0C3ltdFsYLhdkscKqy5BwQPar9FFWiAooopgf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Both the retroorbital fat and muscles are involved in the development of Graves' opthalmopathy. Cytokine released from fibroblast and pre-adipocytes accentuate the secretion of hyaluronic acid-like molecules, which increase the osmotic pressure in the tissues causing fluid accumulation and, in particular, disruption of the muscle bundles. This figure shows the marked swelling of the retroorbital muscles, often well visualized on MRI or CT scanning in such patients. The consequence of retroorbital swelling is proptosis (exophthalmos) not well illustrated here since this may depend on both the anatomy of the orbit and the degree of swelling.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_43_43699=[""].join("\n");
var outline_f42_43_43699=null;
var title_f42_43_43700="Supraperiosteal local infiltration";
var content_f42_43_43700=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F87820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F87820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Supraperiosteal (local) infiltration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 445px; height: 476px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    For supraperisoteal infiltration, insert the needle into the mucobuccal fold centered on the tooth to be anesthetized. The bevel of the needle should be facing the bone. Aim towards the maxilla and, once contact is made with the bone, withdraw the needle&nbsp;one mm. Aspirate to ensure you are not in a vessel and inject one to two mL local anesthetic at the apex of the root tip.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dubash BD, Hershkin AT, Seider PJ, Casey GM. Oral and Maxillofacial Regional Anesthesia. New York Society of Regional Anesthesia. Copyright &copy; NYSORA.",
"     <a href=\"file://www.nysora.com\" style=\"font-style: italic;\" target=\"_blank\">",
"      www.nysora.com",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_43_43700=[""].join("\n");
var outline_f42_43_43700=null;
var title_f42_43_43701="Congestive hepatopathy";
var content_f42_43_43701=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Congestive hepatopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/43/43701/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/43/43701/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/43/43701/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/43/43701/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/43/43701/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/43/43701/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/43/43701/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver's complex vascular supply and high metabolic activity make it particularly vulnerable to circulatory disturbances. The severity and characteristics of hepatic injury depend upon the blood vessels that are involved and the degree to which injury is related to passive congestion or diminished perfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43701/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several well-recognized forms of vascular injury to the liver, including Budd-Chiari syndrome, hepatic sinusoidal obstruction syndrome, passive congestion due to heart failure, hepatic infarction, and ischemic hepatitis. Congestive hepatopathy refers to hepatic manifestations attributable to passive hepatic congestion, as occurs in patients with right sided heart failure. Passive congestion often coexists with reduced cardiac output, making their relative contributions to hepatic injury intertwined. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/0/43013?source=see_link\">",
"     \"Pathogenesis of liver injury in circulatory failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will focus on passive congestion with a brief discussion on constrictive pericarditis, while discussions on Budd-Chiari syndrome, hepatic sinusoidal obstruction syndrome, ischemic hepatitis, and hepatic infarction are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/22/3434?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/4/40009?source=see_link\">",
"     \"Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18568?source=see_link\">",
"     \"Ischemic hepatitis, hepatic infarction, and ischemic cholangiopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any cause of right-sided heart failure can result in hepatic congestion, including constrictive pericarditis, mitral stenosis, tricuspid regurgitation, cor pulmonale, and cardiomyopathy. Tricuspid regurgitation in particular can be associated with severe hepatic congestion because of the transmission of right ventricular pressure directly into the hepatic veins.",
"   </p>",
"   <p>",
"    Patients with hepatic congestion are usually asymptomatic. In such patients, hepatic congestion may be suggested only by abnormal liver biochemical tests during routine evaluation.",
"   </p>",
"   <p>",
"    Symptomatic patients may present with jaundice, which may be mistaken for biliary obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43701/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients with acute cardiac decompensation may have jaundice and a significant increase in serum aminotransferases, simulating acute viral hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43701/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Right upper quadrant discomfort (due to stretching of the liver capsule) and ascites may also be present.",
"   </p>",
"   <p>",
"    Several cases of fulminant hepatic failure with coma, some resulting in death, have been reported in patients with congestive heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43701/abstract/2,4-7\">",
"     2,4-7",
"    </a>",
"    ]. Most have been in the setting of superimposed shock and hepatic ischemia rather than passive congestion alone.",
"   </p>",
"   <p>",
"    A number of physical findings may be present depending in part upon the severity of the congestion and its chronicity. In addition to jaundice, patients may have hepatomegaly, which can be massive. A normal liver span on physical examination as measured by the liver dullness is 10 to 12 cm for men and 8 to 11 cm for women (by ultrasound, a normal liver is typically less than 16 cm in the midclavicular line). The liver edge is typically firm, smooth, and somewhat tender. Splenomegaly is uncommon, but like cardiac ascites, represents transmitted central venous hypertension rather than liver disease.",
"   </p>",
"   <p>",
"    Hepatojugular reflux is generally present and is useful in differentiating hepatic congestion from either primary intrahepatic liver disease or Budd-Chiari syndrome. In patients with significant tricuspid regurgitation, the liver may be pulsatile, with palpable presystolic pulsations corresponding to prominent \"v waves\" on a right atrial pressure tracing. A loss of hepatic pulsatility in a patient with long-standing congestive hepatopathy suggests progression to cardiac cirrhosis.",
"   </p>",
"   <p>",
"    The most common liver biochemical abnormality is a mild elevation in the serum bilirubin level, which occurs in up to 70 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43701/abstract/8\">",
"     8",
"    </a>",
"    ]. The total serum bilirubin is usually less than 3",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    most of which is unconjugated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43701/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients with severe, usually acute, right-sided heart failure can develop striking hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43701/abstract/9\">",
"     9",
"    </a>",
"    ]. The total serum bilirubin level was a predictor of mortality and morbidity in one report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43701/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The precise cause of the hyperbilirubinemia is uncertain. Contributing factors may include hepatocellular dysfunction, hemolysis, pulmonary infarction, canalicular obstruction due to distended hepatic veins, medications, and superimposed sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43701/abstract/9\">",
"     9",
"    </a>",
"    ]. Serum bilirubin levels correlate with right atrial pressures but not with the cardiac output [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43701/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other liver biochemical tests are usually only mildly increased. The serum alkaline phosphatase level is usually normal or only minimally elevated even in the presence of jaundice, helping distinguish jaundice due to congestion from biliary obstruction. Serum aminotransferase levels are elevated in about one-third of patients, but typically no more than two to three times the upper limit of normal. Occasional patients have higher levels of elevation, probably because of coexisting ischemic injury due to decreased cardiac output [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43701/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. The degree of elevation in aminotransferases in such patients correlates with the extent of zone 3 necrosis seen on liver biopsy specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43701/abstract/11\">",
"     11",
"    </a>",
"    ]. Striking elevations in aminotransferases (exceeding 1000",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    or 50 times the upper limit of normal) may be seen in patients with hypotension due to heart failure and may cause confusion with viral hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43701/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum albumin levels are decreased in 30 to 50 percent of patients, but are rarely less than 2.5",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    The degree of hypoalbuminemia does not correlate with the degree of histologic liver damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43701/abstract/13\">",
"     13",
"    </a>",
"    ]. Hypoalbuminemia is more likely to be caused by malnutrition and protein-losing gastroenteropathy due to increased intestinal lymphatic pressure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/50/3881?source=see_link\">",
"     \"Protein-losing gastroenteropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prothrombin time is mildly abnormal in many patients. The cause is incompletely understood. It may in part be due to impaired hepatic synthesis of coagulation factors II, V, VII, IX, and X. However, the prothrombin time may not correct completely with administration of vitamin K, suggesting that other coagulation defects (such as disseminated intravascular coagulation) may also contribute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43701/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum ammonia levels may occasionally be elevated. Even more rarely, patients may have hepatic encephalopathy in the absence of any other evidence of liver dysfunction. The mechanism leading to hyperammonemia in heart failure is unknown, but in most cases it appears to be related to heart failure itself rather than to liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43701/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic congestion should be suspected in patients with the above clinical and laboratory features in a setting suggestive of congestive heart failure or other cardiac condition associated with elevated central venous pressure. Other causes of liver dysfunction should also be considered, including biliary obstruction, acute or chronic viral hepatitis, hepatic infiltrative disorders, and drug or herbal medication toxicity, depending upon the clinical setting.",
"   </p>",
"   <p>",
"    In addition to a careful history (especially for risk factors for liver disease and medications that might contribute to hepatic injury) and a physical examination, a reasonable evaluation might include serologic testing for viral hepatitis, hemochromatosis, Wilson disease (especially in a young person), autoimmune hepatitis, alpha-1 antitrypsin deficiency, celiac disease, thyroid dysfunction, a right upper quadrant ultrasound with Doppler studies of the portal and hepatic veins and hepatic artery, EKG, and a cardiac ultrasound. Other imaging approaches to identify hepatic congestion, including diffusion-weighted magnetic resonance imaging, are under study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43701/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34090?source=see_link\">",
"     \"Approach to the patient with abnormal liver biochemical and function tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with ascites should undergo a diagnostic paracentesis, which typically reveals a high ascitic protein content, usually greater than 2.5",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    reflecting the relatively well-preserved serum albumin levels and the contribution of \"hepatic lymph\" to the ascites. The increased protein is presumed to be due to the rupture of hepatic lymphatics, which are rich in protein. The serum to ascites albumin gradient is &ge;1.1, reflecting portal hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43701/abstract/17\">",
"     17",
"    </a>",
"    ]. A markedly elevated serum N-terminal-proBNP level distinguished ascites due to heart failure from ascites due to cirrhosis in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43701/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/43/14010?source=see_link\">",
"     \"Evaluation of adults with ascites\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Improvement in liver biochemical tests with treatment of the underlying cardiac condition provides support for the diagnosis. A liver biopsy can help confirm the diagnosis in equivocal cases (particularly in patients with coexisting liver disease) and establish the severity of histologic injury. Before considering a percutaneous liver biopsy, careful attention should be given to coagulation parameters, and a percutaneous biopsy should not be performed in patients with ascites. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/58/29608?source=see_link\">",
"     \"Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"nutmeg liver\" has been used classically to describe the gross appearance of a congested liver. This description reflects reddish central areas (representing sinusoidal congestion and bleeding into atrophic regions surrounding enlarged hepatic veins) with contrasting yellowish areas that represent either normal liver tissue or fatty liver. The liver tends to be enlarged with a purple hue and prominent hepatic veins.",
"   </p>",
"   <p>",
"    Microscopic examination shows sinusoidal engorgement, degeneration, and variable degrees of hemorrhagic necrosis in zone 3 of the hepatic acinus, fatty change, and variable degrees of cholestasis with occasional bile thrombi in the canaliculi. Bile thrombi are more commonly seen in patients with severe jaundice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43701/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with chronic or recurrent heart failure, reticulin and collagen accumulate in zone 3, eventually causing fibrous bands to extend outward from the central veins, occasionally linking with portal tracts to produce a lesion called cardiac sclerosis that resembles micromodular cirrhosis. Progressive fibrosis may lead to bridging between adjacent hepatic venules, producing rings of fibrosis around the spared portal regions that characterizes \"cardiac cirrhosis\" (or, more accurately, cardiac fibrosis). The histologic pattern is distinct from other forms of cirrhosis where fibrous bands tend to link adjacent portal areas.",
"   </p>",
"   <p>",
"    Fibrosis can also involve terminal hepatic venules, causing phlebosclerosis. The regeneration of periportal hepatocytes may result in discrete nodules, producing a pattern known as nodular regenerative hyperplasia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22791?source=see_link\">",
"     \"Focal nodular hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cornerstone of management for congestive hepatopathy is treatment of the underlying heart disease. Hepatic congestion and its clinical features, including jaundice and ascites, may respond dramatically to diuretics. Care should be given to avoid excess diuresis, which could impair hepatic perfusion and precipitate zone 3 necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43701/abstract/7\">",
"     7",
"    </a>",
"    ]. Of paramount importance is maintenance of cardiac output. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, patients may have an underlying coagulopathy, making them particularly sensitive to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    anticoagulation. Thus, coagulation status should be monitored closely if warfarin anticoagulation is being considered. Similar concerns relate to other drugs that require hepatic metabolism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis in patients with congestive hepatopathy is predicted mostly by the severity of the underlying heart disease. Liver disease rarely contributes significantly to morbidity or mortality.",
"   </p>",
"   <p>",
"    Early histologic changes associated with passive congestion may resolve with medical therapy to treat the underlying cardiac condition. By contrast, prolonged hepatic congestion over months to years can lead to cirrhosis. Most of these patients have either constrictive pericarditis or mitral valve disease and secondary tricuspid insufficiency.",
"   </p>",
"   <p>",
"    The presence of cirrhosis does not necessarily signal a poor prognosis. Such patients uncommonly develop serious sequelae of chronic liver disease such as variceal bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43701/abstract/9,19\">",
"     9,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CONSTRICTIVE PERICARDITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constrictive pericarditis is associated with clinical and pathologic changes in the liver similar to those seen in the Budd-Chiari syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43701/abstract/20\">",
"     20",
"    </a>",
"    ]. Hepatic vein pressures are generally higher than those seen in patients with right-sided heart failure, making patients with constrictive pericarditis relatively more likely to develop hepatic necrosis and ultimately cirrhosis.",
"   </p>",
"   <p>",
"    Patients with pericardial constriction may present with two types of complaints: those related to fluid overload, ranging from peripheral edema to anasarca; and those related to diminished cardiac output in response to exertion, such as fatigability and dyspnea on exertion. Constriction should be considered in any patient with an unexplained elevation in jugular venous pressure, particularly if there is a history of a predisposing condition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hepatomegaly, a pulsatile liver, massive ascites, and peripheral edema are common. By contrast, jaundice is characteristically absent for unclear reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43701/abstract/21\">",
"     21",
"    </a>",
"    ]. The clinical features described are relatively nonspecific, making it easy to mistake the underlying cause for primary hepatic cirrhosis or Budd-Chiari syndrome. Thus, a high index of suspicion for the diagnosis must be maintained. Important clues include elevated jugular venous pressure, Kussmaul's sign (a rise in the jugular venous pressure on inspiration), a pericardial knock, and pericardial calcification on chest radiograph. A correct diagnosis is critical since pericardiectomy is curative if performed early. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatic congestion can result from any cause of right-sided heart failure, including constrictive pericarditis, mitral stenosis, tricuspid regurgitation, cor pulmonale, and cardiomyopathy.",
"     </li>",
"     <li>",
"      Hepatic congestion should be suspected in patients with clinical and laboratory features suggestive of congestive heart failure or other cardiac condition associated with elevated central venous pressure. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to a careful history (especially for risk factors for liver disease and medications that might contribute to hepatic injury) and a physical examination, a reasonable evaluation might include serologic testing for viral hepatitis, hemochromatosis, Wilson disease (especially in a younger person), alpha-1 antitrypsin deficiency, celiac disease, autoimmune hepatitis, thyroid dysfunction, a right upper quadrant ultrasound with Doppler studies of the portal and hepatic veins and hepatic artery, EKG, and a cardiac ultrasound. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34090?source=see_link\">",
"       \"Approach to the patient with abnormal liver biochemical and function tests\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The cornerstone of management is treatment of the underlying heart disease. Care should be given to avoid excess diuresis, which could impair hepatic perfusion.",
"     </li>",
"     <li>",
"      Patients who require",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      anticoagulation for their cardiac condition should be monitored closely, since patients with congestive hepatopathy are at increased risk for excessive anticoagulation.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43701/abstract/1\">",
"      Giallourakis CC, Rosenberg PM, Friedman LS. The liver in heart failure. Clin Liver Dis 2002; 6:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43701/abstract/2\">",
"      Moussavian SN, Dincsoy HP, Goodman S, et al. Severe hyperbilirubinemia and coma in chronic congestive heart failure. Dig Dis Sci 1982; 27:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43701/abstract/3\">",
"      Cohen JA, Kaplan MM. Left-sided heart failure presenting as hepatitis. Gastroenterology 1978; 74:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43701/abstract/4\">",
"      LOGAN RG, MOWRY FM, JUDGE RD. Cardiac failure simulating viral hepatitis. Three cases with serum transaminase levels above 1,000. Ann Intern Med 1962; 56:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43701/abstract/5\">",
"      Nouel O, Henrion J, Bernuau J, et al. Fulminant hepatic failure due to transient circulatory failure in patients with chronic heart disease. Dig Dis Sci 1980; 25:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43701/abstract/6\">",
"      CASE RECORDS of the Massachusetts General Hospital; case 44212. N Engl J Med 1958; 258:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43701/abstract/7\">",
"      Kisloff B, Schaffer G. Fulminant hepatic failure secondary to congestive heart failure. Am J Dig Dis 1976; 21:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43701/abstract/8\">",
"      Dunn GD, Hayes P, Breen KJ, Schenker S. The liver in congestive heart failure: a review. Am J Med Sci 1973; 265:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43701/abstract/9\">",
"      SHERLOCK S. The liver in heart failure; relation of anatomical, functional, and circulatory changes. Br Heart J 1951; 13:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43701/abstract/10\">",
"      Allen LA, Felker GM, Pocock S, et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail 2009; 11:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43701/abstract/11\">",
"      Bynum TE, Boitnott JK, Maddrey WC. Ischemic hepatitis. Dig Dis Sci 1979; 24:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43701/abstract/12\">",
"      Denis C, De Kerguennec C, Bernuau J, et al. Acute hypoxic hepatitis ('liver shock'): still a frequently overlooked cardiological diagnosis. Eur J Heart Fail 2004; 6:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43701/abstract/13\">",
"      RICHMAN SM, DELMAN AJ, GROB D. Alterations in indices of liver function in congestive heart failure with particular reference to serum enzymes. Am J Med 1961; 30:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43701/abstract/14\">",
"      Jafri SM. Hypercoagulability in heart failure. Semin Thromb Hemost 1997; 23:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43701/abstract/15\">",
"      BESSMAN AN, EVANS JM. The blood ammonia in congestive heart failure. Am Heart J 1955; 50:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43701/abstract/16\">",
"      Dogan Y, Soylu A, Kilickesmez O, et al. The value of hepatic diffusion-weighted MR imaging in demonstrating hepatic congestion secondary to pulmonary hypertension. Cardiovasc Ultrasound 2010; 8:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43701/abstract/17\">",
"      Runyon BA. Cardiac ascites: a characterization. J Clin Gastroenterol 1988; 10:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43701/abstract/18\">",
"      Sheer TA, Joo E, Runyon BA. Usefulness of serum N-terminal-ProBNP in distinguishing ascites due to cirrhosis from ascites due to heart failure. J Clin Gastroenterol 2010; 44:e23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43701/abstract/19\">",
"      Naschitz JE, Slobodin G, Lewis RJ, et al. Heart diseases affecting the liver and liver diseases affecting the heart. Am Heart J 2000; 140:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43701/abstract/20\">",
"      Solano FX Jr, Young E, Talamo TS, Dekker A. Constrictive pericarditis mimicking Budd-Chiari syndrome. Am J Med 1986; 80:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43701/abstract/21\">",
"      Arora A, Tandon N, Sharma MP, Acharya SK. Constrictive pericarditis masquerading as Budd-Chiari syndrome. J Clin Gastroenterol 1991; 13:178.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3592 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-5CF79EDF2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_43_43701=[""].join("\n");
var outline_f42_43_43701=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CONSTRICTIVE PERICARDITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34090?source=related_link\">",
"      Approach to the patient with abnormal liver biochemical and function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/22/3434?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/12/12490?source=related_link\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/43/14010?source=related_link\">",
"      Evaluation of adults with ascites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22791?source=related_link\">",
"      Focal nodular hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18568?source=related_link\">",
"      Ischemic hepatitis, hepatic infarction, and ischemic cholangiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/4/40009?source=related_link\">",
"      Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/0/43013?source=related_link\">",
"      Pathogenesis of liver injury in circulatory failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/58/29608?source=related_link\">",
"      Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/50/3881?source=related_link\">",
"      Protein-losing gastroenteropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_43_43702="Drug-eluting intracoronary stents: General principles";
var content_f42_43_43702=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Drug-eluting intracoronary stents: General principles",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/43/43702/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/43/43702/contributors\">",
"     J Dawn Abbott, MD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/43/43702/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/43/43702/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/43/43702/contributors\">",
"     Stephan Windecker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/43/43702/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/43/43702/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/43/43702/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-eluting stents (DES) reduce the rate of restenosis and, accordingly, target lesion revascularization compared to bare metal stents (BMS). DES consist of a standard metallic stent, a polymer coating, and an anti-restenotic drug (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    or a derivative of sirolimus or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ) that is mixed within the polymer and is released over a period as short as days to as long as one year after implantation to reduce the local proliferative healing response. Four types of DES are currently approved: sirolimus-eluting, paclitaxel-eluting, zotarolimus-eluting, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    - stents (",
"    <a class=\"graphic graphic_table graphicRef65603 \" href=\"mobipreview.htm?11/39/11901\">",
"     table 1",
"    </a>",
"    ); the first two are uncommonly used.",
"   </p>",
"   <p>",
"    This topic will present the mechanisms of benefit of DES and discuss a few procedural and safety issues. The discussions of the comparison of DES to BMS and of one DES to another are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1081?source=see_link\">",
"     \"Drug-eluting compared to bare metal intracoronary stents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/62/16360?source=see_link\">",
"     \"Comparison of drug-eluting intracoronary stents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS OF BENEFIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late lumen loss and restenosis after nonstent interventions are caused by a combination of acute recoil, negative remodeling (arterial contraction) of the treated segment, and local neointimal hyperplasia. In contrast, late lumen loss after stenting is due solely to in-stent neointimal hyperplasia as the main benefit of stents is to prevent recoil and negative remodeling. Stents retain a larger acute lumen diameter (than balloon angioplasty) that offsets the reduction in lumen diameter from neointimal hyperplasia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/46/24298?source=see_link&amp;anchor=H4#H4\">",
"     \"Intracoronary stent restenosis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The restenosis benefit of DES compared to BMS results from inhibition of in-stent neointimal hyperplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43702/abstract/1\">",
"     1",
"    </a>",
"    ], which is reflected as a lesser degree of late in-stent lumen loss at six to nine months (0.1 to 0.4 versus 0.9 to 1.0 mm with BMS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43702/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Neointimal suppression is sustained at two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43702/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Neointimal suppression is sustained at two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43702/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biologic characteristics of the four available antirestenotic drugs used in DES include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43702/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       Sirolimus",
"      </a>",
"      is a macrocyclic triene antibiotic that has immunosuppressive and antiproliferative properties and inhibits the intracellular mammalian target of rapamycin (mTOR), thereby affecting cell cycle regulation. Sirolimus-eluting stents (SES) were developed to prevent the proliferation of smooth muscle cells and other cell types seen with restenosis after PCI. (See",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/35/27190?source=see_link\">",
"       \"Sirolimus: Patient drug information\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       Paclitaxel",
"      </a>",
"      interferes with the function of the microtubules responsible for proper chromosome segregation during cell division. It was first used as an antineoplastic agent. Paclitaxel-eluting stents (PES), like SES, were developed to prevent the proliferation of smooth muscle and other cell types seen with restenosis.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"       Everolimus",
"      </a>",
"      , is a semi-synthetic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      derivative in which the hydroxyl group at position C40 of sirolimus has been alkylated with a 2-hydroxyethyl group and that was shown in early small studies to be effective at preventing restenosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43702/abstract/8\">",
"       8",
"      </a>",
"      ]. It is slightly more liphophilic than sirolimus, and therefore it is more rapidly absorbed into the arterial wall. Zotarolimus is a derivative of sirolimus, in which the C40 position is modified by a tetrazole ring, resulting in a shorter circulating half-life of the drug. It is an equipotent analogue of sirolimus in vitro and in vivo was specifically developed for delivery from drug-eluting stents. Similar to everolimus, the compound is highly lipophilic, which is favorable for cellular uptake.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The length of time over which the drugs are eluted is presented in table form (",
"    <a class=\"graphic graphic_table graphicRef65603 \" href=\"mobipreview.htm?11/39/11901\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFICACY AND SAFETY COMPARED TO BMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;DES are preferred to BMS for most patients as there is strong evidence from randomized trials and large PCI registry data bases that DES significantly lower the rate of target lesion revascularization. With regard to their safety, the preponderance of evidence suggests that DES have similar rates of death and myocardial infarction (MI) to BMS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1081?source=see_link\">",
"     \"Drug-eluting compared to bare metal intracoronary stents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relative rates of stent thrombosis, which can manifest in either MI or death, between DES and BMS have been evaluated and the cumulative risk of stent thrombosis is similar. Stent thrombosis develops in approximately 1 percent of patients during the first year after placement. Very late stent thrombosis occurs at an annual rate of less than 1 percent; this rate may be somewhat higher with some first generation DES compared to BMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43702/abstract/9\">",
"     9",
"    </a>",
"    ] while the risk appears similar with second generation DES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43702/abstract/10\">",
"     10",
"    </a>",
"    ]. The discussion of stent thrombosis is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=see_link&amp;anchor=H19#H19\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Comparison of DES and BMS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     HYPERSENSITIVITY REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic reactions, including hypersensitivity, to infusion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    are well documented. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=see_link&amp;anchor=H32#H32\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'Taxanes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is not known whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    if delivered locally but for long periods of time can lead to hypersensitivity reactions. Most reports of possible hypersensitivity reactions associated with DES have attributed these reactions to concomitant medications such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    rather than the stent.",
"   </p>",
"   <p>",
"    In a review of the United States Food and Drug Administration database through 2004, there were 262 unique cases that included hypersensitivity symptoms after placement of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    stents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43702/abstract/11\">",
"     11",
"    </a>",
"    ]. Placement of a DES was thought to be a probable or possible cause in only ten cases. This report also identified 17 cases not in the database, including four autopsies that were probably or certainly caused by the stent; nine of these patients had symptoms that lasted more than four weeks. Intrastent eosinophilic inflammation, thrombosis, and lack of intimal healing were noted in the autopsied cases.",
"   </p>",
"   <p>",
"    There have been several reported cases of acute interstitial pneumonitis, a type of hypersensitivity reaction, which led to death within 20 days after placement a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    eluting stent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43702/abstract/12\">",
"     12",
"    </a>",
"    ]. While (paclitaxel) causality cannot be proven with certainty in these three cases, it is plausible given the report of cases in patients who have received the drug to treat cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22792?source=see_link\">",
"     \"Acute interstitial pneumonia (Hamman-Rich syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38344?source=see_link&amp;anchor=H4#H4\">",
"     \"Taxane-induced pulmonary toxicity\", section on 'Interstitial pneumonitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     CORONARY ARTERY ANEURYSMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary artery aneurysms (CAA) have been rarely reported after placement of drug-eluting stents (DES) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43702/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. In a retrospective study of 1197 patients who underwent stenting with DES, CAA were found at follow-up angiography in 15 (1.25 percent); the mean time between placement and CAA diagnosis was 313 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43702/abstract/13\">",
"     13",
"    </a>",
"    ]. Risk factors for the development of CAA included DES placement during acute myocardial infarction or in an occluded vessel, longer or multiple DES, and residual dissection.",
"   </p>",
"   <p>",
"    Other causes of coronary artery aneurysms include congenital and Kawasaki's disease-related aneurysms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/56/14218?source=see_link&amp;anchor=H25#H25\">",
"     \"Congenital and pediatric coronary artery abnormalities\", section on 'Coronary artery aneurysm'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30826?source=see_link&amp;anchor=H242696532#H242696532\">",
"     \"Cardiovascular sequelae of Kawasaki disease\", section on 'Coronary artery aneurysm'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348519696\">",
"    <span class=\"h1\">",
"     USE FOR SPECIFIC LESIONS OR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of DES in specific clinical situations is discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Left main or left anterior descending disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/20/4426?source=see_link\">",
"       \"Management of left main coronary artery disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/22/42343?source=see_link\">",
"       \"Management of significant proximal left anterior descending coronary artery disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Multivessel revascularization, ostial lesions, chronic total occlusion, long lesions (that may require overlapping stents), diffuse disease, bifurcation lesions, small coronary arteries, and intermediate (&lt;50 percent stenosis) lesions. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/22/17770?source=see_link\">",
"       \"Use of intracoronary stents for specific coronary lesions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary PCI for ST elevation myocardial infarction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31721?source=see_link&amp;anchor=H24756048#H24756048\">",
"       \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management\", section on 'Selection of stent type'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Non-ST elevation acute coronary syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=see_link\">",
"       \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Saphenous vein graft stenosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26538?source=see_link&amp;anchor=H12#H12\">",
"       \"Prevention, presentation, and management of saphenous vein graft stenosis\", section on 'Intracoronary stents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with diabetes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30970?source=see_link&amp;anchor=H11#H11\">",
"       \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\", section on 'Stent type'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/63/11258?source=see_link\">",
"       \"Management of coronary heart disease in women\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348519703\">",
"    <span class=\"h1\">",
"     OPTIMAL STENTING TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although restenosis is significantly less common with DES than BMS, it still occurs at a rate between 5 and 10 percent depending on the duration of follow-up and the complexity of the initial lesion. Clinical predictors appear to play a less relevant role in restenosis with DES compared to BMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43702/abstract/16\">",
"     16",
"    </a>",
"    ], while anatomic and technical factors seem to be more important. The incidence and risk factors for DES restenosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/46/24298?source=see_link&amp;anchor=H3#H3\">",
"     \"Intracoronary stent restenosis\", section on 'Drug-eluting stents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/46/24298?source=see_link&amp;anchor=H84738363#H84738363\">",
"     \"Intracoronary stent restenosis\", section on 'Predictors in DES'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When restenosis does occur with DES, it is often a consequence of balloon barotrauma to the artery in areas not covered by the stent, gaps in stent coverage, inadequate stent expansion, or inability of the drug to limit neointimal hyperplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43702/abstract/1,17-20\">",
"     1,17-20",
"    </a>",
"    ]. These concepts are supported by the following observations with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    -eluting stents (SES):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the SIRIUS trial, restenosis in the target lesion vessel segment (including the stent plus 5 mm proximal and distal to the stent) occurred more frequently than restenosis within the stent among patients receiving an SES (8.9 versus 3.2 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43702/abstract/2\">",
"       2",
"      </a>",
"      ]. The respective values in the E-SIRIUS trial were 5.9 and 3.9 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43702/abstract/3\">",
"       3",
"      </a>",
"      ]. The lower rate of in-segment restenosis in E-SIRIUS may have been due to differences in technique. In E-SIRIUS, direct stenting (without predilation) was used in 26 percent of lesions, gaps between stents were avoided with specific targets for vessel overlap, and longer stents were used per lesion length [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43702/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a single center series of 121 patients who had received an SES for the treatment of complex coronary lesions, repeat angiography performed more than 30 days after implantation identified restenosis in 19 (20 lesions) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43702/abstract/18\">",
"       18",
"      </a>",
"      ]. Among the 14 lesions that were assessed by intravascular ultrasound (IVUS), nine had either local injury to the vessel (residual dissection or balloon dilation outside the stented segment) or stent discontinuity (stent fracture or a gap between two stents).",
"     </li>",
"     <li>",
"      In a review of 33 lesions with SES failure, there were 26 in-stent stenoses (including six edge stenoses), four new stenoses more than 5 mm proximal to the stent, four thromboses, and one presumed embolization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43702/abstract/20\">",
"       20",
"      </a>",
"      ]. On IVUS, stent underexpansion (minimum stent area &lt;5.0 mm",
"      <sup>",
"       2",
"      </sup>",
"      ) was present in 22 (67 percent), negative remodeling was noted in four of six edge stenoses, and the four new stenoses were due to an increase in plaque area.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A central principle in the deployment of DES is to cover the entire lesion as well as sites of balloon predilation to cover all areas of balloon barotrauma. Multiple overlapping stents are sometimes required for diffusely diseased segments that cannot be treated adequately with a single stent. On the other hand, overlapping stents and total stent length are associated with an increased risk for restenosis, but the magnitude of the restenosis benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    stents appears similar in overlapping and single stents. Accordingly, the interplay of several factors influences the operator's decision as to the total length of stents deployed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/22/17770?source=see_link&amp;anchor=H10#H10\">",
"     \"Use of intracoronary stents for specific coronary lesions\", section on 'Overlapping stents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These observations stress the importance of optimal stenting techniques to avoid dilution of the anti-restenosis benefit of the DES demonstrated in the clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43702/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24889?source=see_link&amp;anchor=H8#H8\">",
"     \"General principles of the use of intracoronary stents\", section on 'Optimal stenting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7647664\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-eluting coronary stents are not an indication for antimicrobial prophylaxis before dental or invasive procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43702/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/10/43170?source=see_link\">",
"       \"Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/38/18020?source=see_link\">",
"       \"Patient information: Heart stents and angioplasty (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-eluting stents (DES) were developed to enhance the durability of stent therapy. DES inhibit neointimal hyperplasia, a response that may be stimulated by bare-metal stents (BMS).",
"   </p>",
"   <p>",
"    Although all currently approved DES have the same general components, they all differ with respect to the stent platform, polymer, and antirestenotic drug type (",
"    <a class=\"graphic graphic_table graphicRef65603 \" href=\"mobipreview.htm?11/39/11901\">",
"     table 1",
"    </a>",
"    ). Since each DES is unique, differences may be observed with respect to deliverability (ease of placement), efficacy (prevention of restenosis), and safety (stent thrombosis).",
"   </p>",
"   <p>",
"    Our recommendations for the choice of DES are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/62/16360?source=see_link\">",
"     \"Comparison of drug-eluting intracoronary stents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/62/16360?source=see_link&amp;anchor=H21#H21\">",
"     \"Comparison of drug-eluting intracoronary stents\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28651206\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to thank Dr. David O. Williams for his contributions as a Section Editor to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43702/abstract/1\">",
"      Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation 2005; 111:2257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43702/abstract/2\">",
"      Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43702/abstract/3\">",
"      Schofer J, Schl&uuml;ter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43702/abstract/4\">",
"      Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43702/abstract/5\">",
"      Mauri L, Orav EJ, O'Malley AJ, et al. Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stents. Circulation 2005; 111:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43702/abstract/6\">",
"      Aoki J, Colombo A, Dudek D, et al. Peristent remodeling and neointimal suppression 2 years after polymer-based, paclitaxel-eluting stent implantation: insights from serial intravascular ultrasound analysis in the TAXUS II study. Circulation 2005; 112:3876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43702/abstract/7\">",
"      Stefanini GG and Holmes DR. Drug-Eluting Coronary-Artery Stents. N Engl J Med 2013; 368:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43702/abstract/8\">",
"      Grube E, Sonoda S, Ikeno F, et al. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 2004; 109:2168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43702/abstract/9\">",
"      R&auml;ber L, Wohlwend L, Wigger M, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation 2011; 123:2819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43702/abstract/10\">",
"      Baber U, Mehran R, Sharma SK, et al. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol 2011; 58:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43702/abstract/11\">",
"      Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006; 47:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43702/abstract/12\">",
"      Fujimaki T, Kato K, Fukuda S, et al. Acute interstitial pneumonitis after implantation of paclitaxel-eluting stents: a report of two fatal cases. Int J Cardiol 2011; 148:e21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43702/abstract/13\">",
"      Alfonso F, P&eacute;rez-Vizcayno MJ, Ruiz M, et al. Coronary aneurysms after drug-eluting stent implantation: clinical, angiographic, and intravascular ultrasound findings. J Am Coll Cardiol 2009; 53:2053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43702/abstract/14\">",
"      Aoki J, Kirtane A, Leon MB, Dangas G. Coronary artery aneurysms after drug-eluting stent implantation. JACC Cardiovasc Interv 2008; 1:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43702/abstract/15\">",
"      Subramaniam KG, Akhunji Z. Drug eluting stent induced coronary artery aneurysm repair by exclusion. Where are we headed? Eur J Cardiothorac Surg 2009; 36:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43702/abstract/16\">",
"      Kastrati A, Dibra A, Mehilli J, et al. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation 2006; 113:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43702/abstract/17\">",
"      Carrozza JP Jr. Sirolimus-eluting stents: does a great stent still need a good interventionalist? J Am Coll Cardiol 2004; 43:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43702/abstract/18\">",
"      Lemos PA, Saia F, Ligthart JM, et al. Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circulation 2003; 108:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43702/abstract/19\">",
"      Fujii K, Mintz GS, Kobayashi Y, et al. Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. Circulation 2004; 109:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43702/abstract/20\">",
"      Takebayashi H, Kobayashi Y, Mintz GS, et al. Intravascular ultrasound assessment of lesions with target vessel failure after sirolimus-eluting stent implantation. Am J Cardiol 2005; 95:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43702/abstract/21\">",
"      Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116:1736.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1569 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-95F309B6B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_43_43702=[""].join("\n");
var outline_f42_43_43702=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS OF BENEFIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFICACY AND SAFETY COMPARED TO BMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      HYPERSENSITIVITY REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      CORONARY ARTERY ANEURYSMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H348519696\">",
"      USE FOR SPECIFIC LESIONS OR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H348519703\">",
"      OPTIMAL STENTING TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7647664\">",
"      ANTIMICROBIAL PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28651206\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1569\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1569|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/39/11901\" title=\"table 1\">",
"      Coronary artery stents approved in the United States",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22792?source=related_link\">",
"      Acute interstitial pneumonia (Hamman-Rich syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30826?source=related_link\">",
"      Cardiovascular sequelae of Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/62/16360?source=related_link\">",
"      Comparison of drug-eluting intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/56/14218?source=related_link\">",
"      Congenital and pediatric coronary artery abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30970?source=related_link\">",
"      Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=related_link\">",
"      Coronary artery stent thrombosis: Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1081?source=related_link\">",
"      Drug-eluting compared to bare metal intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24889?source=related_link\">",
"      General principles of the use of intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/46/24298?source=related_link\">",
"      Intracoronary stent restenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/63/11258?source=related_link\">",
"      Management of coronary heart disease in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/20/4426?source=related_link\">",
"      Management of left main coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/22/42343?source=related_link\">",
"      Management of significant proximal left anterior descending coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/10/43170?source=related_link\">",
"      Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/38/18020?source=related_link\">",
"      Patient information: Heart stents and angioplasty (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26538?source=related_link\">",
"      Prevention, presentation, and management of saphenous vein graft stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31721?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/35/27190?source=related_link\">",
"      Sirolimus: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38344?source=related_link\">",
"      Taxane-induced pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/22/17770?source=related_link\">",
"      Use of intracoronary stents for specific coronary lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_43_43703="Eosinophilic gastroenteritis";
var content_f42_43_43703=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Eosinophilic gastroenteritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/43/43703/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/43/43703/contributors\">",
"     Calman Prussin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/43/43703/contributors\">",
"     Nirmala Gonsalves, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/43/43703/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/43/43703/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/43/43703/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/43/43703/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/43/43703/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophilic gastroenteritis (EG) represents one member of a family of diseases that includes eosinophilic esophagitis, gastritis, enteritis, and colitis, collectively referred to as eosinophilic gastrointestinal disorders (EGIDs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/1\">",
"     1",
"    </a>",
"    ]. Despite its rarity, eosinophilic gastroenteritis needs to be recognized by the clinician because this treatable disease can masquerade as irritable bowel syndrome. The diagnosis of EG is confirmed by a characteristic biopsy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    eosinophilic ascitic fluid in the absence of infection by intestinal parasites or other causes of intestinal eosinophilia. Eosinophilic esophagitis is a distinct clinical entity and it is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EG has a peak age of onset in the third decade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/2\">",
"     2",
"    </a>",
"    ]. The clinical features of EG are related to the layer(s) and extent of bowel involved with eosinophilic infiltration: mucosa; muscle;",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subserosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/3\">",
"     3",
"    </a>",
"    ]. The prevalence of each subtype is unknown because of reporting and referral biases. Surgical series report a predominance of muscular disease with obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/4\">",
"     4",
"    </a>",
"    ], while medical series primarily describe patients with mucosal involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The disease can affect patients of any age, but typical presentations are in the third through fifth decade with a male predominance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MUCOSAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophilic mucosal infiltration produces nonspecific symptoms which depend upon the organ(s) involved. The entire gastrointestinal tract from esophagus to colon, including bile ducts, can be affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/5,8-10\">",
"     5,8-10",
"    </a>",
"    ]. The previous suggestion that eosinophilic gastroenteritis (EG) has a predilection for the distal antrum and proximal small bowel may have reflected a sampling bias because of the availability of these areas for biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective study of 40 patients, the most common symptoms were abdominal pain, nausea, vomiting, early satiety, and diarrhea, suggesting a possible diagnosis of irritable bowel syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/5\">",
"     5",
"    </a>",
"    ]. Only one-third of patients had a weight loss of 2.4 kg or more. Patients with diffuse small bowel disease can develop malabsorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/3,11\">",
"     3,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various laboratory tests can be abnormal in patients with mucosal EG:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peripheral eosinophil counts are usually elevated, ranging from 5 to 35 percent with an average absolute eosinophil count of 2000",
"      <span class=\"nowrap\">",
"       cells/microL,",
"      </span>",
"      but may be normal in about 20 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/5\">",
"       5",
"      </a>",
"      ]. The absolute eosinophil count rather than percent eosinophils is the best indicator to document eosinophilia.",
"     </li>",
"     <li>",
"      Patients with malabsorption may have the typical laboratory findings of this disorder: abnormal D-xylose test, increased fecal fat excretion, prolonged prothrombin time, and reduced serum iron concentration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/3,11\">",
"       3,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypoalbuminemia and anemia can be induced by a protein-losing enteropathy, impaired iron absorption, and occult gastrointestinal bleeding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/3,11,12\">",
"       3,11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The erythrocyte sedimentation rate is usually normal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/11\">",
"       11",
"      </a>",
"      ], but can be elevated modestly in about 25 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum IgE levels can be elevated, especially in children, and up to 50 percent may be atopic or have a history of food intolerance or allergy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/3,12-14\">",
"       3,12-14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     Barium",
"    </a>",
"    studies of the gastrointestinal tract may suggest the diagnosis but are neither sensitive nor specific. They typically reveal thickening or nodularity in the antrum and a thickened or \"saw-tooth\" mucosa in the small bowel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of mucosal EG is typically confirmed by endoscopic biopsies, which reveal &ge;20 to 25 eosinophils per high power field on microscopic examination (",
"    <a class=\"graphic graphic_picture graphicRef50254 \" href=\"mobipreview.htm?21/5/21593\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/5,16,17\">",
"     5,16,17",
"    </a>",
"    ]. Upper endoscopy with biopsy of the stomach and small intestine is diagnostic in at least 80 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/5,12\">",
"     5,12",
"    </a>",
"    ]. Typical endoscopic findings in mucosal disease include nodular or polypoid gastric mucosa, erythema, or erosions (",
"    <a class=\"graphic graphic_picture graphicRef50409 \" href=\"mobipreview.htm?17/60/18370\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are specific recommendations with respect to the diagnosis of EG:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Biopsies should be taken from both normal and abnormal appearing mucosa because even normal appearing mucosa can demonstrate eosinophilic inflammation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Multiple biopsy samples (at least four to five biopsies per site) should be taken from both the stomach and small intestine including areas with visual abnormalities to overcome sampling error [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/12,18\">",
"       12,18",
"      </a>",
"      ]. Biopsies that reveal increased eosinophils in sheets in conjunction with mucosal architectural abnormalities are diagnostic in the appropriate clinical setting. On the other hand, given its patchy mucosal involvement, even multiple normal mucosal biopsy specimens cannot exclude the diagnosis of EG in some patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one series, surgical biopsy of the terminal ileum was positive for mucosal involvement in five of six patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/5\">",
"     5",
"    </a>",
"    ]. Whether colonoscopic biopsies of the terminal ileum would be equally diagnostic is unknown. In two small series, colonoscopic biopsies revealed the disease in 6 of 11 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/5,17\">",
"     5,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MUSCLE LAYER DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophilic infiltration of the muscle layer of the gastrointestinal tract results in a thickened, rigid gut and symptoms of intestinal obstruction such as nausea, vomiting, and abdominal distention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/3,5,11\">",
"     3,5,11",
"    </a>",
"    ]. Pseudo-achalasia, esophageal stricture, perforation, or obstruction of the gastric outlet, small bowel, or rarely the colon can occur depending on the site of infiltration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/3-5,11,14,15,19,20\">",
"     3-5,11,14,15,19,20",
"    </a>",
"    ]. Food intolerance or allergic history is not usually present in patients with this form of eosinophilic gastroenteritis (EG). Patients may present with a peripheral eosinophilia with absolute eosinophil counts averaging 1000",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/5\">",
"     5",
"    </a>",
"    ]. Muscle involvement has been demonstrated in eosinophilic esophagitis in which it probably contributes to dysphagia by impairing esophageal motility. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of muscle layer disease is typically made after resection of small bowel for obstruction. In less acute presentations,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    studies usually reveal irregular luminal narrowing, especially in the distal antrum and proximal small bowel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/15\">",
"     15",
"    </a>",
"    ]. These findings can mimic those induced by cancer, lymphoma, or other malignancies. Endoscopic biopsies should be performed, but they are often nondiagnostic because mucosal involvement is lacking. In these cases, laparoscopic full thickness biopsy is usually necessary to exclude malignancy, thereby avoiding unnecessary radical resectional surgery by confirming the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUBSEROSAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with subserosal eosinophilic gastroenteritis (EG) present with isolated ascites or ascites in combination with symptoms characteristic of mucosal or muscular EG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/5\">",
"     5",
"    </a>",
"    ]. The diagnostic feature is a marked eosinophilia, up to 88 percent, in the ascitic fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients in this subgroup may have an allergic history and peripheral eosinophil counts as high as 8000",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/5\">",
"     5",
"    </a>",
"    ]. An eosinophilic pleural effusion may also be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29527?source=see_link\">",
"     \"Pleural fluid eosinophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of eosinophilic gastroenteritis (EG) is not well understood. Several epidemiologic and clinical features suggest an allergic component:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately one-half of patients have allergic disease, such as asthma, defined food sensitivities, eczema, or rhinitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/4,5,13\">",
"       4,5,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some patients have elevated serum IgE levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/3,12-14\">",
"       3,12-14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of food allergy as a stimulus to EG has not been as clearly defined as for eosinophilic esophagitis. However, several reports have described an allergic response to food allergens with improvement in disease activity with allergen avoidance with an elemental or elimination diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. In allergic EG patients, but not those with conventional anaphylactic food allergy, a population of IL-5 expressing food allergen specific T cells have been characterized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/24\">",
"     24",
"    </a>",
"    ]. This suggests that food exposure activates IL-5+ T cells in EG, leading to gut eosinophilia.",
"   </p>",
"   <p>",
"    As a result, a thorough allergy history and workup are important in management of this illness. Although food hypersensitivity plays an important role in EG pathogenesis, no food allergy test (skin, patch, or",
"    <span class=\"nowrap\">",
"     RAST/ImmunoCAP",
"    </span>",
"    test) has been shown to effectively identify specific culprit foods leading to clinical improvement.",
"   </p>",
"   <p>",
"    The American Gastroenterological Association (AGA) guideline for the evaluation of food allergies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/25\">",
"     25",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     file://www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Once eosinophils are recruited to the gastrointestinal tract, they are able to persist through the release of eosinophil active cytokines such as interleukin-3, interleukin-5, and granulocyte macrophage-colony stimulating factor (GM-CSF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/26\">",
"     26",
"    </a>",
"    ]. Eotaxin, a chemokine, appears to have a central role in the recruitment of eosinophils into the small intestine in response to antigen challenge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/27\">",
"     27",
"    </a>",
"    ]. Eosinophils may cause local inflammation by release of eosinophil major basic protein, a cytotoxic cationic protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophilic gastroenteritis (EG) should be suspected in any patient with gastrointestinal symptoms associated with peripheral eosinophilia. It should also be considered before making a diagnosis of irritable bowel syndrome. As noted above, the diagnosis of EG can be made in almost all cases by suspicion in the appropriate clinical context and endoscopic or full thickness biopsy or paracentesis.",
"   </p>",
"   <p>",
"    Other diseases in which gastrointestinal symptoms are associated with peripheral eosinophilia usually can be distinguished from EG with simple laboratory tests",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endoscopic biopsies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intestinal parasites such as Ancylostoma, Anisakis, Ascaris, Strongyloides, Toxocara, Trichiura, Capillaria, and Trichinella all cause eosinophilia and should be excluded with careful examination of the stool for ova or parasites",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      appropriate serologic testing. Such stool examination may reveal Charcot-Leyden crystals, which are the product of eosinophil granules. Infection with the dog hookworm, Ancylostoma caninum, mimics EG clinically and pathologically with eosinophilic infiltration of the gut wall and even ascites. Although reported so far only from Australia, the worm has a worldwide distribution and is easy to overlook even on pathologic specimens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24745?source=see_link\">",
"       \"Approach to the patient with eosinophilia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/37/40535?source=see_link\">",
"       \"Diseases with eosinophilic involvement of specific organs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Malignancies, such as lymphoma, gastric cancer, and colon cancer, can present with intestinal obstruction, masses on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      radiography, and eosinophilia. They can be differentiated from EG by endoscopic or full thickness biopsy. Conversely, EG can mimic some of the features of a MALT lymphoma, with bowel wall thickening and marked retroperitoneal lymphadenopathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11850?source=see_link\">",
"       \"Clinical features, diagnosis, and staging of gastric cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/32/8714?source=see_link\">",
"       \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Crohn's disease can usually be differentiated by the typical architectural distortion that is not found in EG. Rarely, Crohn's disease or ulcerative colitis may be associated with peripheral eosinophilia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an eosinophil rich tissue infiltrate. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/0/20490?source=see_link\">",
"       \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Polyarteritis nodosa is associated with systemic manifestations, a markedly elevated erythrocyte sedimentation rate, and perivascular eosinophilia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=see_link\">",
"       \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypereosinophilic syndrome (HES) is an idiopathic condition associated with marked peripheral eosinophilia and may rarely present with predominantly gastrointestinal symptoms. Many EG patients may formally fulfill the diagnostic criterion for HES (AEC &ge;1500",
"      <span class=\"nowrap\">",
"       cells/mL",
"      </span>",
"      present for over six months). However, HES, in contrast to EG, involves other organs such as the heart, lungs, brain, and kidneys and generally has a progressively fatal course [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30090?source=see_link\">",
"       \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\"",
"      </a>",
"      .) Because of the potential for confusion, patients with EG should be counseled that their prognosis is generally good and that they do not have HES.",
"     </li>",
"     <li>",
"      Eosinophilic granuloma (Langerhans cell histiocytosis), which can present as an antral mass, is diagnosed by its typical granulomatous appearance on biopsy specimens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21338?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An eosinophilic gastroenteritis, characterized by abdominal pain, diarrhea, gastrointestinal bleeding, and colitis, may precede or coincide with the vasculitic phase of the Churg-Strauss syndrome. Asthma is the cardinal feature of this disorder (occurring in more than 95 percent of patients) and usually precedes the vasculitic phase by approximately 8 to 10 years. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21383?source=see_link\">",
"       \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the natural history and therapy of eosinophilic gastroenteritis (EG) are limited to case reports and retrospective series of less than 20 patients. Untreated patients with EG may rarely remit spontaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/17\">",
"     17",
"    </a>",
"    ] or progress to severe malabsorption and malnutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There have been no prospective, randomized therapeutic clinical trials. Thus, treatment is empiric and based upon the severity of the clinical manifestations.",
"   </p>",
"   <p>",
"    Patients who are symptomatic or have evidence of malabsorption may be treated with systemic glucocorticoids. Micronutrient deficiencies should be sought and replaced as needed. In cases of severe malabsorption, a dietary consultation may be valuable to help identify nutritional deficits. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38232?source=see_link\">",
"     \"Clinical features and diagnosis of malabsorption\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22279?source=see_link\">",
"     \"Overview of the treatment of malabsorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although food hypersensitivity plays an important role in EG pathogenesis, no food allergy test (skin, patch or allergen specific IgE) has been shown to effectively identify specific culprit foods leading to clinical improvement of EG symptoms or tissue eosinophilia. Thus, at present there is no evidence base to support routine food allergy testing of EG patients for use in clinical decision making. A prospective trial in adults with EG has demonstrated clinical remission with a six-week course of dietary elimination. In this study, three of seven adults undergoing an empiric six food elimination diet and six of six adults undergoing elemental diet had significant reduction in symptoms, complete histologic remission, endoscopic improvement and normalization of peripheral eosinophilia within six weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The empiric elimination diet is similar to the six-food elimination diets employed in EoE, with the patient avoiding soy, wheat, corn, egg, milk, peanut, and seafood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/32\">",
"     32",
"    </a>",
"    ]. While empiric dietary elimination and elemental diets have also demonstrated success in pediatric EoE patients, limitations exist due to patient tolerance. Dietary therapy should be pursued in motivated patients under the guidance of a dietitian trained in eosinophilic gastrointestinal disorders.",
"   </p>",
"   <p>",
"    If dietary measures do not result in decreased symptoms and tissue eosinophilia, we suggest a trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (typically 20 to 40",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    Improvement usually occurs within two weeks regardless of the layer of bowel involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/11,16\">",
"     11,16",
"    </a>",
"    ]. Prednisone should then be tapered rapidly over the next two weeks. However, some patients require more prolonged therapy (up to several months) to produce resolution of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/8,16\">",
"     8,16",
"    </a>",
"    ]. Patients not responding to prednisone can be tried on intravenous glucocorticoids.",
"   </p>",
"   <p>",
"    The subsequent course is variable. Some patients have no recurrences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/3\">",
"     3",
"    </a>",
"    ], or only require periodic glucocorticoid bursts, while most experience recurrent symptoms during or immediately after the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    taper. The latter patients may require long-term, low-dose maintenance therapy with prednisone (eg, 5 to 10",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/3,11,16\">",
"     3,11,16",
"    </a>",
"    ]. Other patients experience periodic flares months to years after the initial episode. They can be treated with another short course of oral prednisone, 20 to 40",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    followed by a rapid taper [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several other approaches have been described in case reports or small series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Successful transition from oral, conventional glucocorticoids to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      (non-enterically coated) was described in patients with EG involving the gastric antrum and small intestine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/33-35\">",
"       33-35",
"      </a>",
"      ]. It should be noted that the formulation of budesonide currently available for gastrointestinal use is in controlled ileal release capsules, which largely bypass the upper gastrointestinal tract.",
"     </li>",
"     <li>",
"      Oral cromolyn (800",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in four divided doses) has been effective for short- and long-term management in some [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/36,37\">",
"       36,37",
"      </a>",
"      ], but not all [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/5\">",
"       5",
"      </a>",
"      ], case reports. This agent works by preventing the release of mast cell mediators, including histamine, platelet-activating factor, and leukotrienes, and also is thought to reduce absorption of antigens by the small intestine.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33024?source=see_link\">",
"       Ketotifen",
"      </a>",
"      (Zaditen), an H1-antihistamine, has been helpful in individual cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/38-40\">",
"       38-40",
"      </a>",
"      ]. The drug is approved for treatment of urticaria in Canada, Europe, and Japan, but is not available in the United States. In adults, it is administered at a starting dose of 1 mg at night and increased to 2 to 4 mg per day for one to four months.",
"     </li>",
"     <li>",
"      The leukotriene antagonist,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      , was effective in some reported cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/41-43\">",
"       41-43",
"      </a>",
"      ] but not in others [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A clinical response to suplatast tosilate (a novel antiallergic drug that suppresses cytokine production including interleukin-4 and interleukin-5 from T helper 2 cells) was described in a single patient [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a preliminary report of four patients, treatment with a humanized anti-interleukin-5 antibody was associated with reduced peripheral and tissue eosinophil counts but had no effect on symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/46\">",
"       46",
"      </a>",
"      ]. Rebound eosinophilia has been observed after the drug was discontinued [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/47\">",
"       47",
"      </a>",
"      ]. A report of nine patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      described significant improvement in symptoms and measures of IgE mediated allergy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43703/abstract/7\">",
"       7",
"      </a>",
"      ]. Tissue eosinophilia was reduced but results were not statistically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The signs and symptoms of eosinophilic gastroenteritis (EG) are related to the layer(s) and extent of bowel involved with eosinophilic infiltration: mucosa; muscle;",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      subserosa. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mucosal disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Muscle layer disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Subserosal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Eosinophilic mucosal infiltration produces nonspecific symptoms, which depend upon the organ(s) involved. Most common symptoms are abdominal pain, nausea, early satiety, vomiting, diarrhea, and weight loss.",
"     </li>",
"     <li>",
"      Eosinophilic infiltration of the muscle layer of the gastrointestinal tract results in a thickened, rigid gut and symptoms of intestinal obstruction such as nausea, vomiting, and abdominal distention. If the disorder is not properly diagnosed, unnecessary radical resectional surgery may be undertaken. Most patients with muscle layer involvement respond dramatically to medical therapy with systemic glucocorticoids. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Muscle layer disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with subserosal EG present with isolated ascites or ascites in combination with symptoms characteristic of mucosal or muscular EG. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Subserosal disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest the following approach, which is based upon observational data and clinical experience:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who are symptomatic or have evidence of malabsorption, we suggest an initial attempt at an empiric elimination diet, an elemental diet, or a six-food elimination diet for six weeks. This approach is similar to dietary interventions used to treat eosinophilic esophagitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/16/44297?source=see_link\">",
"       \"Treatment of eosinophilic esophagitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If a dietary approach is undertaken, patients should be referred to a dietitian to obtain proper education on the foods to avoid. If a history of environmental allergens is identified, these should be treated in conjunction with the diet.",
"     </li>",
"     <li>",
"      If the dietary changes are successful at reducing symptoms, peripheral eosinophilia, and tissue eosinophilia, foods can be added back slowly in a systematic fashion from least allergenic to most allergenic.",
"     </li>",
"     <li>",
"      We follow patients based upon their symptoms and the changes in peripheral eosinophilia. We perform a repeat endoscopy when there is uncertainty regarding the response to treatment",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      degree of ongoing disease activity.",
"     </li>",
"     <li>",
"      In patients who decline a dietary approach or whose symptoms, tissue and peripheral eosinophilia do not improve after the diet, we suggest a trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (20 to 40",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      Improvement usually occurs within two weeks regardless of the layer of bowel involved. Prednisone should then be tapered rapidly over the next two weeks. However, some patients require more prolonged therapy (up to several months) to produce resolution of symptoms. Patients who relapse immediately after steroid cessation may need chronic low dose steroids or transition to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      or other agents as outlined above.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/1\">",
"      Rothenberg ME. Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immunol 2004; 113:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/2\">",
"      Min KU, Metcalf DD. Eosinophilic gastroenteritis. Immunol Allergy Clin North Am 1991; 11:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/3\">",
"      Klein NC, Hargrove RL, Sleisenger MH, Jeffries GH. Eosinophilic gastroenteritis. Medicine (Baltimore) 1970; 49:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/4\">",
"      Yun MY, Cho YU, Park IS, et al. Eosinophilic gastroenteritis presenting as small bowel obstruction: a case report and review of the literature. World J Gastroenterol 2007; 13:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/5\">",
"      Talley NJ, Shorter RG, Phillips SF, Zinsmeister AR. Eosinophilic gastroenteritis: a clinicopathological study of patients with disease of the mucosa, muscle layer, and subserosal tissues. Gut 1990; 31:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/6\">",
"      Chang JY, Choung RS, Lee RM, et al. A shift in the clinical spectrum of eosinophilic gastroenteritis toward the mucosal disease type. Clin Gastroenterol Hepatol 2010; 8:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/7\">",
"      Foroughi S, Foster B, Kim N, et al. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol 2007; 120:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/8\">",
"      Schoonbroodt D, Horsmans Y, Laka A, et al. Eosinophilic gastroenteritis presenting with colitis and cholangitis. Dig Dis Sci 1995; 40:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/9\">",
"      Haberkern CM, Christie DL, Haas JE. Eosinophilic gastroenteritis presenting as ileocolitis. Gastroenterology 1978; 74:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/10\">",
"      Matsushita M, Hajiro K, Morita Y, et al. Eosinophilic gastroenteritis involving the entire digestive tract. Am J Gastroenterol 1995; 90:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/11\">",
"      Cello JP. Eosinophilic gastroenteritis--a complex disease entity. Am J Med 1979; 67:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/12\">",
"      Katz AJ, Goldman H, Grand RJ. Gastric mucosal biopsy in eosinophilic (allergic) gastroenteritis. Gastroenterology 1977; 73:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/13\">",
"      Caldwell JH, Tennenbaum JI, Bronstein HA. Serum IgE in eosinophilic gastroenteritis. Response to intestinal challenge in two cases. N Engl J Med 1975; 292:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/14\">",
"      Landres RT, Kuster GG, Strum WB. Eosinophilic esophagitis in a patient with vigorous achalasia. Gastroenterology 1978; 74:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/15\">",
"      MacCarty RL, Talley NJ. Barium studies in diffuse eosinophilic gastroenteritis. Gastrointest Radiol 1990; 15:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/16\">",
"      Lee CM, Changchien CS, Chen PC, et al. Eosinophilic gastroenteritis: 10 years experience. Am J Gastroenterol 1993; 88:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/17\">",
"      Lee M, Hodges WG, Huggins TL, Lee EL. Eosinophilic gastroenteritis. South Med J 1996; 89:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/18\">",
"      Leinbach GE, Rubin CE. Eosinophilic gastroenteritis: a simple reaction to food allergens? Gastroenterology 1970; 59:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/19\">",
"      Man F, Chiocca JC. Achalasia due to eosinophil infiltration: fact or fiction? Dig Dis Sci 1993; 38:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/20\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 20-1992. A 24-year-old man with asthma and bouts of epigastric pain, nausea, and vomiting. N Engl J Med 1992; 326:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/21\">",
"      Chehade M, Magid MS, Mofidi S, et al. Allergic eosinophilic gastroenteritis with protein-losing enteropathy: intestinal pathology, clinical course, and long-term follow-up. J Pediatr Gastroenterol Nutr 2006; 42:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/22\">",
"      Chen MJ, Chu CH, Lin SC, et al. Eosinophilic gastroenteritis: clinical experience with 15 patients. World J Gastroenterol 2003; 9:2813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/23\">",
"      Gonsalves N, Doerfler B, Yang G, et al. A prospective clinical trial of six food elimination diet or elemental diet in the treatment of adults with eosinophilic gastroenteritis (abstract). Gastroenterology 2009; 136:S1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/24\">",
"      Prussin C, Lee J, Foster B. Eosinophilic gastrointestinal disease and peanut allergy are alternatively associated with IL-5+ and IL-5(-) T(H)2 responses. J Allergy Clin Immunol 2009; 124:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/25\">",
"      American Gastroenterological Association medical position statement: guidelines for the evaluation of food allergies. Gastroenterology 2001; 120:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/26\">",
"      Desreumaux P, Bloget F, Seguy D, et al. Interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 in eosinophilic gastroenteritis. Gastroenterology 1996; 110:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/27\">",
"      Hogan SP, Mishra A, Brandt EB, et al. A critical role for eotaxin in experimental oral antigen-induced eosinophilic gastrointestinal allergy. Proc Natl Acad Sci U S A 2000; 97:6681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/28\">",
"      Talley NJ, Kephart GM, McGovern TW, et al. Deposition of eosinophil granule major basic protein in eosinophilic gastroenteritis and celiac disease. Gastroenterology 1992; 103:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/29\">",
"      Walker NI, Croese J, Clouston AD, et al. Eosinophilic enteritis in northeastern Australia. Pathology, association with Ancylostoma caninum, and implications. Am J Surg Pathol 1995; 19:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/30\">",
"      Fauci AS, Harley JB, Roberts WC, et al. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982; 97:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/31\">",
"      Blackshaw AJ, Levison DA. Eosinophilic infiltrates of the gastrointestinal tract. J Clin Pathol 1986; 39:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/32\">",
"      Kagalwalla AF, Sentongo TA, Ritz S, et al. Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin Gastroenterol Hepatol 2006; 4:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/33\">",
"      Tan AC, Kruimel JW, Naber TH. Eosinophilic gastroenteritis treated with non-enteric-coated budesonide tablets. Eur J Gastroenterol Hepatol 2001; 13:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/34\">",
"      Siewert E, Lammert F, Koppitz P, et al. Eosinophilic gastroenteritis with severe protein-losing enteropathy: successful treatment with budesonide. Dig Liver Dis 2006; 38:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/35\">",
"      Elsing C, Placke J, Gross-Weege W. Budesonide for the treatment of obstructive eosinophilic jejunitis. Z Gastroenterol 2007; 45:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/36\">",
"      Van Dellen RG, Lewis JC. Oral administration of cromolyn in a patient with protein-losing enteropathy, food allergy, and eosinophilic gastroenteritis. Mayo Clin Proc 1994; 69:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/37\">",
"      P&eacute;rez-Mill&aacute;n A, Mart&iacute;n-Lorente JL, L&oacute;pez-Morante A, et al. Subserosal eosinophilic gastroenteritis treated efficaciously with sodium cromoglycate. Dig Dis Sci 1997; 42:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/38\">",
"      Melamed I, Feanny SJ, Sherman PM, Roifman CM. Benefit of ketotifen in patients with eosinophilic gastroenteritis. Am J Med 1991; 90:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/39\">",
"      Katsinelos P, Pilpilidis I, Xiarchos P, et al. Oral administration of ketotifen in a patient with eosinophilic colitis and severe osteoporosis. Am J Gastroenterol 2002; 97:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/40\">",
"      Bolukbas FF, Bolukbas C, Uzunkoy A, et al. A dramatic response to ketotifen in a case of eosinophilic gastroenteritis mimicking abdominal emergency. Dig Dis Sci 2004; 49:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/41\">",
"      Neustrom MR, Friesen C. Treatment of eosinophilic gastroenteritis with montelukast. J Allergy Clin Immunol 1999; 104:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/42\">",
"      Schwartz DA, Pardi DS, Murray JA. Use of montelukast as steroid-sparing agent for recurrent eosinophilic gastroenteritis. Dig Dis Sci 2001; 46:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/43\">",
"      Quack I, Sellin L, Buchner NJ, et al. Eosinophilic gastroenteritis in a young girl--long term remission under Montelukast. BMC Gastroenterol 2005; 5:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/44\">",
"      Daikh BE, Ryan CK, Schwartz RH. Montelukast reduces peripheral blood eosinophilia but not tissue eosinophilia or symptoms in a patient with eosinophilic gastroenteritis and esophageal stricture. Ann Allergy Asthma Immunol 2003; 90:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/45\">",
"      Shirai T, Hashimoto D, Suzuki K, et al. Successful treatment of eosinophilic gastroenteritis with suplatast tosilate. J Allergy Clin Immunol 2001; 107:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/46\">",
"      Prussin C, James SP, Huber MM, et al. Pilot study of anti-IL-5 in eosinophilic gastroenteritis (abstract). J Allergy Clin Immunol 2003; 11:A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43703/abstract/47\">",
"      Kim YJ, Prussin C, Martin B, et al. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. J Allergy Clin Immunol 2004; 114:1449.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2536 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-4F5D24ED7D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_43_43703=[""].join("\n");
var outline_f42_43_43703=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MUCOSAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MUSCLE LAYER DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUBSEROSAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PROGNOSIS AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2536\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2536|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/5/21593\" title=\"picture 1\">",
"      Biopsy eosinophil gastroent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/60/18370\" title=\"picture 2\">",
"      Endosc eosinophil gastroent",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24745?source=related_link\">",
"      Approach to the patient with eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38232?source=related_link\">",
"      Clinical features and diagnosis of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11850?source=related_link\">",
"      Clinical features, diagnosis, and staging of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21338?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30090?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/32/8714?source=related_link\">",
"      Clinical presentation and diagnosis of primary gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/37/40535?source=related_link\">",
"      Diseases with eosinophilic involvement of specific organs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21383?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22279?source=related_link\">",
"      Overview of the treatment of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29527?source=related_link\">",
"      Pleural fluid eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/16/44297?source=related_link\">",
"      Treatment of eosinophilic esophagitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_43_43704="Cancer pain management: General principles and risk management for patients receiving opioids";
var content_f42_43_43704=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cancer pain management: General principles and risk management for patients receiving opioids",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/43/43704/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/43/43704/contributors\">",
"     Russell K Portenoy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/43/43704/contributors\">",
"     Zankhana Mehta, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/43/43704/contributors\">",
"     Ebtesam Ahmed, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/43/43704/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/43/43704/contributors\">",
"     Janet Abrahm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/43/43704/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/43/43704/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/43/43704/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain is highly prevalent in the cancer population. Virtually all patients with malignant disease experience recurrent episodes of acute pain, which may accompany surgery, invasive procedures, or complications, such as a pathological fracture. In addition, chronic pain that is severe enough to warrant opioid therapy is experienced by 30 to 50 percent of patients undergoing active antineoplastic therapy and by 75 to 90 percent of those with advanced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The causes of chronic pain are diverse in this population, and both prevalence and severity vary with the type of neoplasm, stage and extent of disease, prior treatment, comorbidities, and other factors. Tissue injury produced by the neoplasm is the primary etiology in about three-fourths of patients with chronic cancer pain, and the remainder have pain related to the late effects of antineoplastic therapy or to painful comorbidities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=see_link\">",
"     \"Assessment of cancer pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Opioid therapy is the first-line approach for moderate or severe chronic cancer pain. While opioids are effective analgesics, they are potentially abusable drugs. The public health consequences of opioid abuse drive the imperative that all physicians assume responsibility for risk management when these drugs are prescribed for legitimate medical purposes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=see_link\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will cover the general principles of cancer pain management and provide an overview of risk assessment and management in patients treated with opioids. An overview of assessment of cancer pain, a review of specific cancer pain syndromes, the clinical use of opioid analgesics, non-opioid analgesics (including adjuvant analgesics) and non-pharmacologic methods of cancer pain management are covered elsewhere. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE PROBLEM OF UNDERTREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate pain relief can be achieved in 70 to 90 percent of patients when well-accepted treatment guidelines for cancer pain are followed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. Given that most recommended therapies for cancer pain are within the scope of both specialty and primary care medical practice, the treatment of cancer pain should be viewed as a best practice for all medical disciplines involved in the care of this population.",
"   </p>",
"   <p>",
"    Unfortunately, the availability of effective therapy has not eliminated the problem of undertreatment of cancer pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/8-13\">",
"     8-13",
"    </a>",
"    ]. A systematic review suggested that the rate of undertreatment of cancer pain may be over 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/8\">",
"     8",
"    </a>",
"    ]. Furthermore, the odds of undertreatment are twice as high for minority patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The causes of undertreatment are multifactorial and reflect the combined effects of clinician-, patient-, and system-related barriers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/9,14-17\">",
"     9,14-17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinicians often have inadequate knowledge and skills, or attitudes that minimize the importance of pain management. They may be reluctant to prescribe drugs due to concern about side effects or a fear of hastening death through aggressive pain control. &nbsp;",
"     </li>",
"     <li>",
"      Patients may underreport pain because of stoicism, a desire to be liked, or concerns about distracting the physician from antineoplastic treatment. In addition, when opioid therapy is provided, therapeutic nonadherence is believed to be common, perhaps due to fear of addiction or the development of side effects.",
"     </li>",
"     <li>",
"      System-wide impediments to optimal analgesic therapy may include financial concerns (eg, lack of health care insurance coverage, inability to purchase drugs), a limited number of specialists in pain management or palliative care, and an incentive structure in the health care system that does not encourage physicians to manage pain as a priority.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Uncontrolled pain results in unnecessary suffering, decreased ability to cope with illness, interference with activities of daily living, and extended or repeat hospital admissions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/16,18\">",
"     16,18",
"    </a>",
"    ]. Uncontrolled pain may also delay or disrupt anticancer treatment, compromising its effectiveness.",
"   </p>",
"   <p>",
"    Given the profound impact of uncontrolled pain on all aspects of life, and the prevalence and complexity of undertreatment, clinicians must be attuned to the possibility that poorly controlled pain is being under-reported, and that it may be the result of poor access to care, under prescribing,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nonadherence. The risk should be assumed to be particularly high in vulnerable populations, including minorities, the poor or uninsured, and in patients with a history of chemical dependency or other serious psychiatric disease. Awareness of undertreatment and the willingness to confront its causes is a first step toward improving outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PAIN MANAGEMENT WITHIN THE CONTEXT OF PALLIATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among individuals with cancer, pain is best considered as a domain within the broader context of palliative care. Palliative care is an interdisciplinary therapeutic approach that focuses on the comprehensive management of the physical, psychological, social, and spiritual needs of patients with serious or life-threatening disease and their families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overriding goal of palliative care is to reduce suffering and maintain an acceptable quality of life throughout the course of a progressive illness. The principles of palliative care treatment do not only apply to individuals at the end of life. Palliative care focuses on diminishing the burden of illness from the time of diagnosis to death. It must respond to a variety of needs, which may become more complex during the period when the disease is advanced and the patient is actively dying. Effective palliative care considers the needs of both the patient and his or her family, viewing the family as the unit of care. It addresses the nature of grief before the death and into the bereavement period that follows. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29801?source=see_link\">",
"     \"Palliative care: Benefits, services, and models of care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    From the perspective of palliative care, pain assessment and management are major aspects of the care plan that focuses on many domains related to quality of life. Pain management should be integrated into other strategies that are being used to address other key goals, such as the relief of other symptoms (eg, dyspnea, fatigue), coordination of care across sites, appropriate advance care planning, and management of family distress.",
"   </p>",
"   <p>",
"    Like pain management itself, the broader clinical concerns that constitute palliative care should be considered a best practice for all clinicians engaged in the treatment of patients with cancer. At a generalist level, this typically takes the form of multidimensional assessment and intervention in a variety of domains related to preserving function, improving adaptation, and maintaining quality of life. When the clinical issues are complex, particularly when pain is difficult to control or accompanied by other concerns, referral to a palliative care specialist is appropriate.",
"   </p>",
"   <p>",
"    Palliative medicine specialists work in interdisciplinary teams, either in institution-based palliative care programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/20\">",
"     20",
"    </a>",
"    ] or in community-based hospice programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/21\">",
"     21",
"    </a>",
"    ]. In 2006, Hospice and Palliative Medicine was recognized by the American Board of Medical Subspecialties as a formal subspecialty in the United States. It is expected that the number of board certified physician palliative care specialists will increase over time and access to specialist care should grow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pain specialists also are available in other disciplines. However, because pain specialists vary in background, training, interest and accessibility, the clinician seeking help for a patient with challenging pain should ensure that a pain specialist has experience and capability in cancer pain before making a referral.",
"   </p>",
"   <p>",
"    Regardless of the treatment team, assessment of the patient with cancer pain requires a clear understanding of the goals of care in relation to the broader treatment plan. As an illness advances, the goals of the patient and his or her family may evolve, gradually shifting to an emphasis on comfort above all else. As this occurs, decisions about therapy and the information provided to the patient and family may change. Ongoing communication is key to successfully transition the goals of care, provide education and support to the patient and his or her family, and change therapy appropriately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES OF PAIN MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;An effective strategy for cancer pain management is predicated on several broad principles:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A detailed assessment of the pain should be performed initially; careful reassessment is indicated whenever a change occurs. The initial assessment of the patient with cancer pain always includes a history and examination, and often requires imaging or laboratory tests. The approach may be conceptualized as collecting data sufficient to characterize key elements of the pain (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=see_link\">",
"       \"Assessment of cancer pain\"",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A specific pain syndrome, if one can be defined (eg, multifocal bone pain or malignant brachial plexopathy) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21146?source=see_link\">",
"       \"Overview of cancer pain syndromes\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The inferred pathophysiology of the pain (eg, neuropathic pain related to dysfunction of the nervous system, or nociceptive pain related to ongoing tissue injury) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=see_link&amp;anchor=H8#H8\">",
"       \"Assessment of cancer pain\", section on 'Inferred pathophysiology (types of cancer pain)'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The etiology of the pain (ie, its relationship to the disease or another factor)",
"     </li>",
"     <li>",
"      The extent of cancer and the plan for further cancer treatment",
"     </li>",
"     <li>",
"      The goals of care relative to pain management",
"     </li>",
"     <li>",
"      Other \"palliative care concerns\", including management of symptoms other than pain. The somatic symptom burden tends to be high in patients with cancer-related pain, and recognizing and managing somatic symptoms may improve quality of life and functional status [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The second principle recognizes that pain may be addressed by disease-modifying antineoplastic therapy and other interventions directed against the etiology of the pain. Treatments that address the underlying etiology of pain, such as radiation therapy, surgery, or in some cases, chemotherapy, can be integrated into a broader plan of care for symptom control. Treatment of cancer-related pain usually requires close consultation with an oncology specialist, who can provide the necessary information about the availability of antineoplastic therapy.",
"     </li>",
"     <li>",
"      Whether or not primary disease-modifying therapy is possible, a large proportion of patients with pain due to active cancer require symptomatic treatment. The third principle of cancer pain management was originally codified in the World Health Organization's (WHO) \"analgesic ladder,\" which was originally published in the mid-1980s [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/3\">",
"       3",
"      </a>",
"      ], and has had a global influence on clinical practice and policies pertaining to medication availability.",
"      <br/>",
"      <br/>",
"      The basic principle behind the analgesic ladder is a stepwise approach to pain control that is based upon the severity of pain (",
"      <a class=\"graphic graphic_figure graphicRef63298 \" href=\"mobipreview.htm?0/45/724\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Step 1 of the ladder is for patients with mild to moderate cancer-related pain, who should first be treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      or a nonsteroidal antiinflammatory agent (NSAID), possibly combined with an adjuvant drug that provides additional analgesia (ie, a so-called \"adjuvant analgesic\", such as an analgesic antidepressant drug for neuropathic pain), treats a side effect, or manages a coexisting symptom. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=see_link\">",
"       \"Cancer pain management: Adjuvant analgesics (coanalgesics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with moderate or severe pain, including those who do not achieve adequate relief after a trial of an NSAID alone, should be treated with an opioid.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The analgesic ladder promoted the view that one group of opioids should be conventionally used to treat pain of moderate intensity on step 2 of the ladder (previously designated with the misnomer \"weak\" opioids, with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    as the prototype) and another group of drugs (previously designated \"strong\" opioids, with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    as the prototype) used to treat severe pain on step 3. On both steps 2 and 3, the approach indicates the potential for benefit with combination therapy that includes an NSAID or other drugs to enhance analgesia or treat side effects.",
"   </p>",
"   <p>",
"    However, while the analgesic ladder approach provides a framework for the stepwise and systematic approach to managing cancer pain, it should not be viewed as evidence-based or a best practice guideline. Clinical competency in cancer pain management requires a more detailed understanding of the principles of appropriate drug selection, dosing, and other processes of care.",
"   </p>",
"   <p>",
"    Several evidence-based clinical guidelines exist that were built upon the premises incorporated into the analgesic ladder and expanded based upon clinical experience and the results of clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/4,5,7,26-29\">",
"     4,5,7,26-29",
"    </a>",
"    ]. Guidelines for use and selection of opioids for management of cancer-related pain are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=see_link\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to opioids, there are many other options for pain control, which are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef74350 \" href=\"mobipreview.htm?13/9/13468\">",
"     table 1",
"    </a>",
"    ). Adjuvant analgesics, as well as interventional, rehabilitative, psychological, and integrative approaches to pain control are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=see_link\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4488?source=see_link\">",
"     \"Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21098?source=see_link\">",
"     \"Cancer pain management: Interventional therapies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=see_link\">",
"     \"Psychological, rehabilitative, and integrative therapies for cancer pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK ASSESSMENT AND MANAGEMENT FOR PATIENTS RECEIVING OPIOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioids are potentially abusable drugs and safe prescribing requires consideration of the risks associated with drug abuse, addiction, and diversion to the illicit marketplace. Their potential for abuse and addiction results from the \"brain reward\" they induce in biologically predisposed individuals, which is mediated through dopamine pathways in the brain. The public health consequences of opioid abuse drive the imperative that all physicians assume responsibility for risk management when potentially abusable drugs like opioids are prescribed for legitimate medical purposes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/33/27160?source=see_link\">",
"     \"Prescription drug abuse and addiction: Prevention, identification, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Medications with the potential for abuse and addiction such as opioids are regulated, with restrictions on whether and how they can be prescribed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/30\">",
"     30",
"    </a>",
"    ]. In the US, these drugs are designated \"controlled substances\" under a federal law known as the Controlled Substances Act (CSA), which places controlled prescription drugs in one of five &lsquo;schedules&rsquo; based on abuse liability (",
"    <a class=\"graphic graphic_table graphicRef66064 \" href=\"mobipreview.htm?4/37/4701\">",
"     table 2",
"    </a>",
"    ). Under the CSA, most opioids used for cancer pain management are schedule II, which indicates a high liability for abuse and diversion. Both federal and state laws are in force to regulate all scheduled drugs, particularly those in schedule II. Physicians are required to know and comply with these laws. &nbsp;",
"   </p>",
"   <p>",
"    With the recent increase in prescription drug abuse, the federal government has taken additional steps to regulate opioids. In response to a mandate by the US Congress, the Food and Drug Administration has created two Risk Evaluation and Mitigation Strategies (REMS), one for extended-release and long-acting opioids, which has not yet been implemented, and one for transmucosal immediate release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    formulations, which was implemented in March 2012. The REMS program is voluntary for the",
"    <span class=\"nowrap\">",
"     long-acting/extended",
"    </span>",
"    release preparations, but for transmucosal fentanyl preparations, it requires registration of prescribers, pharmacies, distributors, and patients. Furthermore, the REMS for transmucosal fentanyl includes mandatory statements signed by the patient and prescriber, which outline patient and physician responsibilities for safe opioid use. These requirements are optional in the REMS for",
"    <span class=\"nowrap\">",
"     extended-release/long-acting",
"    </span>",
"    opioids, an example of which is provided on a drug-company website for OxyContin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/31\">",
"     31",
"    </a>",
"    ]",
"    <a class=\"external\" href=\"file://www.oxycontinrems.com/\">",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    It is unclear whether implementation of these REMS, especially for the",
"    <span class=\"nowrap\">",
"     extended-release/long-acting",
"    </span>",
"    preparations, will curb the potential for abuse with this group of drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/32\">",
"     32",
"    </a>",
"    ], and the REMS are just one of many changes happening at the federal and state levels that are intended to reduce drug abuse. The intent of these new laws and regulations, which is to reduce opioid abuse, is widely supported by clinicians, regulators, and those in law enforcement. Clinicians have raised concerns, however, that the effort to reduce risk could create barriers to prescribing, the result of which will be more unrelieved pain. These unintended consequences of regulation have been encountered in the past, eg, when multiple-copy prescription programs were used in many states [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/33\">",
"     33",
"    </a>",
"    ]. Achieving a balance in drug regulation between the need to reduce abuse and the need to maintain access to essential medications is very challenging, and the concerns that REMS and other approaches will increase the reluctance of oncologists and other clinicians to use opioids generally, or specific formulations like the transmucosal immediate-release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    drugs specifically, are legitimate. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Historically, the need for risk management during opioid prescription for cancer pain was minimized or ignored. This is not appropriate given the legitimate public health and law enforcement concerns about the impact of abuse. The broad clinical consensus about the central role of opioids in cancer pain management does not negate the obligation on the part of prescribers to assess and manage the possibility of drug abuse, the occurrence of first-time addiction or relapse, or the concern about diversion.",
"   </p>",
"   <p>",
"    Prescribing of opioids should always be preceded by careful risk assessment. If the estimated risk of problematic drug-related behavior is considered to be substantial, a careful strategy is necessary to preempt or minimize problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/5,34-37\">",
"     5,34-37",
"    </a>",
"    ]. Risk assessment requires a clear understanding of the phenomena that are associated with a risk of drug abuse, addiction,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Drug abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"drug abuse\" refers to the use of a drug in a manner that deviates from medical, legal, and social standards. Prescription drugs are abused when taken in any manner that was not prescribed. In the United States, prescription drug abuse has been on the rise for a decade. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36535?source=see_link\">",
"     \"Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Addiction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Addiction is a disease with a strong genetic component that is defined by aberrant drug-taking behavior, characterized by craving, loss of control, compulsive use, and continued use despite harm. The biologic propensity toward addictive disease affects a small minority of the population, probably no more than 10 percent. A personal or family history of alcohol or drug abuse may reveal such a propensity, and individuals with such a history should be considered high risk for problematic drug-related behavior. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/22/2409?source=see_link\">",
"     \"Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36535?source=see_link\">",
"     \"Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Addiction is entirely distinct from the physiologic phenomenon of physical dependence (defined solely by the occurrence of withdrawal symptoms after abrupt dose reduction or the administration of an antagonist) and tolerance (defined solely by the drug-induced loss of effect over time). Although these phenomena presumably occur commonly as addiction evolves, neither are necessary for addiction to occur, and equally important, neither means that abuse or addiction is occurring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diversion is a legal concept, referring to the distribution of a drug into the illicit marketplace. Physicians are required to stop prescribing when there is a strong likelihood that diversion of prescribed drugs is occurring. In the United States, this legal constraint is codified in the Federal Controlled Substances Act, which states that prescribing of a controlled prescription drug (ie, one with the potential for abuse) is legal only if it is for a legitimate medical purpose, and performed within the course of usual professional practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36535?source=see_link\">",
"     \"Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to the requirement that prescribing cease if diversion is occurring, the law states that prescribing may continue legally in the context of suspected abuse or addiction if appropriate medical actions are being taken to stop the behavior, regain control over the prescribing, and manage the medical and psychiatric condition of the patient. Great care must be taken, however, because physicians are subject to review under medical practice regulations, as well as drug laws, and must prescribe within conventionally accepted standards. When it is suspected, consultation with a specialist in addiction medicine, pain medicine or palliative care should be considered in an effort to appropriately diagnose and manage the nature of a drug-related problem. Careful documentation is mandatory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Risk assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;With an understanding of these phenomena, clinicians can stratify the estimated risk of problematic drug-related behavior in individual patients, and judge whether treatment with a controlled prescription drug can proceed without assistance from a specialist. General principles of risk assessment and risk management n patients receiving opioids for treatment of cancer pain are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef50477 \" href=\"mobipreview.htm?23/31/24061\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although numerous questionnaires have been developed for the prediction of risk, none has been adequately validated or is in widespread use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/39\">",
"     39",
"    </a>",
"    ]. However, a high risk of problematic drug-related behavior during treatment with an opioid or other controlled prescription drug can be predicted based upon a simple clinical assessment that includes asking the following three questions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/34,36,37\">",
"     34,36,37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is there a personal history of alcohol or drug abuse?",
"     </li>",
"     <li>",
"      Is there a family history of alcohol or drug abuse?",
"     </li>",
"     <li>",
"      Does the patient have a major psychiatric disorder?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of any of these factors indicates an elevated risk for problematic drug-related behavior. Other factors, such as younger age, smoking history, social isolation or involvement with a drug abuse subculture, a history of multiple automobile accidents, and inability to maintain employment, also may be important to consider when stratifying risk of aberrant drug-related behaviors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36535?source=see_link\">",
"     \"Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Risk management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Competent risk management empowers the clinician to use controlled prescription drugs as broadly and as aggressively as medical indications require.",
"   </p>",
"   <p>",
"    When the risk of aberrant drug-related behavior is assessed as low (as it is in most patients with cancer pain), prescribing of an opioid can proceed with simple and straightforward strategies for monitoring and controlling drug use. The medical record should document that prescribing is occurring in the context of a therapeutic relationship and for a specific medical problem that was evaluated in a routine manner (history, examination, appropriate formulation of diagnosis) at some point. Reassessment should be performed or planned at periodic intervals to ensure that the medication remains necessary and adequate. There should be documentation of each prescription that is written for a controlled substance.",
"   </p>",
"   <p>",
"    In contrast, patients who are considered to be at relatively high risk for aberrant drug-related behavior should have additional \"control measures\" incorporated into therapy (",
"    <a class=\"graphic graphic_table graphicRef50477 \" href=\"mobipreview.htm?23/31/24061\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. As an example, a younger patient with an indolent metastatic osteosarcoma who has a history of polysubstance abuse and admits to ongoing use of marijuana might be managed in any of the following ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Frequent prescriptions with small quantities",
"     </li>",
"     <li>",
"      A signed opioid agreement stipulating the rules about early refills and other potential problems",
"     </li>",
"     <li>",
"      Periodic urine drug testing to ensure abstinence from nonmedical controlled substances such as marijuana",
"     </li>",
"     <li>",
"      Because of concern about street value and abuse liability, the decision might be made to offer treatment with an opioid with a lower abuse potential (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      or transdermal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      ), rather than a highly abused one, such as long-acting",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"       oxycodone",
"      </a>",
"      (Oxycontin).",
"     </li>",
"     <li>",
"      The decision may be made to offer no additional short-acting opioid drug for breakthrough or incident pain, again because of the assumption that these agents are relatively more enticing to those predisposed to drug abuse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some cases, no additional safety measures beyond routine precautions are needed even when risk factors exist because the severity of the disease or the setting of treatment is such that the likelihood of problematic behaviors is essentially zero. It is best if this understanding is documented in the medical record.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7613328\">",
"    <span class=\"h1\">",
"     DRIVING SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive and psychomotor adverse effects of opioids could potentially impair the ability to drive or work safely. Opioids can slow reaction time, cause drowsiness, or cloud judgment, particularly when they are first started, or when doses are increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/40\">",
"     40",
"    </a>",
"    ]. For cancer patients with chronic pain, these effects could be further compounded as a result of the disease state itself, and the concomitant cancer treatment. &nbsp;",
"   </p>",
"   <p>",
"    There are no large trials examining the risk of driving while on opioids. Epidemiologic studies and reviews suggest that motor vehicle accidents and fatalities, and citations for impaired driving, are",
"    <em>",
"     not",
"    </em>",
"    disproportionally increased among patients receiving chronic stable doses of opioids (no dose changes for at least one week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/41\">",
"     41",
"    </a>",
"    ]):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A literature review concluded that the majority of studies found no impaired psychomotor abilities among",
"      <span class=\"nowrap\">",
"       opioid-dependent/tolerant",
"      </span>",
"      patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study, in which cancer patients receiving chronic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      therapy who completed a series of psychological and neurological tests to assess driving ability were compared to cancer patients not on opioids, there was no significant difference in driving ability, although patients on morphine tended to perform less well [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/43\">",
"       43",
"      </a>",
"      ]. The authors concluded that cancer patients receiving long-term therapy with stable doses of morphine do not have psychomotor effects of a kind that would be clearly hazardous in traffic.",
"     </li>",
"     <li>",
"      In another study, which videotaped patients while actually driving, those on chronic opioid therapy versus healthy controls showed neither a difference in driving errors in community or obstacle course driving, nor in tests of attention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No studies have evaluated the effects of chronic opioid therapy on work safety.",
"   </p>",
"   <p>",
"    These data, while limited, support the view that patients who have been on a stable dose of opioids for at least one week who feel no cognitive changes can drive. Clinicians should counsel all patients on chronic opioid therapy about the potential for transient or lasting cognitive impairment that may affect driving or work safety.",
"   </p>",
"   <p>",
"    For patients initiating opioid therapy for chronic pain or changing doses, most experts agree that driving or operating heavy machinery is unsafe and should probably be avoided until a stable dose has been reached [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43704/abstract/41,45,46\">",
"     41,45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/36/579?source=see_link\">",
"       \"Patient information: Managing pain when you have cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain is a highly prevalent symptom in patients with cancer. Adequate pain relief can be achieved in 70 to 90 percent of patients when well-accepted treatment guidelines for cancer pain are followed. However, undertreatment may affect over 40 percent of patients with cancer-related pain. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'The problem of undertreatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Among individuals with cancer, pain is best considered as a domain within the broader context of palliative care, an interdisciplinary therapeutic approach that focuses on the comprehensive management of the physical, psychological, social, and spiritual needs of patients with serious or life-threatening diseases and their families.",
"   </p>",
"   <p>",
"    Most recommended therapies for cancer pain are within the scope of both specialty and primary care medical practice. The adequate treatment of cancer pain should be viewed as a best practice for all medical disciplines involved in the care of this population. When the clinical issues are complex, particularly when pain is difficult to control or accompanied by other concerns, referral to a palliative care specialist may be appropriate. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pain management within the context of palliative care'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    An effective strategy for cancer pain management is predicated on the following broad principles (see",
"    <a class=\"local\" href=\"#H4\">",
"     'General principles of pain management'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goal of the initial assessment (history and examination, imaging",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      laboratory tests) is to characterize key elements of the pain, including the presence of a pain syndrome, if one can be defined, inferred pathophysiology and etiology of the pain, and disease extent as well as prior antineoplastic treatment. Reassessment is indicated whenever a change occurs. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=see_link\">",
"       \"Assessment of cancer pain\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21146?source=see_link\">",
"       \"Overview of cancer pain syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clinicians should always consider the possibility of disease-modifying antineoplastic therapy or other interventions directed against the etiology of the pain.",
"     </li>",
"     <li>",
"      A stepwise and systematic approach to pain control should consider selection of appropriate drugs and prescribing techniques that can optimize their pharmacological outcomes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=see_link\">",
"       \"Cancer pain management with opioids: Optimizing analgesia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Opioids are effective analgesics for cancer pain, but they are potentially abusable drugs. All physicians must assume responsibility for risk assessment and management when these drugs are prescribed for legitimate medical purposes. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Risk assessment and management for patients receiving opioids'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Clinicians should counsel all patients on chronic opioid therapy about the potential for transient or lasting cognitive impairment that may affect driving or work safety. Patients who have been on a stable dose of opioids for at least one week who feel no cognitive changes can drive. However, for patients initiating opioid therapy or changing doses, driving or operating heavy machinery is unsafe and should probably be avoided until a stable dose has been reached. (See",
"    <a class=\"local\" href=\"#H7613328\">",
"     'Driving safety'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/1\">",
"      van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. High prevalence of pain in patients with cancer in a large population-based study in The Netherlands. Pain 2007; 132:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/2\">",
"      Teunissen SC, Wesker W, Kruitwagen C, et al. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage 2007; 34:94.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Cancer pain relief, 2nd, World Health Organization, Geneva 1996.",
"    </li>",
"    <li>",
"     American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain, 6th, American Pain Society, Glenview, IL 2008.",
"    </li>",
"    <li>",
"     Fine P, Portenoy RK. Opioid analgesia. New York: McGraw Hill, 2004. file://www.stoppain.org/pcd/content/forpros/opioidbook.asp (Accessed on April 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/6\">",
"      Quigley C. Opioids in people with cancer-related pain. Clin Evid (Online) 2008; 2008.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/8\">",
"      Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 2008; 19:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/9\">",
"      Fairchild A. Under-treatment of cancer pain. Curr Opin Support Palliat Care 2010; 4:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/10\">",
"      van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007; 18:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/11\">",
"      Kirou-Mauro AM, Hird A, Wong J, et al. Has pain management in cancer patients with bone metastases improved? A seven-year review at an outpatient palliative radiotherapy clinic. J Pain Symptom Manage 2009; 37:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/12\">",
"      Apolone G, Corli O, Caraceni A, et al. Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group. Br J Cancer 2009; 100:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/13\">",
"      Fisch MJ, Lee JW, Weiss M, et al. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol 2012; 30:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/14\">",
"      Oldenmenger WH, Sillevis Smitt PA, van Dooren S, et al. A systematic review on barriers hindering adequate cancer pain management and interventions to reduce them: a critical appraisal. Eur J Cancer 2009; 45:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/15\">",
"      Pargeon KL, Hailey BJ. Barriers to effective cancer pain management: a review of the literature. J Pain Symptom Manage 1999; 18:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/16\">",
"      Potter VT, Wiseman CE, Dunn SM, Boyle FM. Patient barriers to optimal cancer pain control. Psychooncology 2003; 12:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/17\">",
"      Breuer B, Fleishman SB, Cruciani RA, Portenoy RK. Medical oncologists' attitudes and practice in cancer pain management: a national survey. J Clin Oncol 2011; 29:4769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/18\">",
"      McNeill JA, Sherwood GD, Starck PL. The hidden error of mismanaged pain: a systems approach. J Pain Symptom Manage 2004; 28:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/19\">",
"      Billings JA. What is palliative care? J Palliat Med 1998; 1:73.",
"     </a>",
"    </li>",
"    <li>",
"     Information on institution-based palliative care programs available on the website of the Center to Advance Palliative Care. www.capc.org (Accessed on September 06, 2011).",
"    </li>",
"    <li>",
"     Information on community-based hospice programs available on the website of the National Hospice and Palliative Care Organization. file://www.nhpco.org/templates/1/homepage.cfm (Accessed on September 06, 2011).",
"    </li>",
"    <li>",
"     American Academy of Hospice and Palliative Medicine www.aahpm.org/certification/index.html (Accessed on April 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/23\">",
"      Kroenke K, Zhong X, Theobald D, et al. Somatic symptoms in patients with cancer experiencing pain or depression: prevalence, disability, and health care use. Arch Intern Med 2010; 170:1686.",
"     </a>",
"    </li>",
"    <li>",
"     WHO analgesic pain ladder available online. www.who.int/cancer/palliative/painladder/en/ (Accessed on September 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/25\">",
"      Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA 1995; 274:1870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/26\">",
"      Jost L, Roila F, ESMO Guidelines Working Group. Management of cancer pain: ESMO clinical recommendations. Ann Oncol 2008; 19 Suppl 2:ii119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/27\">",
"      Krakowski I, Theobald S, Balp L, et al. Summary version of the Standards, Options and Recommendations for the use of analgesia for the treatment of nociceptive pain in adults with cancer (update 2002). Br J Cancer 2003; 89 Suppl 1:S67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/28\">",
"      Cormie PJ, Nairn M, Welsh J, Guideline Development Group. Control of pain in adults with cancer: summary of SIGN guidelines. BMJ 2008; 337:a2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/29\">",
"      Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012; 13:e58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/30\">",
"      Ellison NM. Regulatory issues for prescribing schedule II opioids at the end of life #198. J Palliat Med 2010; 13:605.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.oxycontinrems.com/.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/32\">",
"      Nelson LS, Perrone J. Curbing the opioid epidemic in the United States: the risk evaluation and mitigation strategy (REMS). JAMA 2012; 308:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/33\">",
"      Wang J, Christo PJ. The influence of prescription monitoring programs on chronic pain management. Pain Physician 2009; 12:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/34\">",
"      Katz NP, Adams EH, Benneyan JC, et al. Foundations of opioid risk management. Clin J Pain 2007; 23:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/35\">",
"      Passik SD, Kirsh KL, Donaghy KB, Portenoy RK. Pain and aberrant drug-related behaviors in medically ill patients with and without histories of substance abuse. Clin J Pain 2006; 22:173.",
"     </a>",
"    </li>",
"    <li>",
"     Portenoy RK. Acute and chronic pain. In: Lowinson &amp; Ruiz&rsquo;s Substance Abuse: A Comprehensive Textbook, 5th, Ruiz P, Strain E (Eds), Lippincott, Williams and Wilkins, Philadelphia 2011. p.695.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/37\">",
"      Miaskowski C. The use of risk-management approaches to protect patients with cancer-related pain and their healthcare providers. Oncol Nurs Forum 2008; 35 Suppl:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/38\">",
"      Gilson AM, Joranson DE. U.S. policies relevant to the prescribing of opioid analgesics for the treatment of pain in patients with addictive disease. Clin J Pain 2002; 18:S91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/39\">",
"      Chou R, Fanciullo GJ, Fine PG, et al. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009; 10:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/40\">",
"      Galski T, Williams JB, Ehle HT. Effects of opioids on driving ability. J Pain Symptom Manage 2000; 19:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/41\">",
"      Schisler RE, Groninger H, Rosielle DA. Counseling patients on side effects and driving when starting opioids #248. J Palliat Med 2012; 15:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/42\">",
"      Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Are opioid-dependent/tolerant patients impaired in driving-related skills? A structured evidence-based review. J Pain Symptom Manage 2003; 25:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/43\">",
"      Sjogren P, Thomsen AB, Olsen AK. Impaired neuropsychological performance in chronic nonmalignant pain patients receiving long-term oral opioid therapy. J Pain Symptom Manage 2000; 19:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/44\">",
"      Byas-Smith MG, Chapman SL, Reed B, Cotsonis G. The effect of opioids on driving and psychomotor performance in patients with chronic pain. Clin J Pain 2005; 21:345.",
"     </a>",
"    </li>",
"    <li>",
"     Canadian Guideline for safe and effective use of opioids for chronic non-cancer pain. National Opioid Use Guideline Group. April 30, 2010. Available online at www.nationalpaincentre.mcmaster.ca/opioid/documents.html (Accessed on May 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43704/abstract/46\">",
"      Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10:113.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2792 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-77B11294E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_43_43704=[""].join("\n");
var outline_f42_43_43704=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE PROBLEM OF UNDERTREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PAIN MANAGEMENT WITHIN THE CONTEXT OF PALLIATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GENERAL PRINCIPLES OF PAIN MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK ASSESSMENT AND MANAGEMENT FOR PATIENTS RECEIVING OPIOIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Drug abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Addiction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Risk assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Risk management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7613328\">",
"      DRIVING SAFETY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PALC/2792\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2792|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/45/724\" title=\"figure 1\">",
"      WHO analgesic ladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2792|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/9/13468\" title=\"table 1\">",
"      Categories of treatment for pain in cancer patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/37/4701\" title=\"table 2\">",
"      US scheds controlled drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/31/24061\" title=\"table 3\">",
"      Principles of risk management during opioid treatment for pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/22/2409?source=related_link\">",
"      Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=related_link\">",
"      Assessment of cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21098?source=related_link\">",
"      Cancer pain management: Interventional therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4488?source=related_link\">",
"      Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21146?source=related_link\">",
"      Overview of cancer pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29801?source=related_link\">",
"      Palliative care: Benefits, services, and models of care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36535?source=related_link\">",
"      Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/33/27160?source=related_link\">",
"      Prescription drug abuse and addiction: Prevention, identification, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=related_link\">",
"      Psychological, rehabilitative, and integrative therapies for cancer pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_43_43705="Naproxen: Drug information";
var content_f42_43_43705=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Naproxen: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/35/44597?source=see_link\">",
"    see \"Naproxen: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/61/27608?source=see_link\">",
"    see \"Naproxen: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F199854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aleve&reg; [OTC];",
"     </li>",
"     <li>",
"      All Day Relief [OTC];",
"     </li>",
"     <li>",
"      Anaprox&reg;;",
"     </li>",
"     <li>",
"      Anaprox&reg; DS;",
"     </li>",
"     <li>",
"      EC-Naprosyn&reg;;",
"     </li>",
"     <li>",
"      Mediproxen [OTC];",
"     </li>",
"     <li>",
"      Midol&reg; Extended Relief [OTC];",
"     </li>",
"     <li>",
"      Naprelan&reg;;",
"     </li>",
"     <li>",
"      Naprosyn&reg;;",
"     </li>",
"     <li>",
"      Pamprin&reg; Maximum Strength All Day Relief [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F199855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Anaprox&reg;;",
"     </li>",
"     <li>",
"      Anaprox&reg; DS;",
"     </li>",
"     <li>",
"      Apo-Napro-Na DS&reg;;",
"     </li>",
"     <li>",
"      Apo-Napro-Na&reg;;",
"     </li>",
"     <li>",
"      Apo-Naproxen EC&reg;;",
"     </li>",
"     <li>",
"      Apo-Naproxen SR&reg;;",
"     </li>",
"     <li>",
"      Apo-Naproxen&reg;;",
"     </li>",
"     <li>",
"      Mylan-Naproxen EC;",
"     </li>",
"     <li>",
"      Naprelan&trade;;",
"     </li>",
"     <li>",
"      Naprosyn&reg;;",
"     </li>",
"     <li>",
"      Naprosyn&reg; E;",
"     </li>",
"     <li>",
"      Naprosyn&reg; SR;",
"     </li>",
"     <li>",
"      Naproxen Sodium DS;",
"     </li>",
"     <li>",
"      Naproxen-NA;",
"     </li>",
"     <li>",
"      Naproxen-NA DF;",
"     </li>",
"     <li>",
"      PMS-Naproxen;",
"     </li>",
"     <li>",
"      PMS-Naproxen EC;",
"     </li>",
"     <li>",
"      PRO-Naproxen EC;",
"     </li>",
"     <li>",
"      Riva-Naproxen;",
"     </li>",
"     <li>",
"      Riva-Naproxen Sodium;",
"     </li>",
"     <li>",
"      Riva-Naproxen Sodium DS;",
"     </li>",
"     <li>",
"      Teva-Naproxen;",
"     </li>",
"     <li>",
"      Teva-Naproxen EC;",
"     </li>",
"     <li>",
"      Teva-Naproxen Sodium;",
"     </li>",
"     <li>",
"      Teva-Naproxen Sodium DS;",
"     </li>",
"     <li>",
"      Teva-Naproxen SR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F199906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F199859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage expressed as naproxen base; 200 mg naproxen base is equivalent to 220 mg naproxen sodium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gout, acute:",
"     </b>",
"     Oral: Initial: 750 mg, followed by 250 mg every 8 hours until attack subsides.",
"     <b>",
"      Note:",
"     </b>",
"     EC-Naprosyn&reg; is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Migraine, acute (unlabeled use):",
"     </b>",
"     Initial: 500-750 mg; an additional 250-500 mg may be given if needed (maximum: 1250 mg in 24 hours).",
"     <b>",
"      Note:",
"     </b>",
"     EC-Naprosyn&reg; is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pain (mild-to-moderate), dysmenorrhea, acute tendonitis, bursitis:",
"     </b>",
"     Oral: Initial: 500 mg, then 250 mg every 6-8 hours; maximum: 1250 mg/day naproxen base",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis:",
"     </b>",
"     500-1000 mg/day in 2 divided doses; may increase to 1.5 g/day of naproxen base for limited time period",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      OTC labeling:",
"     </i>",
"     Pain/fever: 200 mg naproxen base every 8-12 hours; if needed, may take 400 mg naproxen base for the initial dose; maximum: 400 mg naproxen base in any 8- to 12-hour period or 600 mg naproxen base/24 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F199881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/61/27608?source=see_link\">",
"      see \"Naproxen: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage expressed as naproxen base; 200 mg naproxen base is equivalent to 220 mg naproxen sodium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Juvenile idiopathic arthritis:",
"     </b>",
"     Oral: Children &gt;2 years: 10 mg/kg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      OTC labeling:",
"     </i>",
"     Pain/fever: Oral: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F199860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F199861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: use is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F199830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral, as sodium: 220 mg [equivalent to naproxen base 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aleve&reg;: 220 mg [contains sodium 20 mg; equivalent to naproxen base 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     All Day Relief: 220 mg [contains sodium 20 mg; equivalent to naproxen base 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Midol&reg; Extended Relief: 220 mg [contains sodium 20 mg; equivalent to naproxen base 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pamprin&reg; Maximum Strength All Day Relief: 220 mg [contains sodium 20 mg; equivalent to naproxen base 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, liquid gel, oral, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aleve&reg;: 220 mg [contains sodium 20 mg; equivalent to naproxen base 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Combination package, oral, as sodium [strength expressed as base, dose-pack/each package contains]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Naprelan&reg;: Day 1-3: Tablet, controlled release: 750 mg (6s) [contains sodium 75 mg] and Day 4-10: Tablet, controlled release: 500 mg (14s) [contains sodium 50 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gelcap, oral, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aleve&reg;: 220 mg [contains sodium 20 mg; equivalent to naproxen base 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 125 mg/5 mL (500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Naprosyn&reg;: 125 mg/5 mL (473 mL) [contains sodium 39 mg (1.5 mEq)/5 mL; orange-pineapple flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 250 mg, 375 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Naprosyn&reg;: 250 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Naprosyn&reg;: 375 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Naprosyn&reg;: 500 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sodium: 220 mg [equivalent to naproxen base 200 mg], 275 mg [equivalent to naproxen base 250 mg], 550 mg [equivalent to naproxen base 500 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aleve&reg;: 220 mg [contains sodium 20 mg; equivalent to naproxen base 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anaprox&reg;: 275 mg [contains sodium 25 mg; equivalent to naproxen base 250 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anaprox&reg; DS: 550 mg [scored; contains sodium 50 mg; equivalent to naproxen base 500 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mediproxen: 220 mg [contains sodium 20 mg; equivalent to naproxen base 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, controlled release, oral, as sodium [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Naprelan&reg;: 375 mg [contains sodium 37.5 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Naprelan&reg;: 500 mg [contains sodium 50 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Naprelan&reg;: 750 mg [contains sodium 75 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release, enteric coated, oral: 375 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     EC-Naprosyn&reg;: 375 mg, 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F199815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Caplet, suspension, tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088657.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088657.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F199834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food, milk, or antacids to decrease GI adverse effects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension: Shake suspension well before administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release: Swallow tablet whole; do not break, crush, or chew.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F199833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of ankylosing spondylitis, osteoarthritis, and rheumatoid disorders (including juvenile idiopathic arthritis [JIA]); acute gout; mild-to-moderate pain; tendonitis, bursitis; dysmenorrhea; fever",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14306775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Migraine prophylaxis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F199915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Naproxen may be confused with Natacyn&reg;, Nebcin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Anaprox&reg; may be confused with Anaspaz&reg;, Avapro&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Naprelan&reg; may be confused with Naprosyn&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Naprosyn&reg; may be confused with Natacyn&reg;, Nebcin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flogen [Mexico] may be confused with Flovent brand name for fluticasone [U.S., Canada]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flogen [Mexico] may be confused with Floxin brand name for flunarizine [Thailand], norfloxacin [South Africa], ofloxacin [U.S., Canada], and perfloxacin [Philippines]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F199904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (3% to 9%), palpitations (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (3% to 9%), drowsiness (3% to 9%), headache (3% to 9%), lightheadedness (&lt;3%), vertigo (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (3% to 9%), skin eruption (3% to 9%), ecchymosis (3% to 9%), purpura (&lt;3%), rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Fluid retention (3% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (3% to 9%), constipation (3% to 9%), nausea (3% to 9%), heartburn (3% to 9%), diarrhea (&lt;3%), dyspepsia (&lt;3%), stomatitis (&lt;3%), flatulence, gross bleeding/perforation, indigestion, ulcers, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Abnormal renal function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hemolysis (3% to 9%), ecchymosis (3% to 9%), anemia, bleeding time increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: LFTs increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Visual disturbances (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus (3% to 9%), hearing disturbances (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (3% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (&lt;3%), thirst (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, alopecia, anaphylactic/anaphylactoid reaction, angioneurotic edema, arrhythmia, aseptic meningitis, asthma, blurred vision, cognitive dysfunction, colitis, coma, confusion, CHF, conjunctivitis, cystitis, depression, dream abnormalities, dysuria, eosinophilia, eosinophilic pneumonitis, erythema multiforme, exfoliative dermatitis, glossitis, granulocytopenia, hallucinations, hematemesis, hepatitis, hyper-/hypoglycemia, hyper-/hypotension, infection, interstitial nephritis, melena, jaundice, leukopenia, liver failure, lymphadenopathy, menstrual disorders, malaise, MI, muscle weakness, myalgia, oliguria, pancreatitis, pancytopenia, paresthesia, photosensitivity, pneumonia, polyuria, proteinuria, pyrexia, rectal bleeding, renal failure, renal papillary necrosis, respiratory depression, sepsis, Stevens-Johnson syndrome, tachycardia, seizure, syncope, thrombocytopenia, toxic epidermal necrolysis ulcerative stomatitis, vasculitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F199837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to naproxen, aspirin, other NSAIDs, or any component of the formulation; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F199819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with \"aspirin triad\" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including MI and stroke.",
"     </b>",
"     Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. Use caution with fluid retention. Avoid use in heart failure. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Discontinue use with blurred or diminished vision and perform ophthalmologic exam. Periodically evaluate vision in all patients receiving long term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs may increase risk of gastrointestinal irritation, inflammation, ulceration, bleeding, and perforation.",
"     </b>",
"     These events may occur at any time during therapy and without warning. Use caution with a history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, the elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with &le;325 mg of aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); discontinue use at first sign of skin rash or hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aseptic meningitis: May increase the risk of aseptic meningitis, especially in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Do not administer to patients with aspirin-sensitive asthma; severe bronchospasm may occur. Use caution in patients with other forms of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery bypass graft surgery:",
"     <b>",
"      [U.S. Boxed Warning]: Use is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.",
"     </b>",
"     Risk of MI and stroke may be increased with use following CABG surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with decreased hepatic function. Closely monitor patients with any abnormal LFT. Severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution; may cause new-onset hypertension or worsening of existing hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation. Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics, and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Not recommended for use in patients with advanced renal disease. Long-term NSAID use may result in renal papillary necrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid chronic use (unless alternative agents ineffective and patient can receive concomitant gastroprotective agent); nonselective oral NSAID use is associated with an increased risk of GI bleeding and peptic ulcer disease in older adults in high risk category (eg, &gt;75 years or age or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents) (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;2 years of age. Not for self-medication (OTC use) in children &lt;12 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): Prior to self-medication, patients should contact healthcare provider if they have had recurring stomach pain or upset, ulcers, bleeding problems, asthma, high blood pressure, heart or kidney disease, other serious medical problems, are currently taking a diuretic, anticoagulant, other NSAIDs, or are &ge;60 years of age. Recommended dosages and duration should not be exceeded, due to an increased risk of GI bleeding, MI, and stroke. Patients should stop use and consult a healthcare provider if symptoms get worse, newly appear, or continue; if an allergic reaction occurs; if feeling faint, vomit blood or have bloody/black stools; if having difficulty swallowing or heartburn, or if fever lasts for &gt;3 days or pain &gt;10 days. Consuming &ge;3 alcoholic beverages/day or taking longer than recommended may increase the risk of GI bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical/dental procedures: Withhold for at least 4-6 half-lives prior to surgical or dental procedures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F199900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C9 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F199824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F199850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may enhance gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Naproxen absorption rate/levels may be decreased if taken with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, chamomile, coleus, cordyceps, dong quai, evening primrose, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American, Panax, Siberian), grapeseed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, SAMe (S-adenosylmethionine), sweet clover, turmeric, white willow (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F199826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7696306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, the manufacturer classifies naproxen as pregnancy category C. Naproxen crosses the placenta and can be detected in fetal tissue and the serum of newborn infants following",
"     <i>",
"      in utero",
"     </i>",
"     exposure. NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of a NSAID close to conception may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester including: Myocardial degenerative changes, prenatal constriction of the ductus arteriosus, fetal tricuspid regurgitation, failure of the ductus arteriosus to close postnatally; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding (including intraventricular hemorrhage), platelet dysfunction with resultant bleeding; pulmonary hypertension. Because they may cause premature closure of the ductus arteriosus, use of NSAIDs late in pregnancy should be avoided (use after 31 or 32 weeks gestation is not recommended by some clinicians). The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication. A registry is available for pregnant women exposed to autoimmune medications including naproxen. For additional information contact the Organization of Teratology Information Specialists, OTIS Autoimmune Diseases Study, at (877) 311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F199865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates \"compatible\"; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7696309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of naproxen are excreted into breast milk. Naproxen has been detected in the urine of a breast-feeding infant. Breast-feeding is not recommended by the manufacturer. In a study which included 20 mother-infant pairs, there were two cases of drowsiness and one case of vomiting in the breast-fed infants. Maternal naproxen dose, duration, and relationship to breast-feeding were not provided.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F199840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drug may cause GI upset, bleeding, ulceration, perforation; take with food or milk to minimize GI upset.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F199839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Aleve Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     220 mg (80): $12.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Naproxen Sodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     220 mg (40): $7.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Naproxen Comfort Pac Combination)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $74.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Naprosyn Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg/5 mL (480 mL): $88.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Naproxen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg/5 mL (500 mL): $50.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Naprelan Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     375 mg (100): $1025.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (EC-Naprosyn Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     375 mg (100): $231.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $283.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Aleve Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     220 mg (50): $6.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Anaprox DS Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     550 mg (100): $470.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Anaprox Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     275 mg (100): $301.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Flanax Pain Relief Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     220 mg (24): $3.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Mediproxen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     220 mg (1): $0.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Midol Extended Relief Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     220 mg (20): $4.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Naprosyn Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $190.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     375 mg (100): $245.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $299.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Naproxen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $77.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     375 mg (100): $106.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $129.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Naproxen Sodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     220 mg (50): $4.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     275 mg (100): $89.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     550 mg (100): $138.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pamprin All Day Relief Max St Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     220 mg (24): $4.52",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F199828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Occult blood loss, periodic liver function test, CBC, BUN, serum creatinine; urine output",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F199841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acusprain (ZA);",
"     </li>",
"     <li>",
"      Aflamax (PE);",
"     </li>",
"     <li>",
"      Aleve (AU, EE, PL, PY, SG, UY);",
"     </li>",
"     <li>",
"      Anexopen (GR);",
"     </li>",
"     <li>",
"      Antalgin (ES);",
"     </li>",
"     <li>",
"      Apranax (CR, DO, FR, GT, HN, NI, PA, RU, SV, VE);",
"     </li>",
"     <li>",
"      Aprelax (PH);",
"     </li>",
"     <li>",
"      Apronax (EC);",
"     </li>",
"     <li>",
"      Artagen (IN);",
"     </li>",
"     <li>",
"      Artroxen (IT);",
"     </li>",
"     <li>",
"      Bei Li (CL);",
"     </li>",
"     <li>",
"      Bonyl (DK);",
"     </li>",
"     <li>",
"      Crysanal (AU);",
"     </li>",
"     <li>",
"      Daprox (DK);",
"     </li>",
"     <li>",
"      Dysmenalgit (DE);",
"     </li>",
"     <li>",
"      Femex (NL);",
"     </li>",
"     <li>",
"      Flanax (BR);",
"     </li>",
"     <li>",
"      Floginax (IT);",
"     </li>",
"     <li>",
"      Gibixen (IT);",
"     </li>",
"     <li>",
"      Inza (AU, HK);",
"     </li>",
"     <li>",
"      Iraxen (PE);",
"     </li>",
"     <li>",
"      Laser (IT);",
"     </li>",
"     <li>",
"      Leniartil (IT);",
"     </li>",
"     <li>",
"      Licorax (KP);",
"     </li>",
"     <li>",
"      Nafasol (ZA);",
"     </li>",
"     <li>",
"      Naflax (PH);",
"     </li>",
"     <li>",
"      Nalgesin (BG);",
"     </li>",
"     <li>",
"      Naposin (TW);",
"     </li>",
"     <li>",
"      Napoxen (PH);",
"     </li>",
"     <li>",
"      Naprex (PK);",
"     </li>",
"     <li>",
"      Naprium (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Naprius (IT);",
"     </li>",
"     <li>",
"      Naprodil (MX);",
"     </li>",
"     <li>",
"      Naproflex (TH);",
"     </li>",
"     <li>",
"      Naprontag (AR);",
"     </li>",
"     <li>",
"      Naprorex (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Naprosyn (AE, AU, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, CZ, DK, EC, EG, ES, ET, FI, GB, GH, GM, GN, GR, GY, IE, IN, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NO, OM, PE, PT, QA, RU, SA, SC, SD, SE, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Naprosyn LE (TH);",
"     </li>",
"     <li>",
"      Naprosyn LLE (PH);",
"     </li>",
"     <li>",
"      Naprosyn LLE Forte (PH);",
"     </li>",
"     <li>",
"      Naprosyn SR (AU);",
"     </li>",
"     <li>",
"      Naprosyne (BE, FR, NL);",
"     </li>",
"     <li>",
"      Naproxi 250 (IL);",
"     </li>",
"     <li>",
"      Naproxi 500 (IL);",
"     </li>",
"     <li>",
"      Naprux (AR);",
"     </li>",
"     <li>",
"      Naxen (MX, NZ);",
"     </li>",
"     <li>",
"      Naxen F (KP);",
"     </li>",
"     <li>",
"      Naxen-F CR (KP);",
"     </li>",
"     <li>",
"      Naxopren (FI);",
"     </li>",
"     <li>",
"      Naxyn 250 (IL);",
"     </li>",
"     <li>",
"      Naxyn 500 (IL);",
"     </li>",
"     <li>",
"      Noflam (NZ);",
"     </li>",
"     <li>",
"      Norswel (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Novaxen (MX);",
"     </li>",
"     <li>",
"      Nycopren (AT, DK, FI);",
"     </li>",
"     <li>",
"      Prexan (IT);",
"     </li>",
"     <li>",
"      Priaxen (BB, BF, BJ, BM, BS, BZ, CI, ET, GH, GM, GN, GY, JM, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, SR, TN, TT, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Primeral (IT);",
"     </li>",
"     <li>",
"      Prodexin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Pronaxen (SE);",
"     </li>",
"     <li>",
"      Proxen (AE, AT, BH, CH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, TW, YE);",
"     </li>",
"     <li>",
"      Safrosyn S (MY);",
"     </li>",
"     <li>",
"      Seladin (MY, SG);",
"     </li>",
"     <li>",
"      Soden (SG);",
"     </li>",
"     <li>",
"      Sutolin (TW);",
"     </li>",
"     <li>",
"      Synflex (AU, GB, IE);",
"     </li>",
"     <li>",
"      Veradol (AR);",
"     </li>",
"     <li>",
"      Xenar (IT);",
"     </li>",
"     <li>",
"      Xenifar (ID)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F199818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity,  inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F199836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Analgesic: 1 hour; Anti-inflammatory: ~2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Anti-inflammatory: 2-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Analgesic: &le;7 hours; Anti-inflammatory: &le;12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Almost 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 0.16 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99% to albumin; increased free fraction in elderly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Normal renal function: 12-17 hours; End-stage renal disease: No change",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (95%; primarily as metabolites); feces (&le;3%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alun-Jones E and Williams J, &ldquo;Hyponatremia and Fluid Retention in a Neonate Associated With Maternal Naproxen Overdosage,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1986, 24(3):257-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/3723650/pubmed\" id=\"3723650\" target=\"_blank\">",
"        3723650",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/11533352 /pubmed\" id=\"11533352 \" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2011, 27(Suppl A):1-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/21640290/pubmed\" id=\"21640290\" target=\"_blank\">",
"        21640290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berde C, Ablin A, Glazer J, et al, &ldquo;American Academy of Pediatrics Report of the Subcommittee on Disease-Related Pain in Childhood Cancer,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1990, 86(5 Pt 2):818-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/2216644/pubmed\" id=\"2216644\" target=\"_blank\">",
"        2216644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 52(18):1502-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/19017521/pubmed\" id=\"19017521\" target=\"_blank\">",
"        19017521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brooks PM and Day RO, &ldquo;Nonsteroidal Anti-inflammatory Drugs - Differences and Similarities,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1991, 324(24):1716-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/2034249/pubmed\" id=\"2034249\" target=\"_blank\">",
"        2034249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capone ML, Sciulli MG, Tacconelli S, et al, &ldquo;Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 45(8):1295-1301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/15837265/pubmed\" id=\"15837265\" target=\"_blank\">",
"        15837265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al, &ldquo;Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(25):1809-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/11752357/pubmed\" id=\"11752357\" target=\"_blank\">",
"        11752357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clinch D, Banerjee AK, and Ostick G, &ldquo;Absence of Abdominal Pain in Elderly Patients With Peptic Ulcer,&rdquo;",
"      <i>",
"       Age Ageing",
"      </i>",
"      , 1984, 13(2):120-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/6731166/pubmed\" id=\"6731166\" target=\"_blank\">",
"        6731166",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clive DM and Stoff JS, &ldquo;Renal Syndromes Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1984, 310(9):563-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/6363936/pubmed\" id=\"6363936\" target=\"_blank\">",
"        6363936",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Pain,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 2000, 42(1085):73-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/10951654/pubmed\" id=\"10951654\" target=\"_blank\">",
"        10951654",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2012, 94(5):1761-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/23098967/pubmed\" id=\"23098967\" target=\"_blank\">",
"        23098967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Forbes JA, Keller CK, Smith JW, et al, &ldquo;Analgesic Effect of Naproxen Sodium, Codeine, a Naproxen-Codeine Combination and Aspirin on the Postoperative Pain of Oral Surgery,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1986, 6(5):211-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/3540871/pubmed\" id=\"3540871\" target=\"_blank\">",
"        3540871",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Graham DY, &ldquo;Prevention of Gastroduodenal Injury Induced by Chronic Nonsteroidal Anti-inflammatory Drug Therapy,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 1989, 96(2 Pt 2 Suppl):675-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/2642452/pubmed\" id=\"2642452\" target=\"_blank\">",
"        2642452",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gurwitz JH, Avorn J, Ross-Degnan D, et al, &ldquo;Nonsteroidal Anti-inflammatory Drug-Associated Azotemia in the Very Old,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1990, 264(4):471-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/2366280/pubmed\" id=\"2366280\" target=\"_blank\">",
"        2366280",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hawkey CJ, Karrasch JA, Szczepa&ntilde;ski L, et al, &ldquo;Omeprazole Compared With Misoprostol for Ulcers Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(11):727-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/9494149/pubmed\" id=\"9494149\" target=\"_blank\">",
"        9494149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heerdink ER, Leufkens HG, Herings RM, et al, &ldquo;NSAIDs Associated With Increased Risk of Congestive Heart Failure in Elderly Patients Taking Diuretics,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1998, 158(10):1108-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/9605782/pubmed\" id=\"9605782\" target=\"_blank\">",
"        9605782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(4):465-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/22563589/pubmed\" id=\"22563589\" target=\"_blank\">",
"        22563589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holland S, Silberstein SD, Freitag F, et al, &ldquo;Evidence-based Guideline Update: NSAIDs and Other Complementary Treatments for Episodic Migraine Prevention in Adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2012, 78(17):1346-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/22529203/pubmed\" id=\"22529203\" target=\"_blank\">",
"        22529203",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoppmann RA, Peden JG, and Ober SK, &ldquo;Central Nervous System Side Effects of Nonsteroidal Anti-inflammatory Drugs. Aseptic Meningitis, Psychosis, and Cognitive Dysfunction,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1991, 151(7):1309-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/2064481/pubmed\" id=\"2064481\" target=\"_blank\">",
"        2064481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 53(15):e1-e90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/19358937/pubmed\" id=\"19358937\" target=\"_blank\">",
"        19358937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobi J, Fraser GL, Coursin DB, et al, &ldquo;Clinical Practice Guidelines for the Sustained Use of Sedatives and Analgesics in the Critically Ill Adult,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2002, 30(1):119-41. Available at file://www.sccm.org/pdf/sedatives.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/11902253/pubmed\" id=\"11902253\" target=\"_blank\">",
"        11902253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Knodel LC, &ldquo;Preventing NSAID-Induced Ulcers: The Role of Misoprostol,&rdquo;",
"      <i>",
"       Consult Pharm",
"      </i>",
"      , 1989, 4:37-41.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang BA and Finlayson LA, &ldquo;Naproxen-Induced Pseudoporphyria in Patients With Juvenile Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1994, 124(4):639-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/8151484/pubmed\" id=\"8151484\" target=\"_blank\">",
"        8151484",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martinez R, Smith DW, and Frankel LR, &ldquo;Severe Metabolic Acidosis After Acute Naproxen Sodium Ingestion,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1989, 18(10):1102-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/2552870/pubmed\" id=\"2552870\" target=\"_blank\">",
"        2552870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan TO, Anderson A, and Bertram D, &ldquo;Effect of Indomethacin on Blood Pressure in Elderly People With Essential Hypertension Well Controlled on Amlodipine or Enalapril,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 2000, 13(11):1161-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/11078175/pubmed\" id=\"11078175\" target=\"_blank\">",
"        11078175",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nader DA and Schillaci RF, &ldquo;Pulmonary Infiltrates With Eosinophilia Due to Naproxen,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 1983, 83(2):280-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/6822116/pubmed\" id=\"6822116\" target=\"_blank\">",
"        6822116",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Page J and Henry D, &ldquo;Consumption of NSAIDs and the Development of Congestive Heart Failure in Elderly Patients: An Underrecognized Public Health Problem,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2000, 160(6):777-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/10737277/pubmed\" id=\"10737277\" target=\"_blank\">",
"        10737277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pope JE, Anderson JJ, and Felson DT, &ldquo;A Meta-analysis of the Effects of Nonsteroidal Anti-inflammatory Drugs on Blood Pressure,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1993, 153(4):477-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/8435027/pubmed\" id=\"8435027\" target=\"_blank\">",
"        8435027",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pounder R, &ldquo;Silent Peptic Ulceration: Deadly Silence or Golden Silence?&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 1989, 96(2 Pt 2 Suppl):626-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/2642448/pubmed\" id=\"2642448\" target=\"_blank\">",
"        2642448",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rollins DE, Jennison TA, and Jones G, &ldquo;Investigation of Interference by Nonsteroidal Anti-Inflammatory Drugs in Urine Tests for Abused Drugs,&rdquo;",
"      <i>",
"       Clin Chem",
"      </i>",
"      , 1990, 36(4):602-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/2323039/pubmed\" id=\"2323039\" target=\"_blank\">",
"        2323039",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shaunak S, Brown P, and Morgan-Hughes JA, &ldquo;Exacerbation of Idiopathic Parkinson's Disease by Naproxen,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1995, 311(7002):422.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/7640588/pubmed\" id=\"7640588\" target=\"_blank\">",
"        7640588",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Snow V, Weiss K, Wall EM, et al, &ldquo;Pharmacologic Management of Acute Attacks of Migraine and Prevention of Migraine Headache,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2002, 137(10):840-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/12435222/pubmed\" id=\"12435222\" target=\"_blank\">",
"        12435222",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steinhubl SR, &ldquo;The Use of Anti-Inflammatory Analgesics in the Patient With Cardiovascular Disease: What a Pain,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 45(8):1302-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/15837266/pubmed\" id=\"15837266\" target=\"_blank\">",
"        15837266",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Verbeeck RK, &ldquo;Pharmacokinetic Drug Interactions With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1990, 19(1):44-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/2199127/pubmed\" id=\"2199127\" target=\"_blank\">",
"        2199127",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wallace CA, Farrow D, and Sherry DD, &ldquo;Increased Risk of Facial Scars in Children Taking Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1994, 125(5 Pt 1):819-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/7965441/pubmed\" id=\"7965441\" target=\"_blank\">",
"        7965441",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wells TG, Mortensen ME, Dietrich A, et al, &ldquo;Comparison of the Pharmacokinetics of Naproxen Tablets and Suspension in Children,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1994, 34(1):30-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/8132849/pubmed\" id=\"8132849\" target=\"_blank\">",
"        8132849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yeomans ND, Tulassay Z, Juhasz L, et al, &ldquo;A Comparison of Omeprazole With Ranitidine for Ulcers Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(11):719-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/43/43705/abstract-text/9494148/pubmed\" id=\"9494148\" target=\"_blank\">",
"        9494148",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9682 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-564C5304BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_43_43705=[""].join("\n");
var outline_f42_43_43705=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709165\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199854\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199855\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199906\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199859\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199881\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199860\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199861\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199830\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199815\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874744\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199834\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199833\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14306775\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199915\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199904\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199837\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199819\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199900\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199824\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199850\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199826\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7696306\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199865\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7696309\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199840\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199839\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199828\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199841\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199818\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199836\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9682\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9682|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/35/44597?source=related_link\">",
"      Naproxen: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/61/27608?source=related_link\">",
"      Naproxen: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_43_43706="Maintenance immunosuppressive therapy in renal transplantation in adults";
var content_f42_43_43706=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Maintenance immunosuppressive therapy in renal transplantation in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/43/43706/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/43/43706/contributors\">",
"     Brent W Miller, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/43/43706/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/43/43706/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/43/43706/contributors\">",
"     Barbara Murphy, MB, BAO, BCh, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/43/43706/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/43/43706/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/43/43706/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance immunosuppressive therapy is administered to almost all renal transplant recipients to help prevent acute rejection and the loss of the renal allograft. Although an adequate level of immunosuppression is required to dampen the immune response to the allograft, the level of chronic immunosuppression is slowly decreased over time (as the risk of acute rejection decreases) to help lower the overall risk of infection and malignancy; these risks directly correlate with the degree of overall immunosuppression. The type of immunosuppression may also be varied to decrease the risk of developing chronic allograft nephropathy, the most common underlying long-term cause of allograft loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=see_link\">",
"     \"Chronic renal allograft nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal maintenance immunosuppressive therapy in renal transplantation is not established. The major immunosuppressive agents that are currently being used in various combination regimens are corticosteroids (primarily oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF), mycophenolate sodium (myFortic),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (in standard form or microemulsion),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    , and rapamycin (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, approximately 85 percent of transplant recipients were discharged on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    , either with (58 percent) or without (42 percent) glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conventional maintenance regimens consist of a combination of immunosuppressive agents that differ by mechanism of action. This strategy minimizes morbidity and mortality associated with each class of agent while maximizing overall effectiveness. Such regimens may vary by transplant center and geographic area.",
"   </p>",
"   <p>",
"    The regimens and agents used for maintenance immunosuppression following renal transplantation will be reviewed herein. A discussion of induction therapy in renal transplantation is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32649?source=see_link\">",
"     \"Induction immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF MAINTENANCE IMMUNOSUPPRESSIVE REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplanting an immunologically non-identical kidney into a patient without administering immunosuppressive agents invariably results in allograft rejection and loss. Thus, maintenance immunosuppressive therapy is given to practically all recipients of renal allografts.",
"   </p>",
"   <p>",
"    Total body irradiation was one of the first strategies at inducing immunosuppression among solid organ recipients. Subsequently, in the 1960s to the early 1980s, kidney transplant recipients were primarily maintained on the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and steroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Outcomes with this regimen included 50 percent one-year allograft survival and 80 to 90 percent patient survival.",
"   </p>",
"   <p>",
"    This regimen was changed in the late 1980s after several trials showed improved allograft survival with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. The subsequent introduction of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    has permitted a large number of combinations of immunosuppressive agents to be used for maintenance therapy.",
"   </p>",
"   <p>",
"    There are a number of important issues to consider when deciding upon the maintenance immunosuppressive regimen to administer in a particular patient:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk for acute rejection and allograft loss is highest in the first three months after transplantation. As a result, immunosuppression should be at its highest during this period. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32649?source=see_link\">",
"       \"Induction immunosuppressive therapy in renal transplantation in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The occurrence of the most serious side effects of immunosuppressive therapy (infections and malignancy) correlate with the total amount of immunosuppression. It is therefore essential that immunosuppression be tapered slowly to a maintenance level by 6 to 12 months posttransplantation.",
"     </li>",
"     <li>",
"      Allograft survival rates vary among the various immunosuppressive agents due to patient-specific clinical characteristics, such as advanced age, obesity, ethnicity, hyperlipidemia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      delayed allograft function. Immunosuppressive agents should therefore be chosen in part based on specific patient characteristics.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other issues that must be taken into account are related to the \"immunologic\" history of the patient.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is the patient sensitized? (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25946?source=see_link\">",
"       \"C4d staining in renal allografts and treatment of antibody mediated rejection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Is this the first kidney transplant or a retransplant?",
"     </li>",
"     <li>",
"      How many acute rejection episodes has the patient had?",
"     </li>",
"     <li>",
"      What is the degree of HLA matching or mismatching? (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/57/11159?source=see_link\">",
"       \"HLA matching and graft survival in kidney transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      What is the risk of recurrent disease? (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33722?source=see_link\">",
"       \"Focal segmental glomerulosclerosis in the transplanted kidney\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/54/32614?source=see_link\">",
"       \"Membranoproliferative glomerulonephritis: Recurrence after transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39367?source=see_link\">",
"       \"IgA nephropathy: Recurrence after transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34088?source=see_link&amp;anchor=H26073572#H26073572\">",
"       \"Membranous nephropathy and renal transplantation\", section on 'Introduction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Did the patients receive lymphocyte-depleting therapy at the time of transplantation?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We and most transplant centers currently utilize a maintenance regimen consisting of triple immunosuppression therapy with a calcineurin inhibitor (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ), an anti-metabolite (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil or Mycophenolate sodium), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/3\">",
"     3",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    are also used by some transplant centers in triple therapy regimens, often in place of the calcineurin inhibitor or the antimetabolite or with low dose calcineurin inhibitor without an antimetabolite.",
"   </p>",
"   <p>",
"    As delineated in numerous multicenter randomized controlled trials and meta-analyses, triple immunosuppressive regimens are generally associated with greater than 90 percent allograft survival at one year in combination with acute rejection rates of less than 20 percent. These are the clinical outcomes traditionally used to compare the efficacy of various immunosuppressive regimens. (See subsequent sections for details concerning some of these studies). Issues surrounding the relative benefits and risks of administering",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"      sirolimus",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"      everolimus",
"     </a>",
"    </span>",
"    in triple drug regimens are also reviewed below and separately.",
"   </p>",
"   <p>",
"    However, a principal unresolved issue is the relationship between maintenance immunosuppressive regimens and long-term allograft survival among the general transplant population. An accurate assessment of this correlation is limited by even pivotal trials' ability to accurately anticipate and enroll a truly representative sample of the real world transplant population. This issue has assumed increasing importance since, despite the marked improvement in one-year allograft survival with current immunosuppressive regimens, the incidence of allograft loss over time remains significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. This is principally due to chronic allograft nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=see_link\">",
"     \"Chronic renal allograft nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other immunosuppressive regimens have therefore been evaluated. The general strategy is to minimize the toxicity associated with triple immunosuppressive regimens and possibly enhance long-term allograft survival without compromising short-term allograft survival. These regimens frequently involve withdrawal, avoidance, or minimization of either corticosteroids or calcineurin-inhibitors. Double immunosuppressive therapy with a calcineurin inhibitor and an anti-metabolite is therefore administered in some centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/3\">",
"     3",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    is also used in double therapy regimens, often in place of the calcineurin inhibitor or the antimetabolite. A regimen consisting of a calcineurin inhibitor and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is also used. There are also a few centers that maintain selected patients on a single agent, generally a calcineurin inhibitor, with reportedly good results. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/4/21577?source=see_link\">",
"     \"Withdrawal or avoidance of glucocorticoids after renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/9/17562?source=see_link\">",
"     \"Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=see_link\">",
"     \"Chronic renal allograft nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We and most transplant centers continue to prefer the administration, to most patients, of a maintenance regimen consisting of triple immunosuppression therapy with a calcineurin inhibitor, an anti-metabolite, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . This is consistent with the 2009 KDIGO clinical practice guidelines for kidney transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/11\">",
"     11",
"    </a>",
"    ]. This approach is principally because triple immunosuppression therapy regimens are associated with relatively decreased acute rejection rates, and there are limited data concerning long-term results with",
"    <span class=\"nowrap\">",
"     double/single",
"    </span>",
"    therapy regimens. In addition, there are no absolute criteria that enable the clinician to predict who will do well with the decreased level of immunosuppression associated with other regimens.",
"   </p>",
"   <p>",
"    Exceptions to our approach include recipients of HLA two-haplotype allografts and HLA identical allografts:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As shown in multiples studies, recipients of HLA two-haplotype living related allografts are at significantly lower risk of rejection and allograft loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/12\">",
"       12",
"      </a>",
"      ]; we maintain such patients on steroids and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil (or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ) or steroids and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      (or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ). One exception is black recipients who despite this HLA-advantage have been shown to have increased rates of acute rejection even in the early period after transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/13\">",
"       13",
"      </a>",
"      ]. We continue low-dose calcineurin inhibitors in black 2-haplotype living related recipients.",
"     </li>",
"     <li>",
"      Recipients of HLA identical allografts from a monozygotic twin usually receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      and steroids only for three months. They are subsequently maintained without immunosuppressive medication given that the allograft and recipient are immunologically identical [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/14-17\">",
"       14-17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2009 KDIGO guidelines also suggest that, among patients at low immunologic risk and who receive induction therapy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy should be discontinued during the first week after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/11\">",
"     11",
"    </a>",
"    ]. This is based on the desire to minimize long-term corticosteroid exposure, thereby decreasing the risk of adverse effects with this agent.",
"   </p>",
"   <p>",
"    We do not agree with this recommendation. A well designed long-term prospective study of corticosteroid withdrawal in the first week after transplantation found that this strategy resulted in double the rate of chronic allograft nephropathy compared with continuance of low-dose corticosteroid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/18\">",
"     18",
"    </a>",
"    ]. We therefore continue low dose corticosteroid therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/4/21577?source=see_link\">",
"     \"Withdrawal or avoidance of glucocorticoids after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A reduction in the dose of immunosuppressive drugs is often well tolerated in stable patients but careful monitoring is essential to prevent underimmunosuppression. By comparison, complete withdrawal of all maintenance therapy is",
"    <strong>",
"     not",
"    </strong>",
"    recommended (except in recipients of HLA identical allografts from a monozygotic twin), since it frequently leads to late acute rejection or accelerated chronic rejection. These complications most often occur in patients who are not compliant or who cannot afford to pay for the medications. However, there are occasional reports of patients in whom the complete withdrawal of immunosuppression medications was associated with long-term allograft survival, thereby implying the development of donor-specific nonreactivity via unclear mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/19\">",
"     19",
"    </a>",
"    ]; this form of tolerance has been observed in renal and liver transplant recipients in particular [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important issue is the optimal immunosuppressive strategy among patients with recurrent acute rejection episodes. Among such patients who are being administered triple immunosuppressive therapy, we switch to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    (if they are on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (if they are on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ). The combination of tacrolimus and mycophenolate may cause more severe gastrointestinal side effects than that observed with mycophenolate alone. If these agents are already in use, then consideration is given for the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    with mycophenolate mofetil and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . We avoid the use of the combination of sirolimus plus a calcineurin inhibitor (either cyclosporine or tacrolimus) because both calcineurin inhibitors are synergistically nephrotoxic when used with sirolimus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/9/17562?source=see_link\">",
"     \"Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448642464\">",
"    <span class=\"h1\">",
"     CALCINEURIN INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We administer a maintenance regimen consisting of triple immunosuppression therapy. This includes a calcineurin inhibitor (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ), an anti-metabolite (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    ), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . Either cyclosporine or tacrolimus is used in over 90 percent of kidney transplant recipients in the United States, with tacrolimus currently being more popular (85 versus 12 percent use in kidney transplant patients prior to hospital discharge) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    is preferred principally because several studies have reported that it is associated with fewer acute rejections than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and is possibly associated with improved allograft survival. However, compared with cyclosporine, tacrolimus is more likely to increase the risk of post-transplant diabetes mellitus, which may result in decreased allograft survival among affected patients.",
"   </p>",
"   <p>",
"    Thus, via both positive and negative effects, the relative net result of a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    -based immunosuppressive regimen versus a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    -based regimen remains unclear. Overall, an accurate interpretation of the literature is clouded by the administration of different cyclosporine formulations over time, and variations in outcomes among those with different clinical features. As an example, a 2005 meta-analysis of the relative efficacy of tacrolimus and cyclosporine that involved 30 trials found decreased acute rejection rates and a lower risk of allograft loss at six months with tacrolimus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/23\">",
"     23",
"    </a>",
"    ]. By comparison, we found no difference in renal allograft survival outcomes with these two agents using more recent registry data (1996 to 2000) that were limited to nondiabetic recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the optimal calcineurin inhibitor is unclear in most patients undergoing kidney transplantation. We generally prefer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    because it is associated with decreased acute rejection rates and similar overall costs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/25\">",
"     25",
"    </a>",
"    ]. This is in agreement with the 2009 KDIGO guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, tacrolimus is associated with acceptable rates of post-transplant diabetes mellitus (which appears to be dose-related) and, compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , is better tolerated and preferred by patients. Relatively decreased doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    are also permitted when mycophenolate is used with tacrolimus, because this agent, unlike cyclosporine, does not lower mycophenolate levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448642509\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal transplant recipients were maintained on the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and steroids before the introduction of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in the early 1980s. This regimen was changed after several trials showing improved early allograft survival with cyclosporine therapy were published in the late 1980s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A large number of studies have been published showing the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/23,26,27\">",
"     23,26,27",
"    </a>",
"    ]. The following is a brief survey of some of these trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The long-term efficacy of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      was largely confirmed in a 1993 trial comparing the effects of different immunosuppressive regimens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/26\">",
"       26",
"      </a>",
"      ]. Triple therapy with cyclosporine (3 to 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day), steroids, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      resulted in better allograft function and fewer chronic changes on allograft biopsy than seen in patients on any two-drug regimen, such as steroids and azathioprine alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/26\">",
"       26",
"      </a>",
"      ]. As an example, the degree of renal injury as estimated from a \"chronic damage\" index on renal biopsy was 1.5 with triple therapy versus 3.2 to 4.3 with any two-drug combination.",
"     </li>",
"     <li>",
"      Benefits with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      were also found in a review of data from the Collaborative Transplant Study of patients with long-term graft function who were maintained on cyclosporine therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/27\">",
"       27",
"      </a>",
"      ]. At 10 years post-transplantation, the highest allograft survival rates among deceased donor kidney recipients were observed among those who had received cyclosporine at a dose of 3 to 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day when measured one year post-surgery; by comparison, the lowest survival was observed among those administered cyclosporine at less than 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day at the same period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given that most centers use either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    as part of the maintenance immunosuppressive regimen, an important issue is relative efficacy and adverse effects associated with both agents. This is discussed separately. (See",
"    <a class=\"local\" href=\"#H448642464\">",
"     'Calcineurin inhibitors'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H448642595\">",
"     'Efficacy versus cyclosporine'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H448642602\">",
"     'Toxicity compared to cyclosporine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The optimal maintenance dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/3,28\">",
"     3,28",
"    </a>",
"    ]. This is an extremely important issue because of the two limiting factors associated with chronic cyclosporine administration: cost and nephrotoxicity. Once daily or twice daily dosing appear to be equivalent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H15\">",
"     'Target levels'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448642516\">",
"    <span class=\"h3\">",
"     Effect of withdrawal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The withdrawal of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    has been associated in a number of studies with an increased incidence of late acute rejection and a possible reduction in long-term allograft survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/6,30-38\">",
"     6,30-38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis published in 2000, which in part evaluated 13 studies examining",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      withdrawal, found that such withdrawal was associated with an increased incidence of acute rejection, but no reduction in long-term allograft survival [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/37\">",
"       37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Similar findings were noted in a 2005 systematic review of calcineurin inhibitor withdrawal from",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      -based therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/38\">",
"       38",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Blacks and patients with a higher number of HLA-DR mismatches appear to be at particular risk following the cessation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/9/17562?source=see_link\">",
"     \"Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=see_link\">",
"     \"Chronic renal allograft nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A related, but separate, issue is the replacement of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    with non-nephrotoxic immunosuppressive agents among patients with cyclosporine-induced nephrotoxicity or chronic allograft nephropathy, which may result in improved renal function. This issue is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=see_link&amp;anchor=H8#H8\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\", section on 'Withdrawal of cyclosporine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=see_link\">",
"     \"Chronic renal allograft nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448642523\">",
"    <span class=\"h3\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another important consideration among patients maintained on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is that several drugs interfere with its metabolism, and therefore may cause either overdosing with deterioration of renal function or underdosing with an increased incidence of rejection. Reviewed briefly, the following agents increase blood cyclosporine levels:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Calcium channel blockers &ndash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       Verapamil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/61/42969?source=see_link\">",
"       nicardipine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"     </li>",
"     <li>",
"      Antifungal agents &ndash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"       Ketoconazole",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"     </li>",
"     <li>",
"      Antibiotics &ndash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"       Erythromycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"     </li>",
"     <li>",
"      Grapefruit juice",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Common medications that decrease blood",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    levels (by inducing hepatic metabolism of cyclosporine) include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anticonvulsants &ndash; Barbiturates,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"     </li>",
"     <li>",
"      Antituberculous agents &ndash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"       Isoniazid",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (For additional information on drug interactions, use the Lexi-Interact drug interactions program provided by UpToDate).",
"   </p>",
"   <p>",
"    Other nephrotoxins may worsen the renal toxicity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , such as nonsteroidal antiinflammatory drugs, aminoglycosides, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    . In addition, an HMG CoA reductase inhibitor (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    ) can cause rhabdomyolysis and rarely acute renal failure when given with cyclosporine. This effect may be mediated at least in part by a cyclosporine-induced impairment in metabolism of the statin. Starting with small doses may obviate this problem, thereby allowing these drugs to be used. Muscle toxicity is less common with some of the statins, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    , even when given with cyclosporine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29546?source=see_link\">",
"     \"Lipid abnormalities after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448642530\">",
"    <span class=\"h3\">",
"     Use of drugs that slow cyclosporine metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate yet related issue is the administration of drugs &ndash; particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    &ndash; that slow",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    metabolism, thereby decreasing cost by allowing the use of much lower doses of cyclosporine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/39\">",
"     39",
"    </a>",
"    ]. A paucity of data exists concerning the potential side effects of life-long ketoconazole therapy or the long-term allograft survival with combination therapy. In a prospective 10 year randomized Egyptian study of 100 patients administered cyclosporine with or without ketoconazole, the ketoconazole group had significantly lower chronic allograft nephropathy rates (6 versus 23 patients), costs, and cyclosporine doses, and similar rates of acute rejection, hepatotoxicity, and metabolic complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    is given, adequate absorption requires acid gastric secretions with a pH below 3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Thus, it is commonly recommended to take ketoconazole with soda or tonic and avoid antacids, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/29/29141?source=see_link\">",
"     sucralfate",
"    </a>",
"    , proton pump inhibitors such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    , and H2-blockers, which can lead to decreased ketoconazole absorption and a potential reduction in blood",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    to subtherapeutic levels unless the cyclosporine dose is increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448642537\">",
"    <span class=\"h3\">",
"     Microemulsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoral is an oral preparation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    that involves a unique microemulsion formulation. The microemulsion is miscible in water and has improved pharmacokinetic bioavailability when compared to the standard oral preparation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Neoral formulation has the following advantages compared with Sandimmune [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/44-50\">",
"     44-50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Twice the bioavailability.",
"     </li>",
"     <li>",
"      Less intraindividual and interindividual variability.",
"     </li>",
"     <li>",
"      Reduced time (more than 30 percent) to maximal concentration (Tmax).",
"     </li>",
"     <li>",
"      The maximum concentration may be nearly 80 percent higher, but trough (12 hour) levels are essentially unchanged [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Absorption and drug levels that are less susceptible to the effects of food (particularly fatty foods); this makes administration and monitoring more convenient [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]. Unlike Sandimmune, Neoral is not dependent upon bile salts for absorption.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Trials have confirmed that Neoral is equivalent to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    for prevention of graft rejection and no differences have been shown in graft or patient survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Most centers initiate cyclosporine therapy with the microemulsion preparation in new transplant patients. The efficacy and safety of converting patients from the standard cyclosporine formulation to the microemulsion was evaluated in a multicenter double-blind study of 262 patients in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/56\">",
"     56",
"    </a>",
"    ]. With careful monitoring, this conversion was as safe as continuing therapy with the standard formulation; in addition, a lower incidence of adverse events occurred among those converted to Neoral as compared to those maintained with Sandimmune. Similar findings were reported in a Canadian study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dose of the microemulsion is 10 to 20 percent lower than standard",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/58\">",
"     58",
"    </a>",
"    ]; however, the exact conversion dose must be carefully undertaken, since not all patients require a dose reduction. In one study, logistic regression analysis found that, among patients being converted from maintenance standard cyclosporine to microemulsion, those with maintenance doses of &ge;4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    were most likely to require lower doses of microemulsion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, since lower doses of Neoral are most commonly utilized, this conversion may have the added advantage of cost savings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/58\">",
"     58",
"    </a>",
"    ]. Another cost-effective alternative is the administration of a generic preparation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , which has been approved by the Food and Drug Administration (FDA) in the United States (see below).",
"   </p>",
"   <p>",
"    As previously mentioned, a study that evaluated a six-month treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    along with Neoral and steroids (phase A), and over 15 more months without corticosteroids found that mycophenolate and azathioprine had similar efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Azathioprine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The effectiveness of Neoral versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    is discussed below. (See",
"    <a class=\"local\" href=\"#H448642588\">",
"     'Tacrolimus'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448642574\">",
"    <span class=\"h3\">",
"     Gengraf",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gengraf is a modified formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    that is AB rated as equivalent by the FDA of the United States. A multicenter study of 50 stable renal transplant recipients found that the pharmacokinetics of Gengraf were equivalent and indistinguishable from those of Neoral [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/61\">",
"     61",
"    </a>",
"    ]. Gengraf was also well tolerated and interchangeable with Neoral in these patients.",
"   </p>",
"   <p>",
"    Little data are available concerning the relative effects of Gengraf and Neoral on clinical outcomes. A single center retrospective study found that acute rejections were common with Gengraf compared to Neoral [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/62\">",
"     62",
"    </a>",
"    ]. Further study is required to better understand the relative equivalence of these formulations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448642581\">",
"    <span class=\"h3\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the Eon and Sidmak preparations are modified formulations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    that have been deemed bioequivalent with Neoral by the FDA of the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448642588\">",
"    <span class=\"h2\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    (FK506) is a macrolide immunosuppressant that possesses similar but more potent (on a milligram to milligram basis) immunosuppressant properties than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . This agent was initially approved by the FDA for use in liver transplantation. This contributes to difficulty in interpreting the efficacy of new immunosuppressive agents since the FDA mandates the use of cyclosporine in the comparison regimen in many studies of new immunosuppressive drugs.",
"   </p>",
"   <p>",
"    The mechanism of action of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    is similar to that of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . Tacrolimus binds to an immunophilin, FKBP (",
"    <strong>",
"     FK",
"    </strong>",
"    506",
"    <strong>",
"     B",
"    </strong>",
"    inding",
"    <strong>",
"     P",
"    </strong>",
"    rotein), which has peptidyl-prolyl isomerase activity. The drug's immunosuppressive action is mediated via blockade of calcineurin mediated T cell receptor signal transduction and inhibition of IL-2 transcription [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/63\">",
"     63",
"    </a>",
"    ]. By inhibiting cytokine gene transcription, tacrolimus suppresses T cell and T cell-dependent B cell activation.",
"   </p>",
"   <p>",
"    Since",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    is more water-soluble than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , it is not as dependent upon bile salts for absorption. However, food intake can reduce the absorption of tacrolimus by up to 40 percent; thus, it is recommended that this agent be taken on an empty stomach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. In addition, tacrolimus is best absorbed in the morning, and there is some evidence suggests that this agent can be given once a day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/66\">",
"     66",
"    </a>",
"    ]. Further, limited evidence suggests that an extended release formulation (Prograf XL) that is designed to be given once per day is safe and effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448642595\">",
"    <span class=\"h3\">",
"     Efficacy versus cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, differences in absorption between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and the various",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    preparations may have significant clinical impact. Although there are conflicting data, it may also help understand the differing results of some of the subsequent trials that have compared the efficacy of tacrolimus and cyclosporine.",
"   </p>",
"   <p>",
"    Although many trials have shown similar graft survival outcomes with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    when compared to Sandimmune-brand",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    -based regimens in the setting of renal transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/68\">",
"     68",
"    </a>",
"    ], the incidence of acute rejection may be less with tacrolimus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/68-71\">",
"     68-71",
"    </a>",
"    ]. The multicenter FK506 Kidney Transplant Study Group randomly assigned 412 cadaveric renal transplant recipients to either tacrolimus or Sandimmune-brand cyclosporine based immunosuppressive regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/69\">",
"     69",
"    </a>",
"    ]. Sandimmune and tacrolimus resulted in similar graft survival rates at one year. However, tacrolimus was associated with a significantly decreased incidence of biopsy proven acute rejection episodes (30.7 versus 46.4 percent) and requirement for antilymphocyte antibody therapy (10.7 versus 25.1 percent).",
"   </p>",
"   <p>",
"    The relative effectiveness of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    versus Neoral is unclear. In some studies, tacrolimus has reportedly had lower acute rejection rates. Despite this, both agents are associated with similarly excellent allograft survival rates, although some studies report an advantage of one agent over the other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/25,72-79\">",
"     25,72-79",
"    </a>",
"    ]. Examples of some of these studies include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As previously mentioned, the ELITE study found that, at one year, low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      , and corticosteroids (with daclizumab induction) had superior allograft survival and rejections versus standard and low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      -based (Neoral or Sandimmune) regimens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/72\">",
"       72",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Efficacy in combination with tacrolimus'",
"      </a>",
"      below.)However, significantly higher rates of PTDM developed in patients receiving low-dose tacrolimus (8.4 percent) versus those receiving standard-dose cyclosporine (6 percent), low-dose cyclosporine (4.2 percent), and low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      (6.6 percent).",
"     </li>",
"     <li>",
"      In a prospective six month study, 560 patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      microemulsion plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      and corticosteroids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/74\">",
"       74",
"      </a>",
"      ]. Tacrolimus was associated with significantly lower rates of acute rejection (19.6 versus 37.3 percent) and corticosteroid-resistant rejection (9.4 versus 21 percent). Follow-up at two years found that the composite endpoint of allograft loss, patient death, and biopsy-proven acute rejection was significantly lower with tacrolimus (26 versus 43 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized controlled trial,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil resulted in a significantly lower rate of steroid resistant rejection that required antilymphocyte therapy compared with Neoral plus mycophenolate mofetil (5.6 versus 12 percent at two years) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/75,76\">",
"       75,76",
"      </a>",
"      ]. At three years, tacrolimus plus mycophenolate provided markedly increased allograft survival only among those with delayed graft function (84 versus 50 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To help assess the relative efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , a 2005 meta-analysis and meta-regression was performed based upon 30 trials consisting of 4102 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/23\">",
"     23",
"    </a>",
"    ]. Tacrolimus was associated with a significantly lower risk of allograft loss at six months (RR of 0.56, 95% CI 0.36-0.86), which was independent of cyclosporine formulation or concentration but was diminished with increased doses of tacrolimus. Although not always statistically significant, allograft loss at later time points also favored tacrolimus (RR of 0.77 [CI 0.58-1.02] at one year, 0.74 [0.46-1.21] at two years, and 0.71 [0.52-0.96] at three years). In addition, a relatively decreased acute rejection risk at one year was noted with tacrolimus (RR of 0.66, 95% CI 0.6-0.79).",
"   </p>",
"   <p>",
"    However, no difference in allograft survival rates was observed with these two agents in a retrospective study of nondiabetic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/24\">",
"     24",
"    </a>",
"    ]. Based upon data from the United States Renal Data System during the years 1996 to 2000, allograft survival rates were similar among those who received either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (hazard ratio of 1.031). In addition, a retrospective study from the USRDS database found that a regimen of cyclosporine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    was associated with a lower risk for allograft failure than tacrolimus, mycophenolate, and prednisone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the variabilities concerning many of these studies (such as dosing, absorption, types of concurrent immunosuppressive agents, comorbid conditions (particularly diabetes mellitus), lack of randomization), further study is required to better understand the relative benefits of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . Overall, tacrolimus is associated with decreased acute rejection rates and similar overall costs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448642602\">",
"    <span class=\"h3\">",
"     Toxicity compared to cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    has a toxicity profile slightly different from that of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . Although not consistently observed, both short- and long-term studies in liver and renal transplant recipients suggest that tacrolimus is at least as nephrotoxic as cyclosporine. Tacrolimus can also cause hyperkalemia, hyperuricemia, and rarely the hemolytic-uremic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reported differences in non-renal toxicity with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    as compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/23,81-84\">",
"     23,81-84",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      More prominent neurologic side effects, such as tremor and headache",
"     </li>",
"     <li>",
"      More frequent incidence of post-transplant diabetes",
"     </li>",
"     <li>",
"      More frequent diarrhea, dyspepsia, and vomiting",
"     </li>",
"     <li>",
"      A hypertrophic cardiomyopathy, which has been reported in children",
"     </li>",
"     <li>",
"      More frequent alopecia",
"     </li>",
"     <li>",
"      Increased proclivity to polyoma virus infection",
"     </li>",
"     <li>",
"      Less frequent hirsutism, gingival hyperplasia, and hypertension",
"     </li>",
"     <li>",
"      Severe neutropenia has been reported with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    in causing post-transplant diabetes mellitus and in patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    nephrotoxicity as well as other issues relating to tacrolimus toxicity are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/40/26250?source=see_link\">",
"     \"New onset diabetes after transplant (NODAT) in renal transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=see_link\">",
"     \"Chronic renal allograft nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/7/6266?source=see_link\">",
"     \"Clinical manifestations and diagnosis of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/45/42712?source=see_link\">",
"     \"Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\"",
"    </a>",
"    .)In addition, converting from cyclosporine to tacrolimus may provide significant benefits in serum lipid levels. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29546?source=see_link\">",
"     \"Lipid abnormalities after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To minimize these side effects,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is sometimes switched for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . A paucity of data exists concerning the efficacy of substituting cyclosporine for tacrolimus among renal transplant recipients initially treated with a tacrolimus-based immunosuppressive regimen. A short-term study found that, among stable patients, this conversion was safe without the induction of rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/85\">",
"     85",
"    </a>",
"    ]. It is unclear if this conversion is similarly safe in patients with intolerable adverse effects resulting from tacrolimus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448642609\">",
"    <span class=\"h2\">",
"     Target levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring of plasma or whole blood",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    trough levels is routinely used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/86\">",
"     86",
"    </a>",
"    ]. With this approach, doses of cyclosporine are adjusted to maintain 12 hour trough levels of 200 to 300",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    for the first three months post-transplant; after this period, we subsequently taper doses to maintain trough levels between 50 to 150",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"   </p>",
"   <p>",
"    Although",
"    monitoring of trough levels (12 hours post-dose) of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is common practice, there is a poor correlation between clinical outcome and drug exposure as assessed using this strategy. Attention has therefore been given to the use of two-hour peak cyclosporine or C2 levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2007 systematic review evaluated 29 studies (only 10 were randomized controlled trials) concerning the clinical benefits of C2 level monitoring among kidney, liver, and cardiac transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/87\">",
"     87",
"    </a>",
"    ]. Although this approach may permit dose reductions in stable patients, there were no significant short-term clinical benefits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, among kidney transplant recipients, the two-hour post-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    level (C2) may correlate more closely with exposure, with higher C2 concentrations being associated with decreased acute rejection rates in the first year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/89-91\">",
"     89-91",
"    </a>",
"    ]. Proposed C2 targets are 1000 to 1500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in the first six months post-transplantation and 800 to 900",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in months 6 to 12 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/92,93\">",
"     92,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, long-term C2 targets and any potential benefit on clinical outcomes are unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. One single center study of 100 patients that compared C2 versus C0 monitoring showed no differences in patient or allograft survival, renal function, hypertension, use of antihypertensive and lipid-lowering agents, cholesterol or incidence of post-transplant diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/96\">",
"     96",
"    </a>",
"    ]. Use of C2 monitoring was associated with lower",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    exposure and costs.",
"   </p>",
"   <p>",
"    This same study speculated that use of thymoglobulin for induction therapy allows for a slightly lower C2 target in the early post-transplant period. Target C2 levels were between 1000 and 1200",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in months zero to three and between 600 and 1000",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    for subsequent months, while target trough levels were between 250 and 350",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    and between 100 and 250",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    for the similar post-transplant periods, respectively. Since completion of that study, we have found C2 monitoring helpful and use it frequently when adjusting dosage.",
"   </p>",
"   <p>",
"    Our current C2 target levels are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      800 to 1000",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      in months one to three after transplantation",
"     </li>",
"     <li>",
"      400 to 600",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      for subsequent months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    is utilized, doses are adjusted to attain target whole-blood trough concentrations of 8 to 10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    for the first three months, and 3 to 7",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    after this period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/97\">",
"     97",
"    </a>",
"    ]. When antilymphocyte depleting agents are used, we target tacrolimus to 7-10",
"    <span class=\"nowrap\">",
"     ng/mo",
"    </span>",
"    during the first month and then 3 to 7",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    thereafter. Dosing and levels may be affected by polymorphisms of the multidrug resistance-1 (P-glycoprotein, PGP) and CYP3A5 genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/98-100\">",
"     98-100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANTIMETABOLIC AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Overview of our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, we administer a maintenance regimen consisting of triple immunosuppression therapy. This includes an anti-metabolite (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    ), a calcineurin inhibitor (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or one of the forms of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    is used in nearly 90 percent of kidney transplant recipients in the United States, and mycophenolate is currently vastly more popular (&gt;90 versus 0.6 percent use in kidney transplant patients prior to hospital discharge) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/22,101,102\">",
"     22,101,102",
"    </a>",
"    ]: However, mycophenolate is much more expensive than azathioprine.",
"   </p>",
"   <p>",
"    Despite its increased cost,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    is generally preferred because several studies, particularly some initial pivotal reports, found that acute rejection rates were lower with this agent. However, since these studies used different doses and preparations from that currently administered, these results may not necessarily apply today.",
"   </p>",
"   <p>",
"    As an example, the United States pivotal study analyzed outcomes with relatively low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) versus high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (1000 to 1500 mg two times per day) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/103\">",
"     103",
"    </a>",
"    ]. By comparison, we use azathioprine at doses of 2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, and mycophenolate doses that rarely exceed 1000 mg two times per day. In addition, the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    preparation was unmodified (Sandimmune) the pivotal mycophenolate studies and not the more readily absorbed modified preparation (Neoral, etc.) that is currently in use. Furthermore, registry data studies relied upon information from an era in which overall results were inferior to outcomes currently obtained (resulting in selection bias against azathioprine) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/104-107\">",
"     104-107",
"    </a>",
"    ]. Additional data suggest similar long-term allograft survival rates, as well as similar acute rejection rates when these agents are administered with cyclosporine microemulsion. An analysis of the Scientific Registry of Transplant Recipients (SRTR) of patients transplanted between 1998 and 2006 showed that the combination of azathioprine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    was associated with similar outcomes as mycophenolate and tacrolimus among renal transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/108\">",
"     108",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Efficacy versus azathioprine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Given current evidence,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil appear to be",
"    <strong>",
"     similar",
"    </strong>",
"    in terms of acute rejection rates and long-term allograft survival rates. In addition, azathioprine is markedly less expensive, although costs may vary by geographic region and country.",
"   </p>",
"   <p>",
"    Thus,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    is our anti-metabolic agent of choice in most low-risk kidney transplant recipients. We also use azathioprine in men planning to become fathers while on immunosuppressive therapy and in women of child bearing age, as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    is teratogenic. Mycophenolate is contraindicated in pregnancy and is listed as a category D drug (positive evidence of risk) for use in pregnancy by the FDA. As a result, females of childbearing potential should have a negative pregnancy test within one week prior to beginning therapy. Two reliable forms of contraception should be used beginning four weeks prior to, during, and for six weeks after therapy. (See",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/56/22406?source=see_link\">",
"     \"Mycophenolate: Patient drug information\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11241?source=see_link\">",
"     \"Pregnancy in women with underlying renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By comparison, although the data are sparse, we prefer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil in those we consider to be at higher immunologic risk for rejection or disease recurrence. This includes patients with the following clinical features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of anti-HLA antibodies (whether donor specific or not) detected by cytotoxicity, flow cytometry, ELISA",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      magnetic beads (Luminex)",
"     </li>",
"     <li>",
"      Retransplants",
"     </li>",
"     <li>",
"      Immunologic cause of renal disease, such as systemic lupus erythematosus or rapidly progressive glomerulonephritis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We also use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    in patients with gout who require the continuation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29668?source=see_link\">",
"     febuxostat",
"    </a>",
"    , agents that are relatively contraindicated in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/14/3303?source=see_link&amp;anchor=H8#H8\">",
"     \"Hyperuricemia and gout in renal transplant recipients\", section on 'Xanthine oxidase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An acceptable alternative strategy, which is most commonly used, is the administration of MMF as the anti-metabolic agent for most patients. This is the choice of nearly 90 percent of transplant centers in the United States. With this strategy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    is used in men planning to become fathers and in women of child bearing age, given that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    is contraindicated in pregnancy.",
"   </p>",
"   <p>",
"    Because gastrointestinal side effects are common with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and these side effects tend to be less common with enteric-coated mycophenolic acid (myFortic), we prefer enteric-coated mycophenolic acid over mycophenolate mofetil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/109\">",
"     109",
"    </a>",
"    ]. If patients do not tolerate the enteric-coated formulation, we lower the dose or consider switching to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    (Imuran), a precursor of 6-mercaptopurine, is an antimetabolite. The usual maintenance dose is 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, although it is 2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    at some centers. Higher initial doses (5",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    combined with monitoring of 6-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/54/35685?source=see_link\">",
"     thioguanine",
"    </a>",
"    nucleotide levels in red blood cells is associated with an approximately 20 percent reduction in the acute rejection rate as compared to lower doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/45\">",
"     45",
"    </a>",
"    ]. These levels may be obtained commercially.",
"   </p>",
"   <p>",
"    Several large trials that directly compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil found that mycophenolate possibly lowered the risk of acute rejection compared with azathioprine. A review of these trials is found elsewhere. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Mycophenolate'",
"    </a>",
"    below.) This has led most centers to prefer mycophenolate as the antimetabolite agent of choice as part of the maintenance immunosuppressive regimen.",
"   </p>",
"   <p>",
"    However, these studies are not consistent with current practice since they were performed with older preparations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H448642537\">",
"     'Microemulsion'",
"    </a>",
"    above.) In part to better address the issue of relative efficacy of these two agents, the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    Mofetil versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    for Prevention of Acute Rejection in Renal Transplantation trial was initiated. This and other studies are discussed below. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Efficacy versus azathioprine'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukopenia is the most serious side effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . The immunosuppressive effect of azathioprine is not related to the reduction in white blood cell count; as a result, it is not necessary to increase the dose to achieve leukopenia.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    should be temporarily withheld if the white cell count falls below",
"    <span class=\"nowrap\">",
"     3000/mm3",
"    </span>",
"    or if the count drops by 50 percent between blood draws. Recovery usually occurs within one to two weeks. The drug can then be restarted at a lower dose and increased gradually to the usual maintenance dose while monitoring the white cell count.",
"   </p>",
"   <p>",
"    On occasion,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    has to be discontinued because of recurrent or persistent leukopenia. Severe leukopenia can occur if xanthine oxidase inhibitors such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29668?source=see_link\">",
"     febuxostat",
"    </a>",
"    (used for the treatment of hyperuricemia and gout) are given with azathioprine. Allopurinol and febuxostat inhibit the activity of xanthine oxidase which also plays a role in the metabolism of azathioprine. Thus, allopurinol and febuxostat should generally be",
"    <strong>",
"     avoided",
"    </strong>",
"    in patients treated with azathioprine. If, however, the patient has severe gout and either allopurinol or febuxostat must be used, we reduce the azathioprine dose (by at least 50 percent) and carefully monitor the white blood cell count. Even with this approach however, azathioprine may need to be discontinued. As previously mentioned, a better choice is switching from azathioprine to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    which does not interact with xanthine oxidase inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/14/3303?source=see_link\">",
"     \"Hyperuricemia and gout in renal transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another potentially serious side effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , which requires decreasing the dose or even stopping the drug, is hepatotoxicity. This complication is manifested by abnormal liver function tests, usually showing a cholestatic picture. The diagnosis of azathioprine-induced liver disease is one of exclusion and the patient should be evaluated for other more serious causes of hepatic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=see_link\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    has also been linked to the development of skin cancer, the most common malignancy in renal transplant patients. As a result, patients taking azathioprine for a prolonged period should be instructed to avoid direct exposure to sunlight or to use heavy sun screens when exposed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Mycophenolate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil (MMF) is rapidly metabolized to mycophenolic acid, which impairs lymphocyte function by blocking purine biosynthesis via inhibition of the enzyme inosine monophosphate dehydrogenase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]. Mycophenolate was developed as a replacement for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    for maintenance immunosuppression. It is not nephrotoxic, and has less bone marrow toxicity than azathioprine. However, gastrointestinal toxicity can occur, usually manifested by gastritis and diarrhea.",
"   </p>",
"   <p>",
"    We administer MMF at a dose of 1000 mg two times per day during the first hospital admission; patients are discharged, usually at post operative day 5, on 500 mg two times per day [particularly with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ] or 1000 mg two times per day if the patient is receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or is perceived to be at high risk for rejection (HLA incompatible transplant, high PRA, or second transplant).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Efficacy versus azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of multicenter trials have been published concerning the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . Several studies, particularly some initial pivotal reports, found that acute rejection rates were lower with mycophenolate. However, these studies may be flawed. Given current evidence, azathioprine and mycophenolate mofetil appear to be similar in terms of acute rejection rates and long-term allograft survival rates. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Overview of our approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following is a general survey of some of these trials, including some of the early and pivotal trials that first showed a decreased rate of acute rejection with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/80,103,112-117\">",
"     80,103,112-117",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      (2 to 3",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      in divided doses) to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      in 499 patients who were also treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      and equine-derived antithymocyte globulin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/103\">",
"       103",
"      </a>",
"      ]. Although 6 and 12 month patient and graft survival were similar in the two groups, mycophenolate was associated with fewer first rejection episodes (18 to 20 versus 38 percent with azathioprine) and fewer episodes of rejection or treatment failure manifested by graft loss, death, or withdrawal from therapy (31 versus 48 percent). At three years posttransplantation, graft and patient survival, renal function, and safety were similar among the three treatment groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/116\">",
"       116",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A post-hoc analysis of this trial showed that lower rejection rates among African Americans were only evident with the use of the higher dose of mycophenolate mofetil at 1.5 grams two times per day and not the lower dose at 1 gram two times per day [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/117\">",
"       117",
"      </a>",
"      ]. The reasons for this finding are unclear but probably not related to pharmacokinetic differences of race [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/118\">",
"       118",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another trial was a randomized clinical report by the Tricontinental",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    Mofetil Renal Transplantation Study Group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/114\">",
"     114",
"    </a>",
"    ]. It also compared the effectiveness of mycophenolate mofetil at two doses, 3",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    (164 patients) and 2",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    (173 patients), to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (100 to 150",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    166 patients). Patients were also treated with equivalent doses of corticosteroids and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and followed for one year. Compared with azathioprine, mycophenolate was associated with a lower incidence of treatment failure at six months (35 and 38 percent versus 50 percent), a lower incidence of rejection (16 and 20 percent versus 36 percent), a decreased use of antilymphocyte antibody for severe or steroid-resistant rejection episodes (5 and 9 percent versus 15.4 percent), and a nonsignificant trend toward improved graft survival at one year.",
"    <br/>",
"    <br/>",
"    At three years both mycophenolate groups continued to show a nonsignificant trend toward better graft survival and a lower rate of graft loss from rejection as compared to the azathioprine group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/119\">",
"     119",
"    </a>",
"    ]. However, a 15-year follow-up study of 133 Australian patients who participated in the initial trial reported no difference in mortality, allograft survival, cancer incidence or kidney function after the first year (underpowered to detect a difference with this number of patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/120\">",
"     120",
"    </a>",
"    ]. By five years, 42 percent of patients on mycophenolate had switched to azathioprine, whereas few patients assigned to receive azathioprine crossed over to mycophenolate. Despite this large crossover, intention-to-treat and as-treated analyses yielded similar results which supports the use of azathioprine which is substantially less expensive than mycophenolate.",
"   </p>",
"   <p>",
"    These studies are not consistent with current practice, since they were performed with older preparations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H448642537\">",
"     'Microemulsion'",
"    </a>",
"    above.) In part to better address the issue of the relative efficacy of these two agents, the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    Mofetil versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    for Prevention of Acute Rejection in Renal Transplantation trial (MYSS) was initiated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/60\">",
"     60",
"    </a>",
"    ]. In this study, 336 patients undergoing a deceased donor renal transplant were randomly assigned to mycophenolate mofetil or azathioprine, with both groups also receiving cyclosporine microemulsion and corticosteroids. Corticosteroids were continued for the first six months (phase A), after which they were slowly withdrawn and patients were followed for another 15 or more months (phase B).",
"   </p>",
"   <p>",
"    The incidence of clinical rejection was the same for both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    in phase A (34 and 35 percent, respectively) and phase B (16 and 12 percent, respectively). In addition, adverse effects, rates of allograft loss, and serum creatinine concentration were the same in both groups. However, mycophenolate was approximately 15 times more expensive than azathioprine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A five-year follow-up of patients in the MYSS trial found that the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    groups had a similar mean GFR (47 versus 49",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2, respectively) and incidence of allograft loss (6.1 and 6.8 percent), late rejection (21.2 versus 25.3 percent), and patient mortality (both 4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/122\">",
"     122",
"    </a>",
"    ]. In addition, the number of adverse events was the same with both agents, while similar outcomes were observed with or without corticosteroid withdrawal. Because the cost of azathioprine was significantly lower than the cost of mycophenolate mofetil, the authors concluded that azathioprine should be preferred over mycophenolate mofetil for maintenance immunosuppression therapy.",
"   </p>",
"   <p>",
"    Although the study was not powered to look at long term survival, the number of patients enrolled was equivalent to the United States Pivotal trial that compared MMF and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    that led to the approval of MMF. In addition, an enrollment of over 3000 patients would be required to have a 20 percent power to show a statistical difference in graft survival between the two agents; this is 10 times the number enrolled in either the MYSS or MMF trial.",
"   </p>",
"   <p>",
"    Nearly all of these studies compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    with MMF when used in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . This may not necessarily be relevant to the combination of MMF plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , which is currently the most common combination of an antimetabolic agent plus a calcineurin inhibitor. The popularity of this combination may be related, in part, to some evidence of a decreased risk of subclinical rejection on protocol biopsies as well as other benefits. (See next section).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Efficacy in combination with tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    has also been successfully utilized as the third agent in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    -based regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/72,104,123-125\">",
"     72,104,123-125",
"    </a>",
"    ]. This was best shown in The Efficacy Limiting Toxicity Elimination (ELITE) Symphony study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/72\">",
"     72",
"    </a>",
"    ]. In this trial, 1645 kidney transplant recipients were randomly assigned to one of four immunosuppressive arms: conventional dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , corticosteroids and mycophenolate mofetil or daclizumab induction therapy, mycophenolate mofetil, and corticosteroids with one of the following three agents: low-dose cyclosporine (target trough level of 50 to 100",
"    <span class=\"nowrap\">",
"     ng/mL),",
"    </span>",
"    low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    (target trough level of 4 to 8",
"    <span class=\"nowrap\">",
"     ng/mL),",
"    </span>",
"    or low-dose tacrolimus (target trough level of 3 to 7",
"    <span class=\"nowrap\">",
"     ng/mL).",
"    </span>",
"   </p>",
"   <p>",
"    At",
"    one year, the low dose",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"      tacrolimus",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"      mycophenolate",
"     </a>",
"    </span>",
"    group had the highest allograft survival rates (94 versus 89 to 93 percent), highest glomerular filtration rates (65 versus 57 to 60",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    and lowest allograft rejection rates (12 versus 24 to 37 percent). Significantly, higher rates of post-transplant diabetes mellitus (PTDM) developed in patients receiving low-dose tacrolimus (8.4 percent) versus those receiving standard-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (6 percent), low-dose cyclosporine (4.2 percent), and low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    (6.6 percent). However, benefits with this regimen may not generalize over the long term, since the study population had few diabetics and black patients, and follow-up was only one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a second randomized trial that had a median follow-up of eight years trial, 150 recipients of either a deceased donor or non-HLA identical living donor first kidney transplant were randomly assigned to receive as maintenance therapy",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"      tacrolimus",
"     </a>",
"     /MMF,",
"    </span>",
"    <span class=\"nowrap\">",
"     tacrolimus/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"      sirolimus",
"     </a>",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"      cyclosporine",
"     </a>",
"     /sirolimus",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/127\">",
"     127",
"    </a>",
"    ]. All patients received daclizumab induction and maintenance glucocorticoids. Tacrolimus was targeted to a trough level of 10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    during the first two months post transplant, 6to 10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    for three to six, and then 4 to 8",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    thereafter; cyclosporine was initially targeted to 200 to 250",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and 100 to 200",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    thereafter. A loading dose of sirolimus was given the evening after surgery and targeted to 6 to 10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and MMF was given 1 g twice daily. The following results were observed at a median of eight years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute rejection occurred less frequently in the",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"        tacrolimus",
"       </a>",
"       /MMF",
"      </span>",
"      group (12 percent) compared with the",
"      <span class=\"nowrap\">",
"       tacrolimus/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"        sirolimus",
"       </a>",
"      </span>",
"      group (30 percent) and",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"        cyclosporine",
"       </a>",
"       /sirolimus",
"      </span>",
"      group (28 percent). (p = 0.9 comparing the three groups; p = 0.03 comparing the",
"      <span class=\"nowrap\">",
"       tacrolimus/sirolimus",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       cyclosporine/sirolimus",
"      </span>",
"      groups combined)",
"     </li>",
"     <li>",
"      The mean estimated GFR was higher in the",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"        tacrolimus",
"       </a>",
"       /MMF",
"      </span>",
"      group versus the combined average GFR of the",
"      <span class=\"nowrap\">",
"       tacrolimus/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"        sirolimus",
"       </a>",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"        cyclosporine",
"       </a>",
"       /sirolimus",
"      </span>",
"      groups at 12, 24, and 84 months.",
"     </li>",
"     <li>",
"      The risk of dying with a functioning graft was higher in the",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"        tacrolimus",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"        sirolimus",
"       </a>",
"      </span>",
"      group compared with the",
"      <span class=\"nowrap\">",
"       tacrolimus/MMF",
"      </span>",
"      group (26 versus 12 percent, respectively) or the",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"        cyclosporine",
"       </a>",
"       /sirolimus",
"      </span>",
"      group (26 versus 4 percent, respectively).",
"     </li>",
"     <li>",
"      There was no difference in graft survival between the groups at eight years.",
"     </li>",
"     <li>",
"      There were more viral infections among those treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      , but no difference in infections requiring hospitalization.",
"     </li>",
"     <li>",
"      The percentage of patients requiring antilipid therapy was higher among those treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      but the incidence of new onset diabetes was not different between groups.",
"     </li>",
"     <li>",
"      There were more protocol violations (defined as the patient stopping one or both maintenance drugs for at least one year or the addition of another maintenance drug) among patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest a long-term overall benefit to maintenance therapy with MMF compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Chronic allograft nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon animal models and some clinical evidence, there is a suggestion that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    may help prevent chronic allograft rejection, a benefit that may be independent of its effect on lowering the incidence of acute rejection. Whether conversion to mycophenolate from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    in patients with chronic graft dysfunction will stabilize or improve renal function has not yet been determined. Routine conversion of stable patients from azathioprine to mycophenolate is not currently recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=see_link\">",
"     \"Chronic renal allograft nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Long-term outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the initial pivotal trials failed to show a survival benefit with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , some investigators postulated that this was due to the relatively small number of enrolled patients. This factor, combined with the observation that mycophenolate may lower the risk of chronic allograft rejection, prompted an analysis of pooled data and large databases to assess the long-term impact of mycophenolate mofetil:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When data from the three pivotal trials previously mentioned were pooled and analyzed, censored graft survival at four years was significantly improved by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (86 versus 82 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/105\">",
"       105",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In a review of 66,744 renal transplant recipients in the United States Renal transplant Scientific Registry, allograft and patient survival were significantly better with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      versus that observed with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/106\">",
"       106",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, these studies have significant limitations, including retrospective design, bias in choice of immunosuppressive agent, and limited information concerning dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/107\">",
"     107",
"    </a>",
"    ]. As previously mentioned, long-term data from the MYSS study reveal that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil are similar in terms of long-term allograft survival rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/122\">",
"     122",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Efficacy versus azathioprine'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Trough levels and CNIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trough levels of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    appear to be lowered by concurrent administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/128-130\">",
"     128-130",
"    </a>",
"    ]. This effect is not observed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . If tacrolimus is substituted for cyclosporine in the patient concurrently taking mycophenolate, we frequently decrease the dose of mycophenolate by 50 percent. Although the use of tacrolimus compared to CyA increases MMF exposure by 20 to 30 percent, we believe that a 50 percent reduction is appropriate since, compared with a 25 percent reduction, it may be associated with fewer gastrointestinal side effects and anemia, and it may also limit the costs of an enhanced pill burden.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Gastrointestinal effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent diarrhea, the most frequent adverse reaction to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    , is the principal reason underlying its discontinuation. A small study found that approximately 40 percent of patients with diarrhea had a Crohn's disease-like enterocolitis, with the remainder suffering from infectious enterocolitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/131\">",
"     131",
"    </a>",
"    ]. The only effective therapy for the Crohn's-like disease was a reduction or discontinuation of mycophenolate, which was associated with an increased risk for rejection. Dose reduction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    withdrawal of mycophenolate mofetil due to gastrointestinal complications may also increase the risk of allograft failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an attempt to improve the upper gastrointestinal tolerability of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    , an enteric coated formulation of mycophenolate sodium (myFortic) has been developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/87,133-136\">",
"     87,133-136",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 423 patients, enteric-coated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      sodium at a dose of 720 mg BID was therapeutically equivalent to MMF at 1000 mg BID, with similar safety characteristics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/133\">",
"       133",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In another one year study of stable renal transplant patients, conversion from MMF to myFortic could be safely performed, as safety and efficacy measures were similar between the two groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/134\">",
"       134",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, there were no significant differences in gastrointestinal side effects between the two agents in these studies.",
"   </p>",
"   <p>",
"    Marked symptomatic benefits with the enteric formulation were first reported in a multicenter prospective study in which patients with significant gastrointestinal complaints with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil were converted to enteric-coated mycophenolate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/137\">",
"     137",
"    </a>",
"    ]. Switching significantly lowered gastrointestinal symptoms improved overall patient well-being. Similar findings have been observed in other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who will be on a proton pump inhibitor, we prefer to use enteric coated mycophenolic acid (myFortic) initially.",
"   </p>",
"   <p>",
"    In the patient with marked gastrointestinal side effects with MMF, we first switch to myFortic from MMF at a molecularly equivalent dose. If that is ineffective, we lower the dose further or consider switching to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Target levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the future, the measurement and monitoring of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/54/35685?source=see_link\">",
"     thioguanine",
"    </a>",
"    concentrations may permit better immunosuppressive management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/139-144\">",
"     139-144",
"    </a>",
"    ]. We do not obtain these tests now since they are not routinely available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15127996\">",
"    <span class=\"h3\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have reported decreased serum concentrations and mycophenolic acid (MPA) exposure associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (CellCept), but not mycophenolic acid (MyFortic) among patients who were concurrently receiving proton pump inhibitors such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/145-149\">",
"     145-149",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This issue was examined in a subset analysis of a study that compared the area under the curve (ie, exposure) of MPA among 135 patients who received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil dosed at either 1.5 g twice daily for five days followed by 1g twice daily, or 1g twice daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/150\">",
"     150",
"    </a>",
"    ]. Fifty-eight percent of patients were concurrently taking a proton pump inhibitor. Although there was a decrease in MPA concentration at 2 and 12 hours postdose in patients who were taking a proton pump inhibitor compared to those who were not, there were no significant differences demonstrated in the overall MPA area under the curve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/150\">",
"     150",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448644239\">",
"    <span class=\"h1\">",
"     CORTICOSTEROIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, we administer a maintenance regimen consisting of triple immunosuppression therapy. This includes",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , an anti-metabolite (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    ), and a calcineurin inhibitor (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There is no consensus on the optimal dose or maintenance schedule of steroids following renal transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/151\">",
"     151",
"    </a>",
"    ]. As part of a triple agent immunosuppressive regimen, we currently administer oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at a dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for the first three days post-transplant, which is then lowered to 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for the first week. The daily dose is then tapered every week by 5 mg, resulting in: 15",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for one week; 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for one week and then 5",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    In the absence of acute rejection, we generally reduce steroids to a dose of 5 mg per day by one month following kidney transplantation.",
"   </p>",
"   <p>",
"    In an attempt to minimize toxicity and to decrease overall immunosuppression, slow tapering and ultimate withdrawal of steroids has also been attempted. We do",
"    <strong>",
"     NOT",
"    </strong>",
"    routinely discontinue or switch to alternate-day steroids unless the patient is having problems with side effects (including worsening glucose control, or hypercholesterolemia, difficulties in blood pressure control, or severe irritability or rage disorder) and has had stable renal allograft function with no episodes of acute rejection within the preceding 6 to 12 months. However, switching to alternate-day steroids does not necessarily reduce side effects associated with corticosteroids. A reduction in the daily corticosteroid dose to 2.5 mg daily may be attempted among otherwise stable patients who have adverse side effects attributed in part to corticosteroids.",
"   </p>",
"   <p>",
"    Withdrawal of steroids compared to continuance of 5 mg per day of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is not associated with improvement in insulin sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/152\">",
"     152",
"    </a>",
"    ]. The removal of steroids may magnify the myelosuppressive action of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , mycophenolic mofetil or mycophenolic acid, and the white count must therefore be monitored carefully.",
"   </p>",
"   <p>",
"    Steroid avoidance is also associated with increased risks of recurrent glomerulonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/153\">",
"     153",
"    </a>",
"    ]. In one large retrospective study, rapid steroid withdrawal was associated with a higher risk of recurrent glomerulonephritis compared to continued steroids (hazard ratio 4.86, 95% CI 2.34-10.07). This study showed no difference between groups in patient, graft or death-censored graft survival, suggesting no benefit and possible harm from steroid avoidance in patients with a history of glomerulonephritis.",
"   </p>",
"   <p>",
"    Corticosteroid withdrawal or avoidance in renal transplantation is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/4/21577?source=see_link\">",
"     \"Withdrawal or avoidance of glucocorticoids after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     MAMMALIAN TARGET OF RAPAMYCIN INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    , the first mammalian target of rapamycin (mTOR) inhibitor approved by the FDA, is a macrolide antibiotic produced by the fungus, Streptomyces hygroscopicus.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     Everolimus",
"    </a>",
"    is the major metabolite of sirolimus. Everolimus has also been approved by the FDA and has a similar efficacy and safety profile as sirolimus. The efficacy of sirolimus for primary maintenance immunosuppressive therapy in kidney transplant recipients is well documented. However, early posttransplantation complications of sirolimus, particularly delayed allograft function, poor wound healing, and an increased incidence of lymphoceles, have limited the de novo use of sirolimus at some centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/154\">",
"     154",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accurate analysis of the benefits and adverse effects associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    is complicated by the myriad possible combinations of immunosuppressive agents, different patient groups enrolled, and difficulty in fully isolating the effects of sirolimus alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/155-168\">",
"     155-168",
"    </a>",
"    ]. As above, another mTOR inhibitor,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    , the major metabolite of sirolimus, has also been developed.",
"   </p>",
"   <p>",
"    A systematic review of the mammalian target of rapamycin (mTOR) inhibitors (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    ) for initial maintenance immunotherapy in kidney transplantation evaluated 27 and 5 trials that included sirolimus or everolimus, respectively, with one head-to-head trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/155\">",
"     155",
"    </a>",
"    ]. The principal finding was",
"    <strong>",
"     no",
"    </strong>",
"    significant difference in allograft or patient survival with any comparison.",
"   </p>",
"   <p>",
"    The following additional findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When substituted for calcineurin inhibitors, the mTOR inhibitors were associated with a significantly lower serum creatinine concentration and no difference in acute rejection rates, but with increased bone marrow suppression.",
"     </li>",
"     <li>",
"      When substituted for antimetabolic agents, the mTOR inhibitors significantly decreased rates of acute rejection and cytomegalovirus infection. However, hypercholesterolemia was increased.",
"     </li>",
"     <li>",
"      Compared to high dose rapamycin inhibitor plus standard dose calcineurin inhibitors, low dose rapamycin inhibitor plus standard dose calcineurin inhibitors had significantly higher acute rejection and glomerular filtration rates.",
"     </li>",
"     <li>",
"      Compared to high dose rapamycin inhibitor plus reduced dose calcineurin inhibitors, low dose rapamycin inhibitor plus standard dose calcineurin inhibitors resulted in significantly lower acute rejection and glomerular filtration rates.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A limitation of this systematic review is that follow-up was limited to two years. A randomized control trial that was published after this systematic review and had a median follow-up of eight years suggested a benefit associated with MMF and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and either tacrolimus or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/127\">",
"     127",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Efficacy in combination with tacrolimus'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Several retrospective studies of large databases have found that long-term allograft survival was inferior with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/166,167,169\">",
"     166,167,169",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an analysis of over 23,000 allograft recipients, four year allograft loss was significantly higher in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      plus Neoral versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      plus Neoral treated patients (hazard ratio of 1.22) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/166\">",
"       166",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of 44,915 kidney transplant recipients reported that the hazard ratio for overall allograft loss was 1.47 (95% CI 1.32-1.63) with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil plus tacrolimus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/167\">",
"       167",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third study of 58,131 patients found that, among deceased donor recipients, allograft survival with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil was significantly lower at five years than with other immunosuppressive regimens (57 percent versus 68 to 74 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/169\">",
"       169",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the PRECAUTIONS section of the package insert has a statement regarding the safety and efficacy of de novo use of rapamycin without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . This was based upon interim results of a clinical trial of de novo renal transplant recipients that showed a much higher biopsy-confirmed acute rejection rate for those who, after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"     basiliximab",
"    </a>",
"    induction, received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    , MMF, and steroids compared to patients who received cyclosporine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and steroids (17.5 and 2.5 percent, respectively). The reported death rates were also higher (6 and 2.9 percent, respectively). The trial has since been terminated.",
"   </p>",
"   <p>",
"    It is possible that initiating maintenance immunosuppressive therapy with a calcineurin inhibitor and then switching to an mTOR inhibitor after a few months may provide adequate immunosuppression but minimize the nephrotoxicity associated with calcineurin inhibitors. This was tested in three randomized trials including the ZEUS multicenter open label trial, the Spare-the-Nephron trial, and the ORION Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/170-172\">",
"     170-172",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the ZEUS trial,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    was compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    among 300 kidney transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/170\">",
"     170",
"    </a>",
"    ]. Following induction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"     basiliximab",
"    </a>",
"    and 4.5 months of maintenance therapy with cyclosporine, MMF and corticosteroids, patients were assigned to receive MMF, corticosteroids and either everolimus (dosed to trough levels of 6 to 10",
"    <span class=\"nowrap\">",
"     ng/ml)",
"    </span>",
"    or cyclosporine. At 12 months, the everolimus regimen was associated with a higher GFR compared with cyclosporine (71.8 versus 61.9 ml per 1.73m2, respectively) with a mean difference of 9.8",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2.",
"    <br/>",
"    <br/>",
"    However, although the total number of acute rejections was the same between groups at 12 months, the incidence of rejection was higher in the cyclosporine group before randomization, and despite this bias against cyclosporine, the incidence of acute rejection was significantly higher in the everolimus group after randomization (15 versus 3 percent).",
"    <br/>",
"    <br/>",
"    Compared with cyclosporine, everolimus was associated with higher mean lipid concentrations, increased urinary protein excretion, and lower hemoglobin concentrations. Other side effects that were higher in the everolimus group included aphthous stomatitis, diarrhea, herpes infection, thrombocytopenia and back pain, whereas hyperuricemia was more common in the cyclosporine group.",
"   </p>",
"   <p>",
"    The multicenter Spare-the-Nephron trial included 299 low-risk patients assigned to either continue a center-specific calcineurin inhibitor or be started on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    between 30-180 days after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/171\">",
"     171",
"    </a>",
"    ]. All patients continued to receive MMF (1 to 1.5 g twice daily) and corticosteroids dosed according to center. Sirolimus was adjusted to trough levels of 5 to 10",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    By intention-to-treat analysis, the sirolimus group had a greater improvement in iothalamate-measured GFR than the calcineurin group at 12 months (24.4 versus 5.2 percent). At 24 months there was a trend toward greater improvement in GFR in the sirolimus group that was not statistically significant (8.6 versus 3.4 percent).",
"    <br/>",
"    <br/>",
"    There was no difference in the rate of acute rejection reported at 12 months; there was a nonsignificant trend toward a lower rate of rejection after 12 months in the sirolimus group (2.9 versus 8 percent, p = 0.07). The rate of adverse events was the same between groups.",
"   </p>",
"   <p>",
"    These data together with the results from the Zeus trial suggest GFR may be better maintained in low-risk patients who are switched to an MTOR inhibitor.",
"   </p>",
"   <p>",
"    However in the ORION study there was no benefit associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    -based regimens in which calcineurin inhibitors were withdrawn or avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/172\">",
"     172",
"    </a>",
"    ]. ORION was an open-label randomized multicenter trial in which 469 renal allograft recipients were assigned to receive one of the following: sirolimus plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    for 13 weeks followed by withdrawal of tacrolimus (group 1); sirolimus plus MMF (group 2); and tacrolimus plus MMF (group 3). All patients received glucocorticoids and induction with daclizumab. There was no difference between groups in the GFR or patient or graft survival at one and two years.",
"    <br/>",
"    <br/>",
"    The rate of biopsy-confirmed acute rejection was higher in the group that did not receive any tacrolimus. The high rate of acute rejection, most which occurred during the first six months, resulted in sponsor-termination of group 2, which limits interpretation of study outcomes at two years. The rate of drug discontinuation due to adverse effects was higher in the sirolimus groups.",
"   </p>",
"   <p>",
"    Switching from calcineurin inhibitors to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    may have an antitumor effect among transplant recipients who have had squamous-cell carcinoma. This was suggested by a randomized multicenter trial that included 120 patients who were taking calcineurin inhibitors and had at least one squamous-cell carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/173\">",
"     173",
"    </a>",
"    ]. Survival free of squamous cell recurrence was longer among patients who were switched from calcineurin inhibitors to sirolimus (target trough concentration of 6 to 12",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    compared with those who continued calcineurin inhibitors (16 versus 7 months, respectively). However, the occurrence of serious side effects was much more common in the sirolimus group (60 versus 14), and 23 percent of patients discontinued sirolimus because of side effects. Side effects tended to be more common among patients who underwent rapid conversion to sirolimus (ie, within seven days) compared with those who had a more gradual conversion, and included edema, proteinuria, aphthous ulcers, diarrhea, pneumonitis, dyspnea and fever, among others.",
"   </p>",
"   <p>",
"    The long-term impact of calcineurin-sparing regimens has not been evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/174\">",
"     174",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, we use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    as part of a maintenance immunosuppressive regimen in the following patient subsets in whom this agent may have particular utility:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who have histologically-proven calcineurin inhibitor toxicity despite low levels and doses of the calcineurin inhibitor. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=see_link\">",
"       \"Chronic renal allograft nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with malignancy (eg, skin cancers and Kaposi's sarcoma), either in remission or being actively treated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34170?source=see_link\">",
"       \"Development of malignancy following solid organ transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      After treatment of B cell post-transplantation lymphoproliferative disease (PTLD). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=see_link\">",
"       \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A detailed discussion of the adverse effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    in renal transplantation is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/9/17562?source=see_link\">",
"     \"Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448640914\">",
"    <span class=\"h1\">",
"     BELATACEPT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the numerous costimulatory pathways for T cell activation identified thus far, that provided by the interaction of CD28 on the T cell surface with its antigen presenting cell surface ligands, B7-1 or B7-2 (CD80 and CD86, respectively), has been most studied. T cell anergy and apoptosis induced by T cell receptor signaling alone is prevented by signaling through CD28.",
"   </p>",
"   <p>",
"    Multiple studies have evaluated the effectiveness of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/41/43669?source=see_link\">",
"     belatacept",
"    </a>",
"    , a fusion protein consisting of a mutated, high affinity receptor for B7-1 and B7-2 and a portion of an immunoglobulin molecule, LEA29Y (belatacept) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/175-178\">",
"     175-178",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 218 low risk patients undergoing renal transplantation received induction therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"       basiliximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, and corticosteroids and were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or high or low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/41/43669?source=see_link\">",
"       belatacept",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/179\">",
"       179",
"      </a>",
"      ]. At six months, the adjudicated acute rejection rate was similar in all three groups when acute rejection was defined as histologic evidence of acute rejection with at least a 0.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      increase above the baseline serum creatinine. However, the incidence of investigator treated rejection was 26 and 29 percent in the intensive and less-intensive Belatacept-treated patients, respectively and only 16 percent among the cyclosporine-treated patients. At 12 months, the glomerular filtration rate was significantly higher with both intensive and less-intensive belatacept than it was with cyclosporine, and chronic allograft nephropathy was less common with both regimens of belatacept than with cyclosporine (29, 20, and 44 percent, respectively). The incidence of post-transplantation lymphoproliferative disease (PTLD) was 6 percent in the high dose belatacept group and 0 percent in the low dose belatacept and cyclosporine groups. Importantly, target trough cyclosporine levels beyond 2 months were extremely high (150 to 300",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      and emphasizes the nephrotoxicity and contribution of relatively high-dose cyclosporine to the development of chronic allograft nephropathy (CAN).",
"      <br/>",
"      <br/>",
"      Extension of this study for an additional four years found that the GFR remained stable with belatacept [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/176\">",
"       176",
"      </a>",
"      ]. PTLD was noted in one patient treated with cyclosporine, but no one administered belatacept. Serious gastrointestinal disorders were more frequent with belatacept (12 versus 8 percent).",
"     </li>",
"     <li>",
"      In a phase III trial, the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/41/43669?source=see_link\">",
"       Belatacept",
"      </a>",
"      Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (or BENEFIT trial) assessed a more intensive (MI) or less intensive (LI) regimen of belatacept versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (trough levels 100 to 250",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      after one month) in adults receiving a kidney transplant from living or standard criteria deceased donors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/177\">",
"       177",
"      </a>",
"      ]. Belatacept patients experienced a higher incidence and grade of acute rejection episodes (22 percent versus 17 percent versus 7 percent in the MI, LI, and cyclosporine arms). The acute rejections tended to be of a higher Banff severity with more Banff 1B or higher rejections. GFRs were better with belatacept (65 versus 63 versus 50",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      respectively). Overall patient safety parameters were similar between groups, but posttransplant lymphoproliferative disorder was more common with belatacept (five patients with belatacept versus one patient with cyclosporine). Of the five patients who were receiving belatacept and developed PTLD, two had central nervous system PTLD, which was lethal.",
"      <br/>",
"      <br/>",
"      Thus, belatacept was associated with superior renal function and similar",
"      <span class=\"nowrap\">",
"       patient/graft",
"      </span>",
"      survival versus relatively high dose cyclosporine at one year posttransplant, despite a higher rate of early acute rejection. This emphasizes the contribution of relatively high-dose cyclosporine to CAN.",
"     </li>",
"     <li>",
"      A second phase III trial utilized a similar design as the previously described study in expanded criteria donor kidney transplant recipients (BENEFIT-EXT) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/178\">",
"       178",
"      </a>",
"      ]. Patient and graft survival with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/41/43669?source=see_link\">",
"       belatacept",
"      </a>",
"      was similar to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , but fewer belatacept patients reached the composite renal impairment endpoint versus cyclosporine. The mean measured glomerular filtration rate was 4 to 7",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      higher on belatacept (52 versus 50 versus 45",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      and the incidence of acute rejection was similar across, although the severity of rejection tended to be higher with belatacept with Banff II B rejections occurring in nine versus five versus three patients, respectively. The overall rates of infection and malignancy were similar between groups. Similar to the BENEFIT study, more cases of posttransplant lymphoproliferative disorder (PTLD) occurred on belatacept. Five patients in the belatacept arm versus zero patients in the cyclosporine arm experienced PTLD and four of five in the belatacept arm suffered PTLD of the central nervous system that was lethal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29173170\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detail concerning drug interactions of maintenance immunosuppressants, and suggestions for their management, are described in the table (",
"    <a class=\"graphic graphic_table graphicRef81998 \" href=\"mobipreview.htm?14/44/15042\">",
"     table 1",
"    </a>",
"    ). Additional information is available in the Lexi-Interact&trade; drug interactions program provided by UpToDate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22826520\">",
"    <span class=\"h1\">",
"     ADJUSTING IMMUNOSUPPRESSION IN INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The protocol for adjusting the immunosuppressive regimen among patients with infection varies among institutions but generally depends upon the severity of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/43/43706/abstract/180-182\">",
"     180-182",
"    </a>",
"    ]. We generally do not modify the maintenance immunosuppression regimen among otherwise stable patients who develop community-acquired infections (such as bronchitis, pneumonia, cystitis, cellulitis, etc). All clinicians would withhold all immunosuppressive agents except low dose corticosteroids among patients with life-threatening infections or evidence of sepsis. Among patients with moderate infection (ie, require admission and intravenous antibiotics but not septic), some clinicians withhold one agent (typically the antimetabolite such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ). Others do not alter the immunosuppressive regimen among patients with moderately severe bacterial infection but decrease the corticosteroid dose among patients with moderately severe fungal infections.",
"   </p>",
"   <p>",
"    The adjustment of immunosuppression among patients with CMV or BK viruses is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29738?source=see_link&amp;anchor=H34#H34\">",
"     \"Cytomegalovirus infection in renal transplant recipients\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Our recommendations concerning induction immunosuppressive therapy in renal transplantation are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32649?source=see_link\">",
"       \"Induction immunosuppressive therapy in renal transplantation in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Maintenance immunosuppressive therapy is administered to renal transplant recipients to prevent acute rejection and the loss of the renal allograft. Although an adequate level of immunosuppression is required to dampen the immune response to the allograft, the level of chronic immunosuppression is slowly decreased over time to help lower the overall risk of infection and malignancy; these risks directly correlate with the degree of overall immunosuppression.",
"     </li>",
"     <li>",
"      The major immunosuppressive agents that are currently being used in various combination regimens are corticosteroids (primarily oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil (MMF), mycophenolate sodium (myFortic),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (in standard form or microemulsion),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      , and rapamycin (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       Sirolimus",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific issues related to each of these agents include efficacy and side effects. Given that each agent is almost invariably administered in combination with other agents, efficacy of a particular drug is best discussed related to its role as part of a specific combination of immunosuppressive agents. These issues are discussed in multiple sections. These include corticosteroids (see",
"      <a class=\"local\" href=\"#H448644239\">",
"       'Corticosteroids'",
"      </a>",
"      above), antimetabolic agents (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, and mycophenolate sodium) (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Antimetabolic agents'",
"      </a>",
"      above), calcineurin inhibitors (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H448642464\">",
"       'Calcineurin inhibitors'",
"      </a>",
"      above), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      &nbsp;(see",
"      <a class=\"local\" href=\"#H28\">",
"       'Mammalian target of rapamycin inhibitors'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      A large number of combinations of immunosuppressive agents have been evaluated in randomized controlled trials. These include triple immunosuppressive therapy (calcineurin inhibitor, anti-metabolite, and corticosteroids), double immunosuppressive therapy with different combinations, and single agent therapy, generally with a calcineurin inhibitor. Important issues to consider when deciding upon the immunosuppressive protocol to administer in a particular patient include time post-transplantation, patient-specific factors, and the immunologic history of the patient. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview of maintenance immunosuppressive regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the administration of maintenance immunosuppressive therapy to kidney allograft recipients (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The optimal immunosuppressive regimen is unclear.",
"     </li>",
"     <li>",
"      Other than recipients of HLA two-haplotype allografts and HLA identical allografts from a monozygotic twin, we suggest the administration of a maintenance regimen consisting of triple immunosuppression therapy with a calcineurin inhibitor, an anti-metabolite, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We aim for the following regimen and doses:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We administer oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at a dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for the first three days post-transplant, which is then lowered to 20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for the first week. The daily dose is then tapered every week by 5 mg, resulting in: 15",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for one week; 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for one week and then 5",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      In the absence of acute rejection, we generally reduce steroids to a dose of 5 mg per day by one month following kidney transplantation.",
"     </li>",
"     <li>",
"      Among the available antimetabolic agents, we suggest the administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      in most patients rather than MMF (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We administer azathioprine at 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, which is adjusted for leukopenia. We use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil in those we consider to be at higher immunologic risk for rejection or disease recurrence and in patients with gout who require the continuation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      An acceptable alternative strategy, which is most commonly used, is the administration of MMF as the anti-metabolic agent for most patients. With this strategy, azathioprine is used in men planning on becoming fathers and in women of child bearing age, as mycophenolate is teratogenic. Mycophenolate is contraindicated in pregnancy.",
"      <br/>",
"      <br/>",
"      We initiate MMF at a dose of 1000 mg two times per day during the first hospital admission. Patients are discharged to home at doses ranging from 500 mg two times per day (particularly with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ) to 1000 mg two times per day (if the patient is receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or is perceived to be at high risk for rejection).",
"      <br/>",
"      <br/>",
"      In patients who will be on a proton pump inhibitor, we prefer to initially use enteric coated mycophenolic acid (myFortic) at a molecularly equivalent dose. The MMF dose of 500 mg two times per day is equivalent to myFortic 360 mg two times per day. In patients who develop marked gastrointestinal side effects with MMF, we switch to myFortic. If this switch is ineffective, we lower the dose further or consider switching to azathioprine.",
"     </li>",
"     <li>",
"      Among the available calcineurin inhibitors, we suggest the administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This is because rejection rates are lower, and GFR tends to be higher than with cyclosporine. We administer tacrolimus at doses ranging from 1 to 4 mg twice per day, with doses adjusted to attain target whole-blood trough concentrations of 7 to 10",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      for the first three months, and 3 to 7",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      after this period.",
"      <br/>",
"      <br/>",
"      If cyclosporine is administered, we prefer cyclosporine microemulsion, which is administered at 3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day. If monitoring of plasma or whole blood cyclosporine trough levels is used, doses of cyclosporine are adjusted to maintain 12 hour trough levels of 200 to 300",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      for the first three months post-transplant; after this period, we subsequently taper doses to maintain trough levels between 50 to 150",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"      When C2 monitoring is used, we use C2 target levels of 800 to 1000",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      in months one to three after transplantation and C2 targets of 400 to 600",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      for subsequent months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with recurrent acute rejection episodes who are being administered triple immunosuppressive therapy, alternate combinations can be tried. We avoid the use of the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      plus a calcineurin inhibitor (either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ) because both calcineurin inhibitors are synergistically nephrotoxic when used with sirolimus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/9/17562?source=see_link\">",
"       \"Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among recipients of HLA two-haplotype allografts, we administer",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      plus an antimetabolic agent OR prednisone plus a calcineurin inhibitor.",
"     </li>",
"     <li>",
"      Among recipients of HLA identical allografts from a monozygotic twin, we administer",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      at 50",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at 5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for three months only. After the third month, they are maintained without immunosuppressive medication.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/1\">",
"      Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 1999; 353:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/2\">",
"      Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351:2715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/3\">",
"      Wong W, Venetz JP, Tolkoff-Rubin N, Pascual M. 2005 immunosuppressive strategies in kidney transplantation: which role for the calcineurin inhibitors? Transplantation 2005; 80:289.",
"     </a>",
"    </li>",
"    <li>",
"     file://srtr.transplant.hrsa.gov/annual_reports/2011/ (Accessed on March 15, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/5\">",
"      Carpenter CB. Immunosuppression in organ transplantation. N Engl J Med 1990; 322:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/6\">",
"      Helderman JH, Van Buren DH, Amend WJ Jr, Pirsch JD. Chronic immunosuppression of the renal transplant patient. J Am Soc Nephrol 1994; 4:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/7\">",
"      A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at three years. The Canadian Multicentre Transplant Study Group. N Engl J Med 1986; 314:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/8\">",
"      Ponticelli C, Minetti L, Di Palo FQ, et al. The Milan clinical trial with cyclosporine in cadaveric renal transplantation. A three-year follow-up. Transplantation 1988; 45:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/9\">",
"      Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/10\">",
"      Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011; 11:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/11\">",
"      Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 Suppl 3:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/12\">",
"      Aydingoz SE, Takemoto SK, Pinsky BW, et al. The impact of human leukocyte antigen matching on transplant complications and immunosuppression dosage. Hum Immunol 2007; 68:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/13\">",
"      Ojo AO, Port FK, Held PJ, et al. Inferior outcome of two-haplotype matched renal transplants in blacks: role of early rejection. Kidney Int 1995; 48:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/14\">",
"      Murray JE, Merrill JP, Harrison JH. Renal homotransplantation in identical twins. 1955. J Am Soc Nephrol 2001; 12:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/15\">",
"      Weil R 3rd, Starzl TE, Porter KA, et al. Renal isotransplantation without immunosuppression. Ann Surg 1980; 192:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/16\">",
"      Gumprich M, Woeste G, Kohlhaw K, et al. Living related kidney transplantation between identical twins. Transplant Proc 2002; 34:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/17\">",
"      Krishnan N, Buchanan PM, Dzebisashvili N, et al. Monozygotic transplantation: concerns and opportunities. Am J Transplant 2008; 8:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/18\">",
"      Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/19\">",
"      Remuzzi G. Cellular basis of long-term organ transplant acceptance: pivotal role of intrathymic clonal deletion and thymic dependence of bone marrow microchimerism-associated tolerance. Am J Kidney Dis 1998; 31:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/20\">",
"      Reyes J, Zeevi A, Ramos H, et al. Frequent achievement of a drug-free state after orthotopic liver transplantation. Transplant Proc 1993; 25:3315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/21\">",
"      Starzl TE, Demetris AJ, Murase N, et al. The lost chord: microchimerism and allograft survival. Immunol Today 1996; 17:577.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.ustransplant.org (Accessed on January 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/23\">",
"      Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/24\">",
"      Woodward RS, Kutinova A, Schnitzler MA, Brennan DC. Renal graft survival and calcineurin inhibitor. Transplantation 2005; 80:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/25\">",
"      Hardinger KL, Bohl DL, Schnitzler MA, et al. A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients. Transplantation 2005; 80:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/26\">",
"      Isoniemi, HL, Ahonen, J, Tikkanen, MJ, et al. Long term consequences of different immunosuppressive regimens for renal transplantation. Transplantation 1993; 55:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/27\">",
"      Opelz G, D&ouml;hler B. Cyclosporine and long-term kidney graft survival. Transplantation 2001; 72:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/28\">",
"      Pascual M, Curtis J, Delmonico FL, et al. A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation 2003; 75:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/29\">",
"      Tarantino A, Passerini P, Campise M, et al. Is cyclosporine in renal-transplant recipients more effective when given twice a day than in a single daily dose? Transplantation 2004; 78:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/30\">",
"      Delmonico FL, Conti D, Auchincloss H Jr, et al. Long-term, low-dose cyclosporine treatment of renal allograft recipients. A randomized trial. Transplantation 1990; 49:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/31\">",
"      Dunn J, Golden D, Van Buren CT, et al. Causes of graft loss beyond two years in the cyclosporine era. Transplantation 1990; 49:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/32\">",
"      Sanders CE, Curtis JJ, Julian BA, et al. Tapering or discontinuing cyclosporine for financial reasons--a single-center experience. Am J Kidney Dis 1993; 21:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/33\">",
"      Kasiske BL, Heim-Duthoy K, Ma JZ. Elective cyclosporine withdrawal after renal transplantation. A meta-analysis. JAMA 1993; 269:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/34\">",
"      Heim-Duthoy KL, Chitwood KK, Tortorice KL, et al. Elective cyclosporine withdrawal 1 year after renal transplantation. Am J Kidney Dis 1994; 24:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/35\">",
"      Jha V, Muthukumar T, Kohli HS, et al. Impact of cyclosporine withdrawal on living related renal transplants: a single-center experience. Am J Kidney Dis 2001; 37:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/36\">",
"      Abramowicz D, Manas D, Lao M, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation 2002; 74:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/37\">",
"      Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/38\">",
"      Mulay AV, Hussain N, Fergusson D, Knoll GA. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 2005; 5:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/39\">",
"      Carbajal H, Soltero L, Rodr&iacute;guez-Montalvo C, Vald&eacute;s A. Cyclosporine and low-dose ketoconazole in renal transplant recipients: a single-center experience. Transplantation 2004; 77:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/40\">",
"      el-Agroudy AE, Sobh MA, Hamdy AF, Ghoneim MA. A prospective, randomized study of coadministration of ketoconazole and cyclosporine a in kidney transplant recipients: ten-year follow-up. Transplantation 2004; 77:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/41\">",
"      First MR, Schroeder TJ, Michael A, et al. Cyclosporine-ketoconazole interaction. Long-term follow-up and preliminary results of a randomized trial. Transplantation 1993; 55:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/42\">",
"      Karlix JL, Cheng MA, Brunson ME, et al. Decreased cyclosporine concentrations with the addition of an H2-receptor antagonist in a patient on ketoconazole. Transplantation 1993; 56:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/43\">",
"      Mueller EA, Kovarik JM, van Bree JB, et al. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients--a concentration-controlled comparison with the commercial formulation. Transplantation 1994; 57:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/44\">",
"      Kovarik JM, Mueller EA, van Bree JB, et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation--a multicenter investigation in kidney transplant patients. Transplantation 1994; 58:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/45\">",
"      Bergan S, Rugstad HE, Bentdal O, et al. Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation. Transplantation 1998; 66:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/46\">",
"      Kovarik JM, Mueller EA, van Bree JB, et al. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994; 83:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/47\">",
"      Holt DW, Mueller EA, Kovarik JM, et al. The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclosporine. Transplant Proc 1994; 26:2935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/48\">",
"      Mueller EA, Kovarik JM, van Bree JB, et al. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 1994; 11:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/49\">",
"      Wahlberg J, Wilczek HE, Fauchald P, et al. Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period. Transplantation 1995; 60:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/50\">",
"      Kovarik JM, Mueller EA, Richard F, et al. Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation. Transplantation 1996; 62:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/51\">",
"      Mueller EA, Kovarik JM, van Bree JB, et al. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm Res 1994; 11:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/52\">",
"      Ettenger RE, Smith HT, Kaiser B, et al. Use of Neoral in pediatric renal transplantation. Transplant Proc 1996; 28:2257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/53\">",
"      Kahan BD, Dunn J, Fitts C, et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 1995; 59:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/54\">",
"      Pescovitz MD, Barone G, Choc MG Jr, et al. Safety and tolerability of cyclosporine microemulsion versus cyclosporine: two-year data in primary renal allograft recipients: a report of the Neoral Study Group. Transplantation 1997; 63:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/55\">",
"      Frei UA, Neumayer HH, Buchholz B, et al. Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group. Transplantation 1998; 65:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/56\">",
"      Brennan DC, Barbeito R, Burke J, et al. Safety of Neoral conversion in maintenance renal transplant patients: A one-year, double-blind study. NOVARTIS OLN-353 Study Group. Kidney Int 1999; 56:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/57\">",
"      Keown P, Landsberg D, Halloran P, et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation 1996; 62:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/58\">",
"      Noble S, Markham A. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Drugs 1995; 50:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/59\">",
"      Curtis JJ, Lynn M, Jones PA. Neoral conversion from Sandimmune in maintenance renal transplant patients: an individualized approach. J Am Soc Nephrol 1998; 9:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/60\">",
"      Remuzzi G, Lesti M, Gotti E, et al. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet 2004; 364:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/61\">",
"      Roza A, Tomlanovich S, Merion R, et al. Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation. Transplantation 2002; 74:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/62\">",
"      Taber DJ, Baillie GM, Ashcraft EE, et al. Does bioequivalence between modified cyclosporine formulations translate into equal outcomes? Transplantation 2005; 80:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/63\">",
"      Vella JP, Sayegh MH. Maintenance pharmacological immunosuppressive strategies in renal transplantation. Postgrad Med J 1997; 73:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/64\">",
"      Venkataramanan R, Jain A, Warty VW, et al. Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. Transplant Proc 1991; 23:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/65\">",
"      Steiner RW, Feist AA. The \"generic\" effect of food on tacrolimus pharmacokinetics. Clin Transplant 2011; 25:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/66\">",
"      Hardinger KL, Park JM, Schnitzler MA, et al. Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. Am J Transplant 2004; 4:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/67\">",
"      Silva HT Jr, Yang HC, Abouljoud M, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007; 7:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/68\">",
"      Sonoda T, Takahara S, Takahashi K, et al. Outcome of 3 years of immunosuppression with tacrolimus in more than 1,000 renal transplant recipients in japan. Transplantation 2003; 75:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/69\">",
"      Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/70\">",
"      Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/71\">",
"      Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ 1999; 318:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/72\">",
"      Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357:2562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/73\">",
"      Irish W, Sherrill B, Brennan DC, et al. Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen. Transplantation 2003; 76:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/74\">",
"      Margreiter R, European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/75\">",
"      Johnson C, Ahsan N, Gonwa T, et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/76\">",
"      Ahsan N, Johnson C, Gonwa T, et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. Transplantation 2001; 72:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/77\">",
"      Gonwa T, Johnson C, Ahsan N, et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 2003; 75:2048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/78\">",
"      Kr&auml;mer BK, Montagnino G, Del Castillo D, et al. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. Nephrol Dial Transplant 2005; 20:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/79\">",
"      Bunnapradist S, Daswani A, Takemoto SK. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids. Transplantation 2003; 76:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/80\">",
"      Goldfarb-Rumyantzev AS, Smith L, Shihab FS, et al. Role of maintenance immunosuppressive regimen in kidney transplant outcome. Clin J Am Soc Nephrol 2006; 1:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/81\">",
"      Atkison P, Joubert G, Barron A, et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 1995; 345:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/82\">",
"      Jarzembowski TM, John E, Panaro F, et al. Reversal of tacrolimus-related hypertrophic obstructive cardiomyopathy 5 years after kidney transplant in a 6-year-old recipient. Pediatr Transplant 2005; 9:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/83\">",
"      Binet I, Nickeleit V, Hirsch HH, et al. Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Transplantation 1999; 67:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/84\">",
"      De Rycke A, Dierickx D, Kuypers DR. Tacrolimus-induced neutropenia in renal transplant recipients. Clin J Am Soc Nephrol 2011; 6:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/85\">",
"      Higgins RM, Hart P, Lam FT, Kashi H. Conversion from tacrolimus to cyclosporine in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison. Transplantation 2000; 69:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/86\">",
"      Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol 2007; 2:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/87\">",
"      Johnston A, He X, Holt DW. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. Transplantation 2006; 82:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/88\">",
"      Knight SR, Morris PJ. The clinical benefits of cyclosporine C2-level monitoring: a systematic review. Transplantation 2007; 83:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/89\">",
"      Levy G, Thervet E, Lake J, et al. Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation 2002; 73:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/90\">",
"      Thervet E, Pfeffer P, Scolari MP, et al. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation 2003; 76:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/91\">",
"      Cole E, Maham N, Cardella C, et al. Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients. Transplantation 2003; 75:2086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/92\">",
"      Cole E, Midtvedt K, Johnston A, et al. Recommendations for the implementation of Neoral C(2) monitoring in clinical practice. Transplantation 2002; 73:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/93\">",
"      Citterio F, Scat&agrave; MC, Romagnoli J, et al. Results of a three-year prospective study of C2 monitoring in long-term renal transplant recipients receiving cyclosporine microemulsion. Transplantation 2005; 79:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/94\">",
"      Einecke G, Mai I, Fritsche L, et al. The value of C2 monitoring in stable renal allograft recipients on maintenance immunosuppression. Nephrol Dial Transplant 2004; 19:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/95\">",
"      Einecke G, Sch&uuml;tz M, Mai I, et al. Limitations of C2 monitoring in renal transplant recipients. Nephrol Dial Transplant 2005; 20:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/96\">",
"      Hardinger KL, Schnitzler MA, Koch MJ, et al. Cyclosporine minimization and cost reduction in renal transplant recipients receiving a C2-monitored, cyclosporine-based quadruple immunosuppressive regimen. Transplantation 2004; 78:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/97\">",
"      Gaston RS. Maintenance immunosuppression in the renal transplant recipient: an overview. Am J Kidney Dis 2001; 38:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/98\">",
"      Anglicheau D, Verstuyft C, Laurent-Puig P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003; 14:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/99\">",
"      Thervet E, Anglicheau D, King B, et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003; 76:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/100\">",
"      Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004; 78:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/101\">",
"      Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6:1111.",
"     </a>",
"    </li>",
"    <li>",
"     www.ustransplant.org (Accessed January, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/103\">",
"      Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/104\">",
"      Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation 1999; 67:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/105\">",
"      Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69:2405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/106\">",
"      Meier-Kriesche H, Ojo AO, Arndorfer JA, et al. Mycophenolate mofetil decreases the risk for chronic renal allograft failure. Transplant Proc 2001; 33:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/107\">",
"      Srinivas TR, Kaplan B, Schold JD, Meier-Kriesche HU. The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. Transplantation 2005; 80:S211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/108\">",
"      Schold JD, Kaplan B. AZA/tacrolimus is associated with similar outcomes as MMF/tacrolimus among renal transplant recipients. Am J Transplant 2009; 9:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/109\">",
"      Langone AJ, Chan L, Bolin P, Cooper M. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study. Transplantation 2011; 91:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/110\">",
"      Allison AC, Eugui EM, Sollinger HW. Mycophenolate mofetil (RS-61443): Mechanisms of action and effects in transplantation. Transplant Rev 1993; 7:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/111\">",
"      Sollinger HW, Deierhoi MH, Belzer FO, et al. RS-61443--a phase I clinical trial and pilot rescue study. Transplantation 1992; 53:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/112\">",
"      Lang P, Pardon A, Audard V. Long-term benefit of mycophenolate mofetil in renal transplantation. Transplantation 2005; 79:S47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/113\">",
"      Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 345:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/114\">",
"      A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996; 61:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/115\">",
"      Meier-Kriesche HU, Steffen BJ, Hochberg AM, et al. Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant 2003; 3:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/116\">",
"      Mycophenolate mofetil in cadaveric renal transplantation. US Renal Transplant Mycophenolate Mofetil Study Group. Am J Kidney Dis 1999; 34:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/117\">",
"      Neylan JF. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1997; 64:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/118\">",
"      Pescovitz MD, Guasch A, Gaston R, et al. Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am J Transplant 2003; 3:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/119\">",
"      Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998; 65:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/120\">",
"      Clayton PA, McDonald SP, Chapman JR, Chadban SJ. Mycophenolate versus azathioprine for kidney transplantation: a 15-year follow-up of a randomized trial. Transplantation 2012; 94:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/121\">",
"      Burke GW, Ciancio G. Show me the money--immunosuppression in kidney transplantation. Lancet 2004; 364:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/122\">",
"      Remuzzi G, Cravedi P, Costantini M, et al. Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol 2007; 18:1973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/123\">",
"      Ciancio G, Miller J, Gonwa TA. Review of major clinical trials with mycophenolate mofetil in renal transplantation. Transplantation 2005; 80:S191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/124\">",
"      Squifflet JP, B&auml;ckman L, Claesson K, et al. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation 2001; 72:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/125\">",
"      Mendez R, Gonwa T, Yang HC, et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 2005; 80:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/126\">",
"      Leichtman AB. Balancing efficacy and toxicity in kidney-transplant immunosuppression. N Engl J Med 2007; 357:2625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/127\">",
"      Guerra G, Ciancio G, Gaynor JJ, et al. Randomized trial of immunosuppressive regimens in renal transplantation. J Am Soc Nephrol 2011; 22:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/128\">",
"      Gregoor PJ, de S&eacute;vaux RG, Hen&eacute; RJ, et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 1999; 68:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/129\">",
"      Smak Gregoor PJ, van Gelder T, Hesse CJ, et al. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol Dial Transplant 1999; 14:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/130\">",
"      van Hest RM, Mathot RA, Pescovitz MD, et al. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006; 17:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/131\">",
"      Maes BD, Dalle I, Geboes K, et al. Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation 2003; 75:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/132\">",
"      Bunnapradist S, Lentine KL, Burroughs TE, et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006; 82:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/133\">",
"      Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004; 4:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/134\">",
"      Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004; 4:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/135\">",
"      Budde K, Knoll G, Curtis J, et al. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic). Clin Nephrol 2006; 66:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/136\">",
"      Salvadori M, Holzer H, Civati G, et al. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients. Clin Nephrol 2006; 66:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/137\">",
"      Chan L, Mulgaonkar S, Walker R, et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006; 81:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/138\">",
"      Bolin P, Tanriover B, Zibari GB, et al. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients. Transplantation 2007; 84:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/139\">",
"      Kahan BD, Podbielski J, Napoli KL, et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/140\">",
"      Flechner SM, Feng J, Mastroianni B, et al. The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression. Transplantation 2005; 79:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/141\">",
"      Jeong H, Kaplan B. Therapeutic monitoring of mycophenolate mofetil. Clin J Am Soc Nephrol 2007; 2:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/142\">",
"      Shah S, Collett D, Johnson R, et al. The effect of mycophenolate mofetil and azathioprine dose on renal allograft outcome in the United kingdom. Transplantation 2008; 86:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/143\">",
"      van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008; 86:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/144\">",
"      Kuypers DR, Le Meur Y, Cantarovich M, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 2010; 5:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/145\">",
"      Kofler S, Deutsch MA, Bigdeli AK, et al. Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. J Heart Lung Transplant 2009; 28:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/146\">",
"      Kofler S, Shvets N, Bigdeli AK, et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. Am J Transplant 2009; 9:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/147\">",
"      Rupprecht K, Schmidt C, Rasp&eacute; A, et al. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. J Clin Pharmacol 2009; 49:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/148\">",
"      Miura M, Satoh S, Inoue K, et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther Drug Monit 2008; 30:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/149\">",
"      Schaier M, Scholl C, Scharpf D, et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Rheumatology (Oxford) 2010; 49:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/150\">",
"      Kiberd BA, Wrobel M, Dandavino R, et al. The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: evidence from the CLEAR study. Ther Drug Monit 2011; 33:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/151\">",
"      Hricik DE, Almawi WY, Strom TB. Trends in the use of glucocorticoids in renal transplantation. Transplantation 1994; 57:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/152\">",
"      Midtvedt K, Hjelmesaeth J, Hartmann A, et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol 2004; 15:3233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/153\">",
"      Kukla A, Chen E, Spong R, et al. Recurrent glomerulonephritis under rapid discontinuation of steroids. Transplantation 2011; 91:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/154\">",
"      Hardinger KL, Koch MJ, Brennan DC. Current and future immunosuppressive strategies in renal transplantation. Pharmacotherapy 2004; 24:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/155\">",
"      Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst Rev 2006; :CD004290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/156\">",
"      Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/157\">",
"      MacDonald AS, RAPAMUNE Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/158\">",
"      Groth CG, B&auml;ckman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/159\">",
"      Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/160\">",
"      Morales JM, Wramner L, Kreis H, et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/161\">",
"      Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/162\">",
"      Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 2004; 77:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/163\">",
"      Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004; 77:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/164\">",
"      Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. Transplantation 2006; 81:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/165\">",
"      Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/166\">",
"      Meier-Kriesche HU, Steffen BJ, Chu AH, et al. Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival. Am J Transplant 2004; 4:2058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/167\">",
"      Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 2005; 5:2273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/168\">",
"      Griny&oacute; JM, Cruzado JM. Mycophenolate mofetil and sirolimus combination in renal transplantation. Am J Transplant 2006; 6:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/169\">",
"      Srinivas TR, Schold JD, Guerra G, et al. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant 2007; 7:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/170\">",
"      Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011; 377:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/171\">",
"      Weir MR, Mulgaonkar S, Chan L, et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int 2011; 79:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/172\">",
"      Flechner SM, Glyda M, Cockfield S, et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011; 11:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/173\">",
"      Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012; 367:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/174\">",
"      Flechner SM. Can the nephron be spared? Kidney Int 2011; 79:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/175\">",
"      Kuypers DR, Vanrenterghem YF. Monoclonal antibodies in renal transplantation: old and new. Nephrol Dial Transplant 2004; 19:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/176\">",
"      Vincenti F, Blancho G, Durrbach A, et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 2010; 21:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/177\">",
"      Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/178\">",
"      Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/179\">",
"      Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/180\">",
"      Chen GY, Chen X, King S, et al. Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction. Nat Biotechnol 2011; 29:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/181\">",
"      Flemming A. Sepsis: DAMPening inflammation. Nat Rev Drug Discov 2011; 10:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/43/43706/abstract/182\">",
"      Volk HD, Reinke P, D&ouml;cke WD. Clinical aspects: from systemic inflammation to 'immunoparalysis'. Chem Immunol 2000; 74:162.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7356 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-D8D1174216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_43_43706=[""].join("\n");
var outline_f42_43_43706=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF MAINTENANCE IMMUNOSUPPRESSIVE REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H448642464\">",
"      CALCINEURIN INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H448642509\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H448642516\">",
"      - Effect of withdrawal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H448642523\">",
"      - Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H448642530\">",
"      - Use of drugs that slow cyclosporine metabolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H448642537\">",
"      - Microemulsion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H448642574\">",
"      - Gengraf",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H448642581\">",
"      - Others",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H448642588\">",
"      Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H448642595\">",
"      - Efficacy versus cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H448642602\">",
"      - Toxicity compared to cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H448642609\">",
"      Target levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANTIMETABOLIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Overview of our approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Mycophenolate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Efficacy versus azathioprine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Efficacy in combination with tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Chronic allograft nephropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Long-term outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Trough levels and CNIs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Gastrointestinal effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Target levels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15127996\">",
"      - Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H448644239\">",
"      CORTICOSTEROIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      MAMMALIAN TARGET OF RAPAMYCIN INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H448640914\">",
"      BELATACEPT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29173170\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22826520\">",
"      ADJUSTING IMMUNOSUPPRESSION IN INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7356\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7356|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/44/15042\" title=\"table 1\">",
"      Drug interactions with immunosuppressants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25946?source=related_link\">",
"      C4d staining in renal allografts and treatment of antibody mediated rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=related_link\">",
"      Chronic renal allograft nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/7/6266?source=related_link\">",
"      Clinical manifestations and diagnosis of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29738?source=related_link\">",
"      Cytomegalovirus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33722?source=related_link\">",
"      Focal segmental glomerulosclerosis in the transplanted kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/57/11159?source=related_link\">",
"      HLA matching and graft survival in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/14/3303?source=related_link\">",
"      Hyperuricemia and gout in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39367?source=related_link\">",
"      IgA nephropathy: Recurrence after transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32649?source=related_link\">",
"      Induction immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29546?source=related_link\">",
"      Lipid abnormalities after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/9/17562?source=related_link\">",
"      Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/45/42712?source=related_link\">",
"      Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/54/32614?source=related_link\">",
"      Membranoproliferative glomerulonephritis: Recurrence after transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34088?source=related_link\">",
"      Membranous nephropathy and renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/56/22406?source=related_link\">",
"      Mycophenolate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/40/26250?source=related_link\">",
"      New onset diabetes after transplant (NODAT) in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11241?source=related_link\">",
"      Pregnancy in women with underlying renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/4/21577?source=related_link\">",
"      Withdrawal or avoidance of glucocorticoids after renal transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_43_43707="Monitoring of MTF transsexual persons on cross-hormone therapy";
var content_f42_43_43707=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F67967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F67967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Monitoring of male-to-female transsexual persons on cross-hormone therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Evaluate patient every two to three months in the first year and then&nbsp;one to two&nbsp;times per year afterward to monitor for appropriate signs of feminization and for development of adverse reactions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        2. Measure serum testosterone and estradiol every&nbsp;three months.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        a. Serum testosterone levels should be &lt;55 ng/dL.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        b. Serum estradiol should not exceed the peak physiological range for young healthy females, with ideal levels &lt;200 pg/mL.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        c. Doses of estrogen should be adjusted according to the serum levels of estradiol.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. For individuals on spironolactone, serum electrolytes (particularly potassium) should be monitored every&nbsp;two to three&nbsp;months initially in the first year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4.",
"        <span style=\"font-family: calibri,sans-serif; font-size: 11pt;\">",
"         Routine cancer screening should be performed for colon and prostate cancer, as well as breast cancer (because of high dose estrogen)",
"        </span>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Consider BMD testing at baseline if risk factors for osteoporotic fracture are present (eg, previous fracture, family history, glucocorticoid use, prolonged hypogonadism). In individuals at low risk, screening for osteoporosis should be conducted at age 60 and in those who are not compliant with hormone therapy.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BMD: bone mineral density.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94:3132. Copyright &copy; 2009 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_43_43707=[""].join("\n");
var outline_f42_43_43707=null;
var title_f42_43_43708="Drug and toxin related hypoxia";
var content_f42_43_43708=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs and toxins that cause hypoxia/hypoxemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            By CNS depression",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Opiates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Barbiturates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ethanol, ethylene glycol, methanol, isopropyl alcohol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sedative-hypnotics (usually if co-ingested with another CNS depressant)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tricyclic antidepressants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Clonidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            By impairing oxygen diffusion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Opiates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Salicylates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hydrocarbons (aspiration pneumonitis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Paraquat",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Smoke inhalation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phosgene and chlorine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            By complications",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Any CNS depressant can result in aspiration.",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            By paralysis of the ventilatory muscles",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neuromuscular blockers (pancuronium, vecuronium, succinylcholine, etc.)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Organophosphates and carbamates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Snakebites",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tetanus toxin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Strychnine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Botulinum toxin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Simple asphyxiants (Displace oxygen in the lungs)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methane",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Propane",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nitrogen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carbon dioxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Cellular asphyxiants (Inability to deliver or utilize oxygen by the cell)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carbon monoxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cyanide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            &nbsp;Hydrogen sulfide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methemoglobinemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulfhemoglobinemia",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_43_43708=[""].join("\n");
var outline_f42_43_43708=null;
var title_f42_43_43709="Hemodynamic values of normal recumbent adults";
var content_f42_43_43709=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hemodynamic values of normal recumbent adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mean",
"       </td>",
"       <td class=\"subtitle1\">",
"        Range",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac index, liters/min/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        3.4",
"       </td>",
"       <td>",
"        2.8-4.2",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Stroke volume index, ml/m",
"        <sup>",
"         2",
"        </sup>",
"        /beat",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        30-65",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Arteriovenous oxygen difference, ml per liter of blood",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        30-48",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Arterial saturation, percent",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        94-100",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Pressure*, mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"3\">",
"        Left ventricle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Systolic",
"       </td>",
"       <td class=\"sublist_other\">",
"        130",
"       </td>",
"       <td class=\"sublist_other\">",
"        90-140",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        End-diastolic",
"       </td>",
"       <td class=\"sublist_other\">",
"        7",
"       </td>",
"       <td class=\"sublist_other\">",
"        4-12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"3\">",
"        Left atrium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Maximum",
"       </td>",
"       <td class=\"sublist_other\">",
"        13",
"       </td>",
"       <td class=\"sublist_other\">",
"        6-20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Minimum",
"       </td>",
"       <td class=\"sublist_other\">",
"        3",
"       </td>",
"       <td class=\"sublist_other\">",
"        -2-+9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Mean",
"       </td>",
"       <td class=\"sublist_other\">",
"        7",
"       </td>",
"       <td class=\"sublist_other\">",
"        4-12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"3\">",
"        Pulmonary artery wedge (\"PC\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Maximum",
"       </td>",
"       <td class=\"sublist_other\">",
"        16",
"       </td>",
"       <td class=\"sublist_other\">",
"        9-23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Minimum",
"       </td>",
"       <td class=\"sublist_other\">",
"        6",
"       </td>",
"       <td class=\"sublist_other\">",
"        1-12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Mean",
"       </td>",
"       <td class=\"sublist_other\">",
"        9",
"       </td>",
"       <td class=\"sublist_other\">",
"        6-15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"3\">",
"        Pulmonary artery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Systolic",
"       </td>",
"       <td class=\"sublist_other\">",
"        24",
"       </td>",
"       <td class=\"sublist_other\">",
"        15-28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Diastolic",
"       </td>",
"       <td class=\"sublist_other\">",
"        10",
"       </td>",
"       <td class=\"sublist_other\">",
"        5-16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Mean",
"       </td>",
"       <td class=\"sublist_other\">",
"        16",
"       </td>",
"       <td class=\"sublist_other\">",
"        10-22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"3\">",
"        Right ventricle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Systolic",
"       </td>",
"       <td class=\"sublist_other\">",
"        24",
"       </td>",
"       <td class=\"sublist_other\">",
"        15-28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        End-diastolic",
"       </td>",
"       <td class=\"sublist_other\">",
"        4",
"       </td>",
"       <td class=\"sublist_other\">",
"        0-8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"3\">",
"        Right atrium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Maximum",
"       </td>",
"       <td class=\"sublist_other\">",
"        7",
"       </td>",
"       <td class=\"sublist_other\">",
"        2-14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Minimum",
"       </td>",
"       <td class=\"sublist_other\">",
"        2",
"       </td>",
"       <td class=\"sublist_other\">",
"        -2-+6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Mean",
"       </td>",
"       <td class=\"sublist_other\">",
"        4",
"       </td>",
"       <td class=\"sublist_other\">",
"        -1-+8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"3\">",
"        Venae cavae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Maximum",
"       </td>",
"       <td class=\"sublist_other\">",
"        7",
"       </td>",
"       <td class=\"sublist_other\">",
"        2-14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Minimum",
"       </td>",
"       <td class=\"sublist_other\">",
"        5",
"       </td>",
"       <td class=\"sublist_other\">",
"        0-8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Mean",
"       </td>",
"       <td class=\"sublist_other\">",
"        6",
"       </td>",
"       <td class=\"sublist_other\">",
"        1-10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"3\">",
"        End-diastolic volume index",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Left ventricular, ml/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        70",
"       </td>",
"       <td class=\"sublist_other\">",
"        50-90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"3\">",
"        Resistance, dyn&bull;s/cm",
"        <sup>",
"         5",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Total systemic",
"       </td>",
"       <td class=\"sublist_other\">",
"        1150",
"       </td>",
"       <td class=\"sublist_other\">",
"        900-1400",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Systemic arteriolar",
"       </td>",
"       <td class=\"sublist_other\">",
"        850",
"       </td>",
"       <td class=\"sublist_other\">",
"        600-900",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Total pulmonary",
"       </td>",
"       <td class=\"sublist_other\">",
"        200",
"       </td>",
"       <td class=\"sublist_other\">",
"        150-250",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Pulmonary arteriolar",
"       </td>",
"       <td class=\"sublist_other\">",
"        70",
"       </td>",
"       <td class=\"sublist_other\">",
"        45-120",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Baseline for pressure measurements one-half of anteroposterior chest diameter. 1 mmHg = 133.332 Pascal (PA) = 0.133 kPa.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hurst JW, Rackley CE, Sonnenblick EH, Wenger NK. The Heart: Arteries and veins. 7th ed. McGraw-Hill, Inc, New York 1990. Copyright &copy; 1990 McGraw-Hill Companies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_43_43709=[""].join("\n");
var outline_f42_43_43709=null;
var title_f42_43_43710="Plasma aldosterone renin ratio";
var content_f42_43_43710=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    PAC/PRA ratio in hypertension and hypokalemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 382px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Use of the plasma aldosterone concentration (PAC)-to-plasma renin activity (PRA) ratio to differentiate among different causes of hypertension and hypokalemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Young WF Jr, Hogan M. Renin-independent hypermineralocorticoidism. Trends Endocrinol Metab 1994; 5:97.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_43_43710=[""].join("\n");
var outline_f42_43_43710=null;
var title_f42_43_43711="Serum sickness foot";
var content_f42_43_43711=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F78783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F78783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Foot serum sickness",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 214px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mark H Wener, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_43_43711=[""].join("\n");
var outline_f42_43_43711=null;
